

INNOVATIONS
FOR
HEALTH

CLUSTER
BIOTECHNOLOGY
BAVARIA



BIOTECH IN BAVARIA

A STRONG COMMUNITY FOR HEALTH


REPORT

2020/21

managed by



including more than 300 company profiles



People are at the heart of all efforts

Data is more than numbers. They are meaningful and enable groundbreaking decisions to be made. With each individual data set, our picture of diseases becomes sharper. With every single data set, we can develop better therapies and diagnostic tests. The potential of digitization in healthcare is enormous - it helps improve patients' lives. That's what we're working on - every single day.



CONTENT

Greeting	5
Bavarian Ministry of Economic Affairs	
Bavaria has faced the Challenges and seized the Opportunities	7
Prof. Dr. Horst Domdey – CEO & Spokesman Bavarian Biotechnology Cluster	
Company Development	8
Steady Growth for long-term Success	
Patient Safety must be guaranteed	20
Interview with Dr. Susanne Danhauser-Riedl	
Boom in Biotech due to COVID-19?	24
Interview with Michael Motschmann	
Bavaria's Strength against COVID-19	28
Success in Diagnostics, Vaccines and Drug Development	
COVID-19 Company Survey	30
How the Pandemic shapes the Bavarian Biotech Landscape – a Snapshot	
Pandemic Research & Infection Medicine: Roche and Fraunhofer in Penzberg	32
Interview with Claus Haberda	
Artificial Intelligence in Medicine	36
Interview with Prof. Dr. Daniel Rückert	
DigiMed Bayern	39
Data-Driven Personalized Medicine	
A good Network is essential to a successful Start-up	40
Interview with Dr. Dominik Schumacher & Dr. Jonas Helma-Smets	
International Affairs	44
Bio ^M takes Gold again / European Clusters joining Forces	
Life Science Centers in Bavaria	46
Regional Networks	
European Metropolitan Region Munich	48
An excellent and successful Biotechnology Site	
My Regensburg	50
A Guest Contribution from Dr. Thomas Diefenthal	
Würzburg – Life Science & Start-up Hub in Northern Bavaria	52
A Guest Contribution from Dr. Gerhard Frank	
Company Profiles	55

GREETING

Bavarian Ministry of Economic Affairs, Regional Development, and Energy

Even today, the coronavirus pandemic continues to shape many areas of our lives and how business is carried out. Yet a gradual return to normality can be seen, which is primarily attributable to biotechnology. Biotech is one of the key technologies for the 21st Century, as has been strikingly exhibited once again over the past year and a half. The development of the BioNTech mRNA vaccine now in use all over the world is a tremendous success story 'Made in Germany' - and something to be extremely proud of.

In addition to vaccine development, biotech companies are also making crucial contributions to combating the pandemic in fields such as diagnostics and the development of medicines. Since the outbreak of the COVID-19 crisis, numerous Bavarian companies and scientists have made a remarkable impact in various areas of pandemic control. The Bavarian State Government recognized this great potential at an early stage and launched the Bavarian Therapy Strategy. It provides biotechnology companies in our state with more than 50 million euros in financial support for the development of therapeutics against COVID-19. The initiative put forward by Bavaria has been an important driver for measures at the national level and EU level alike.

Yet the ongoing pandemic is not the only area in which this industry is delivering tremendous results. Already today, our biotech companies are driving the "medicine of tomorrow" forward with a high level of commitment. For some time now, these developments have no longer been taking place exclusively in large industrial companies, but rather primarily in life science start-ups. That is why this field represents a central focus in Bavarian policymaking for research, technology, and innovation. The Bavarian State Government has been providing targeted support for biotechnology start-ups for years - in both the founding



HUBERT AIWANGER

Member of the Bavarian State Parliament
Bavarian State Minister of Economic Affairs, Regional Development, and Energy
Deputy Minister President of Bavaria



ROLAND WEIGERT

Member of the Bavarian State Parliament
State Secretary at the Bavarian Ministry of Economic Affairs, Regional Development, and Energy

and growth phases - and continues to work toward further enhancement in the environmental conditions for start-ups. One example to cite is the availability of venture capital, which is particularly important for the biotechnology sector. With Bavaria's Growth Fund 2, ScaleUp Fund, and ScaleUp Umbrella Fund, we have created three extraordinarily powerful financing instruments for expanding Bavarian start-ups over the past two years. The volume of these three funds alone totals some 415 million euros.

To be sure, biotechnology will continue to provide pioneering and sustainable answers to the major social challenges of our time. That is one of the reasons why this is a decisive and rapidly growing economic factor for both Germany and Bavaria. We are extremely well positioned as a biotechnology site in Germany and in the world, offering an outstanding network of excellence and expertise: From superb teaching and fundamental research to high-performing, innovative companies as well as impactful cluster organizations, start-up centers, and technology transfer offices.

We are looking to grow this diverse, fruitful ecosystem even further in close conjunction with our strong partners in industry and science. To such end, the Bavarian Biotech Report provides us with a helpful overview of current developments in the industry. We hope you'll find this issue beneficial.

Hubert Aiwanger

Roland Weigert

Bio^M - central point of contact for pharma and biotechnology in Munich and Bavaria

- consulting for founders-to-be, start-ups & SMEs
- grant & seed financing support
- pre-seed incubation & m⁴ award
- networking & partnering, matchmaking
- events, conferences & training
- representing Bavarian biotechnology world-wide
- investment opportunities
- online platform with industry news, press releases, job exchange, company database and much more



BAVARIA HAS FACED THE CHALLENGES AND SEIZED THE OPPORTUNITIES



© BioM

PROF. DR.
HORST DOMDEY

CEO and Spokesman
Bavarian Biotechnology Cluster

Although we can't call it a miracle, but it is at least amazing how well the Bavarian biotech industry has navigated itself through the crisis, which was caused by the coronavirus pandemic. The information which Bio^M collected first in May last year and then in May 2021 clearly demonstrates this. The surveys showed that companies' concerns about the consequences of the coronavirus pandemic decreased significantly, even though some challenges for companies increased, such as supply shortages for example.

Since the first day of the pandemic, numerous companies and research teams in Bavaria recognized the need but also the opportunity, that it was the right moment to put the switch on full speed because their contributions were urgently needed. Therefore, incredibly many companies have conducted innovative research to develop test systems and vaccine candidates as well as in drug development, with many positive results.

Another factor which certainly has contributed to the success story has been the cluster effect: interdisciplinary cooperation, the exchange of ideas and concepts, and mutual support have played a more significant role than ever. In order to further expand this cluster effect, we as Bio^M will continue to actively support the biotechnology sector with all its players from industry and academia in Bavaria and beyond.

I have the impression that people have indeed become aware of the importance of the biotechnology industry due to the immense impact of the pandemic on almost all areas of life. And, biotechnology not only offers solutions to combat diseases, it can also be the key to solving other pressing problems of our time, such as climate change or energy supply. It remains to be seen whether the new awareness will have a lasting positive impact on the entire biotech industry. This will also be measurable by the improvement of framework conditions for all segments of the industry.

The brains, the know-how and the right environment – in other words, the necessary potential – are definitely present in Bavaria.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Horst Domdey'. Below the signature, the name 'Prof. Dr. Horst Domdey' is printed in a small, black, sans-serif font.



COMPANY DEVELOPMENT

Steady Growth for long-term Success

Number of Companies

For a number of years now, Bavaria has established itself as one of the leading European locations for the Life Science sector, housing a total of 498 related companies in 2020. Among them are 64 pharmaceutical companies, including a number of global players like GSK, Daiichi Sankyo, Merck, Sharp & Dome (MSD) with European or German headquarters in the region. In addition, the Bavarian Biotech Cluster includes 275 biotechnology companies, 66 CROs and 93 other related companies. A total of 210 biotech companies are based in Bavaria, while 65 are internationally operating companies with a corporate office or site in Bavaria. Because the largest proportion of companies based in the region are highly innovative biotech SMEs, the predominant focus of Bio^M's activities is on supporting this core group, which has its strengths particularly in the area of red biotechnologies.

The 210 Bavarian biotechnology companies are divided into the following areas: therapeutics (56 companies), diagnostics (24), technology platforms, devices and reagents (62), bioinformatics and digital health (26), industrial biotechnology (16), as well as agriculture, food and environment (9). A total of 17 companies cannot be assigned to any of these categories, but are still counted as part of the industry.

Compared to 2019, the total number of companies surveyed by Bio^M has increased by 25%. However, this increase can only be partially attributed to new start-ups and inflows. A large part of the change is due to an expansion of the definition of the "Others" group, which this year includes not only suppliers but also laboratory service providers in the Life Science sector. Previously, the "supplier" category consisted of 30 companies. This change was made in order to achieve better harmonization with the figures covered by BIO Deutschland.


In addition, Bavaria hosts a large number of Universities, University Hospitals and Research Institutes. This enormous density of research activities, active drug development, production and the broad range of analytical services make the Free State a globally recognized hotspot for Life Science developments.

New Companies

COMPANY	CATEGORY	LOCATION
21Dx GmbH	Diagnostics	Munich
Alpspitz Bioscience	Diagnostics	Gattendorf
Analytisches Forschungsinstitut für Non-Target Screening GmbH	Analytics	Augsburg
blaze.bio GmbH	Diagnostics/Devices	Munich
CellUnite GmbH	Devices - stem cell extractor	Munich
Cirlo GmbH	Therapeutics	Wolfratshausen
CoVER Antibodies GmbH	Therapeutics	Erlangen
GRP GmbH	Devices	Haag
IcanoMAB GmbH	Therapeutics	Polling
ImmuCon GmbH	Therapeutics	Martinsried
Knowing01 GmbH	Bioinformatics / Digital Health	Munich
mentalis GmbH	Digital Health	Nuremberg
mk2 Biotechnologies	Devices and Reagents	Munich
Orbit Health GmbH	Digital Health	Neuried
PHIO scientific GmbH	Devices and Reagents	Munich
Roscue Therapeutics GmbH	Therapeutics	Wolfratshausen
SIRS Therapeutics GmbH	Therapeutics	Munich
Virtonomy GmbH	Bioinformatics / Digital Health	Munich
XTransplant GmbH	Therapeutics	Starnberg
Zogenix GmbH	Therapeutics	Munich

THE BAVARIAN BIOPHARMA SECTOR

Number of Companies



Newly founded Companies

Bavaria is particularly characterized by its founder-friendly ecosystem. While 18 new companies were founded in 2019, a total of 20 companies were established in Bavaria in 2020. These figures are quite encouraging when compared with other sectors of the economy. In the region, start-ups encounter a strong network of supporting organizations that offer young entrepreneurs a wide range of practical and theoretical aids. Bio^M and its virtual incubator inQlab were able to help a large number of entrepreneurs to become successful founders over the last years.

Employment

Bavaria's biotech companies differ significantly in terms of sales/size and number of employees. However, the largest share of companies belongs to the category "small (< 49 employees) and medium-sized (< 249 employees) companies". A sign of the steady growth here is the increasing number of companies with more than 100 employees (currently 37), which emulate the regional flagship MorphoSys with its 615 employees. In terms of sheer numbers, however, the Swiss company Roche Diagnostics is the undisputed leader. With 6,800 employees in research and production at the site in Penzberg, Roche is one of the most important employers in the region.

Combined, pharma-, biotech-, and other related companies employ about 44,000 people in Bavaria. As of 2020, around 13,000 people were employed by the pharmaceutical companies. With a total of 21,000 employees, biotech companies are the most important employers in the sector in Bavaria. International companies employed an average of 229 people at their local sites (14,000 in total), while small and medium-sized Bavarian biotech companies have shown strong growth figures as well (33 on average; 7,000 in total).



© BIO Deutschland

DR. VIOLA BRONSEMA

Managing Director BIO Deutschland

„With regard to Germany as a business location, we cannot be interested in local biotech companies, which are among the jewels of the German middle class, being sold abroad. In principle we think it is appropriate for the state to monitor these processes. However, the examination of interested foreign investors should proceed more quickly, and the relevant offices in the Federal Ministry for Economics would also have to be more adequately equipped with the necessary personnel and resources. There could perhaps also be a positive list of recognized “unobjectionable” non-European investors, who would not need to be repeatedly screened.“


Pipeline

The Bavarian biotech landscape is traditionally strongly characterized by drug developers. These are long-term research and development projects that are brought from the initial identification of a drug candidate through preclinical and clinical studies in a lengthy process to regulatory approval. An average of ten to twelve years of development time must be expected before a product is ready for the market. Only one in ten clinical projects started in Phase I of clinical development is ultimately approved. Over the years, the Bavarian industry has been able to generate an impressive pipeline of active ingredients that are currently in preclinical (66) or even clinical (131) phases, which shows an enormous increase since 2013, when 49 candidates were in clinical development. A total of 36 products are currently in Phase I clinical trials, 59 in Phase II and 36 in Phase III. Here, too, the impact of the global coronavirus pandemic is becoming apparent, and many companies in the field of therapeutics and diagnostics have switched their programs to combat COVID-19. In this context, the accelerated approval procedures were a major incentive for many developers to participate in the fight against SARS-CoV-2. Additionally, many companies have moved into support, manufacturing and supply for manufacturers of products to combat COVID-19. In the field of diagnostics, the Bavarian driving forces around **Roche Diagnostics** and **Siemens Healthineers**, as well as smaller companies such as **GNA Biosolutions**, **FRIZ Biochem**, **GeneSurge** and **Mikrogen** were successful in developing various different test systems, some of which were approved.

The largest share of compounds in clinical development falls in the field of cancer therapy with 60 projects, followed by therapeutics against autoimmune diseases with 26 projects. As is the case throughout Germany, the product pipeline in Bavaria is dominated by biopharmaceuticals and, in this case, the active substance group of recombinant antibodies. **MorphoSys**, one of the Bavarian Biotech-Flagships, celebrated a major success receiving the U.S. approval for its cancer drug Monjuvi. The companies **Medigene**, **Minaris**, **Formycon**, **Bavarian Nordic**, **4SC**, **Eisbach Bio** and **AdvanceCOR** also reported promising results in pre-clinical and clinical trials for their drug candidates. They all hope to receive approvals in the coming years.

THE BAVARIAN BIOPHARMA SECTOR

Employment



The development, approval and marketing of a new drug is lengthy and expensive. For this reason, biotechnology and pharmaceutical companies in particular rely on the protection of intellectual property and thus also on patents. Patent protection, which has been repeatedly discussed in the wake of the SARS-CoV-2 vaccine shortage, enables the industry to bear the high investment costs for research and development. Patents protect against imitation for a legally defined period of time, while making inventions generally accessible through published patent specifications. Patent protection is uniformly granted for a period of 20 years worldwide, although several years often elapse between patenting and marketing of medicines as part of the development and clinical approval studies.



“Research into new therapeutic approaches and drugs for patients is a social task that must have much more political and, thus, ultimately also financial support in the future, also due to the experience of the Corona pandemic. The biotech industry is a systemically relevant industry for this.”

MARTIN KRAUSS

Managing Director FGK Clinical Research GmbH

© FGK

Financing / Company News

The economic development of pharmaceutical and biotechnology companies in 2020 was determined to a very large extent by the effects of the global pandemic. However, in contrast to many other sectors, predominantly positive effects were felt here. While the momentum of biotechnology seemed to wane somewhat in previous years, numerous companies have posted record figures in recent quarters. Many companies now hope to continue this positive development in the future. Due to the diverse possibilities that biotechnology offers for combating diseases, public awareness in particular has increased enormously in the meantime. In this context, however, it is also important to mention that not all areas and companies in the biotechnology sector have benefited equally. Depending on their focus, however, many companies have been able to respond to the pandemic-related changes and benefit where appropriate.

The success stories of German researchers and developers have caused a sensation worldwide and brought the entire economic sector into focus. In addition, it has become clear what enormous economic potential lies dormant in the dynamic industrial sector of biotechnology. How much momentum the industry will be able to take with it from the crisis will probably only become clear in the coming years, but the capital market showed a thoroughly positive momentum. U.S. investors in particu-

lar are showing increasing interest in investing in promising companies, including those in Europe and Germany. Some Bavarian company representatives were concerned about the still enormously high legal, tax and bureaucratic hurdles in Germany. The main problem here is that very few local companies manage to scale without the help of (foreign) investors. Although Germany's universities produce first-class specialists and are regarded as innovation drivers, spin-offs, start-ups and small companies are often acquired by large corporations at a very early stage, as they are dependent on capital beyond early funding and seed financing.

Despite the difficult circumstances, however, a whole series of Bavarian companies have succeeded in raising capital and concluding substantial financing rounds in 2020 and 2021.

For 2020:

Immunic Therapeutics from Gräfelfing and Garching-based radiopharmaceutical biotech company **ITM** were each able to secure substantial bonds in the double-digit millions (Immunic EUR 25 million and ITM EUR 40 million) from the European Investment Bank.

Immunic also received USD 103.5 million from a public offering. The company plans to use the money to fund ongoing clinical development of its three lead product candidates.

Bavarian Nordic, a biotechnology company focused on the development of innovative therapies against infectious diseases and cancer with a branch in Martinsried, sold its priority review voucher for a total of EUR 95 million.



CatalYm, based in Martinsried, has closed a EUR 50 million series B financing. The biopharmaceutical start-up, which focuses on novel cancer immunotherapies, plans to use the funds for the clinical development of its GDF-15 anti-cancer antibody.

Freeline Therapeutics, the British gene therapy company with a branch office in Bavaria, has added USD 80 million of new capital to its series C fund, bumping up its original USD 40 million from long-term investor Syncona.

The federal and state governments have made a

DRUG PIPELINE OF BAVARIAN BIOTECH SMEs

Number of Projects by Phase and Indication



As of June 2021. Not included are 26 non-clinical projects of MorphoSys.

total of around EUR 40 million available for the new **Center for Infection Prevention** at the **Technical University of Munich**. The center is intended to bundle the fight against resistant pathogens.



© NanoTemper Technologies

“The corona pandemic has made it easier for us to expand our digital marketing globally, greatly increasing our reach and efficiency. The trend towards more and more complex therapeutics and faster development cycles requires more and more analytics and data science, which is very beneficial for us. Based on our strong BioPhotonics technology platform, we see good opportunities to become a global leader in bioanalytics of complex therapeutics in the coming years.”

DR. PHILIPP BAASKE

CEO, NanoTemper Technologies GmbH

There was also positive news from Waldkraiburg in 2020. **Rosenheim Technical University of Applied Sciences** received funding of EUR 11 million from the Free State of Bavaria for the planned **Center for Biobased Materials (ZBM)**.

Munich-based start-up **Kaia Health**, which is developing a medical app to treat back pain, closed a Series B financing round worth around EUR 23 million. This brings the total funds raised so far by the start-up, which specializes in digital therapies, to USD 50 million.

Tubulis has closed a EUR 10.7 million Series A funding round. The young



© deepc

“Improving radiological diagnostics with our AI platform deepcOS and tested AI applications from leading global partners - this can be developed, tested and validated particularly well in Bavaria with its numerous top hospitals and outstanding research institutions.”

DR. FRANZ PFISTER

CEO, deepc GmbH

Munich-based start-up intends to use the funds to advance the development of a new class of highly stable and effective antibody drug conjugates (ADCs) and to continue growing as a company. The financing round was jointly led by BioMedPartners and High-Tech Gründerfonds (HTGF).

In addition, a number of other companies were able to secure substantial financing in the single-digit million range during 2020. These include **VisionHealth, Mindpax, IRUBIS, iATROS, Mecuris, Kumovis, AdvanceCOR** and **4SC**.

For 2021 (as of September):

Following up on their successes from 2020, **ITM** was able to close a financing round totaling EUR 90 million (USD 109 million) via convertible bonds. ITM intends to use the proceeds to expand its precision oncology pipeline and support the late-stage development and market approval of its lead product candidate.

Cardior Pharmaceuticals, a portfolio company of **Ascenion**, closed a Series B financing for a total of EUR 64 million. Cardior can thus continue to pursue its new approach to the treatment of heart disease and further intensify its research and development with the help of the newly acquired funds.

After the successful financing rounds of 2020, **Immunic Therapeutics** was able to announce the closing of a public offering with a net worth of USD 45 million.

AMSilk, the world’s first industrial supplier of synthetic silk biopolymers, announced the successful closing of a Series C financing totaling EUR 29 million. The financing was provided by a major group of investors and will allow the company to further expand the applications of its innovative product.

Innovative Molecules, a company specializing in the treatment of herpes simplex-induced diseases, has relocated its headquarters to Munich and announced the closing of its EUR 20 million Series A equity financing round.

Leukocare, specializing in the development of biopharmaceutical formulations, has announced the closing of a financing round of approximately USD 17.5 million. The financing itself consists of a USD

THE UNKNOWN IS OUR COMFORT ZONE.

Wer unerforschtes Terrain erobern will, braucht eine besondere Einstellung. Wir loten ständig die Grenzen des Machbaren aus, um Patienten ein besseres Leben zu ermöglichen. Mit der Entwicklung neuer Therapien gegen chronische Erkrankungen.

We discover. We dare. We care.
Jetzt mehr entdecken auf www.glp.com

Galápagos
Pioneering for patients



© OmicEra

„2020/21 was a transformative time that will have a lasting impact on OmicEra. We have further driven the automation and digitalization of our mass spectrometry-based proteomics platform, enabling the analysis of more than 100,000 liquid biopsy samples/year. Based on our platform, we are excited that we could contribute to biomarker discovery projects across various diseases, including the identification of novel biomarker candidates for COVID-19 disease progression. At OmicEra, we will further focus our efforts on maximizing the extraction of clinically relevant information from every biopsy sample using innovative soft- and hardware solutions to revolutionize clinical diagnostics.“

DR. SOPHIA DOLL

CBO & Co-Founder OmicEra Diagnostics GmbH

15 million convertible bond and a USD 2.5 million equity investment. Leukocare plans to use the proceeds to accelerate the further expansion of its business activities in the U.S.

The recently founded start-up **Origin Bio** from Pullach near Munich wants to conquer the field of synthetic biology with specially produced microorganisms and thus produce sustainable raw materials. The company has now raised a total of around USD 15 million for this purpose.

The first funding decision within the framework of the EUR 50 million Bavarian Therapy Strategy goes to **Pieris Pharmaceuticals** from Hallbergmoos near Munich. Pieris intends to use the EUR 14.2 million to accelerate the clinical development of its product candidate. Further grants were awarded to the Martinsried-based companies **Formycon**,



© TUM/Andreas Heddergott

“We need more success stories and more culture for translational research that leads to innovation in healthcare. Bavaria, with its research hotspots like Munich, has the necessary ingredients for this.“

PROF. OLIVER HAYDEN

Director TranslaTUM, Central Institute for Translational Cancer Research of the Technical University of Munich

ethris and Origenis.

In parallel, the BMBF is funding drug research against SARS-CoV-2 at **Eisbach Bio** from Planegg and **Explicat Pharma** from Hohenbrunn with almost EUR 8 million and EUR 4.2 million, respectively, from federal funds. Read more in the COVID-19 part of this report.

Other noteworthy financings in the millions went to companies such as **Kranus Health**, **Orbit Health**, **Smart4Diagnostics**, **VisionHealth**, **HMNC Brain Health**, **mk2 Biotechnologies** and the agritech start-up **Farminsect**.

Munich-based MedTech start-up **deepc** has also successfully closed a seed financing round worth a mid-seven-figure sum. In addition to funding from the Initiative for Industrial Innovators, the company was also able to convince another well-known but undisclosed healthcare investor of its novel development.

Deals and Collaborations

The COVID-19 pandemic has triggered a significant increase in the collaborative spirit among Bavarian companies. In 2020 and 2021, numerous companies of all sizes entered into a variety of collaborations to respond to the challenges of the crisis. In addition to closer cooperation between local companies, a number of noteworthy deals and collaborations with Bavarian participation were concluded in 2020 and 2021.

In 2020 and 2021, **MorphoSys** announced two licensing agreements and collaboration deals. The Bavarian company has partnered up with U.S.-based company Incyte Corporation to further develop and commercialize its proprietary anti-CD19 antibody tafasitamab on a global scale. In addition, MorphoSys has announced a partnership with **Cherry Biolabs**, a young company from Northern Bavaria. Both partners signed an exclusive license agreement for the use of Cherry Biolabs' hemibody technology for several target molecules.

Roche Diagnostics entered into a partnership with the nearby Penzberg Hospital in the field of cancer treatment. The project involves the implementation and further development of a tumor board solution and is designed to support physicians in

making therapy decisions, which can mean faster and more targeted access to appropriate therapies for patients.

As a result of the pandemic, the **Technical University of Munich**, with its site in Straubing, has also entered into a collaboration with the local hospital to ensure faster processing of COVID-19 test results in the surrounding area.

Similarly, Munich-based MedTech company **inveox** supports clinics and laboratories worldwide by supplying SARS-CoV-2 tests, personal protective equipment and disinfectants.

To improve the uptake of viral vectors into cells, Martinsried-based biotech company **SIRION Biotech** has developed a specialized LentiBOOST™ technology. The U.S. company Beam Therapeutics has now entered into a collaboration with SIRION to apply this technology to the development of its own CAR-T product candidates. Under the terms of the agreement, SIRION is granting Beam Therapeutics non-exclusive access to its proprietary lentiviral transduction amplifier for the clinical development and commercialization of Beam's CAR-T programs. SIRION is eligible for undisclosed upfront and milestone payments and will receive royalties tied to future product net sales and commercial success. In addition, SIRION entered into a licensing and collaboration agreement with French Pharma giant Sanofi. Together, the two companies aim to develop improved AAV capsids for gene therapy treatments of life-threatening diseases.

Siemens, one of the world's leading companies in process automation, and Stuttgart-based Exyte, specializing in the design and execution of biopharmaceutical production plants, have agreed to partner on end-to-end solutions for the biopharmaceutical industry. In the future, this partnership aims to help pharmaceutical companies to improve the challenges in the development and mass production of new vaccines and pharmaceuticals in existing production facilities.

Evotec, based in Hamburg and Munich, announced a strategic partnership with **Secarna Pharmaceuticals**, the leading independent European anti-sense drug discovery company. The partnership between the two companies was further expanded

and extended in 2021. The goal of the collaboration is research and development programs of the companies' industrial partners. Evotec also announced news on its collaboration in the field of treatments for neurological diseases with the pharmaceutical company Bristol Myers Squibb. Evotec will receive an option payment of USD 20 million from BMS. In addition, there are opportunities to raise funds in the triple-digit million range through milestone payments. In the event of a successful product launch, Evotec will also receive royalties of up to a low double-digit percentage.

In late 2020, **Secarna** also joined forces with Denali Therapeutics in order to develop novel therapeutics for neurodegenerative diseases.

ViGeneron, based in Planegg, announced a research collaboration with Daiichi Sankyo from Tokyo. The two companies will evaluate ViGeneron's proprietary intravitreally injected vgAAV vectors for delivery of a novel therapeutic protein. Together, they aim to develop a gene therapy treatment for a common eye disease. ViGeneron already signed a global collaboration agreement with Biogen in early January 2021.

ChromoTek, a specialist in nanobody-based reagents, and Absolute Antibody, a leading provider of recombinant antibody technologies, announced their collaboration to produce recombinant antibodies for research applications.

Leukocare and Malvern Panalytical plan to combine their expertise in vaccine formulation and stabilization to improve the availability of vaccines against COVID-19. **Leukocare** and **Formycon**, both based in Martinsried, also agreed to cooperate in the field of high-quality biopharmaceuticals. In addition, Leukocare expands its service offering with Rentschler Biopharma with a joint site in the U.S.



© Fraunhofer-Gesellschaft/Markus Jürgens

DR. LUTZ ZEITLMANN

Abteilungsleiter Forschungskoordination
Life Science and Materials,
Fraunhofer-Gesellschaft

"Munich has both, excellent basic biomedical research facilities and several clinics with outstanding expertise in clinical research. In our view, the availability of seed-funding is sufficient, but the conditions for further funding rounds are still suboptimal. A contribution could be made by more support for deep tech spin-offs, i.e., a spin-off only occurs at later stages of maturity. This would require more intensive further development of the core technologies even before the spin-offs from the research institutions. In this sense, the link between basic research and clinical research, i.e. translational applied research and development within the framework of publicly financed research institutions, could be expanded."



Faster and easier access to new drugs: that is the goal of the cooperation between the Dresden-based start-up PharmAI and the Munich-based company **NanoTemper Technologies**. The two partners want to contribute their respective expertise to the collaboration and enable even small laboratories to enter the field of drug discovery. This would, for example, enable more research into drugs for rare diseases, the development of which is currently rather unprofitable for large pharmaceutical companies.

Immunic and **4SC** have agreed on a revenue-sharing sale for 4SC of Immunic's IMU-838 project. Under the terms of the agreement, 4SC will receive a compensation payment from Immunic in the amount of USD 17.25 million. Immunic had acquired the IMU-838 project from 4SC in September 2016. In addition to a one-time payment, milestone payments and also a share in net sales over a certain period of time were agreed between the two companies. Immunic also announced an in-licensing agreement with the University Medical Center Göttingen.

Munich-based **Pieris** enters into a research collaboration with Roche subsidiary Genentech on therapies for respiratory diseases and ophthalmology. Pieris will receive USD 20 million upfront from the deal and is eligible for more than USD 1.4 billion in additional potential milestone payments plus royalties on commercialized programs.

Dermapharm Holding, headquartered in Grünwald, a manufacturer of branded pharmaceuticals, is expanding its portfolio to include an investment in the field of immunotherapy against COVID-19. To this end, Dermapharm signed an agreement to acquire new shares in CORAT Therapeutics, based in Braunschweig.

Eisbach Bio and a team from the Technical University of Kaiserslautern (TUK) have announced a collaboration to use deep learning to track and trace arising mutations in the genome of SARS-CoV-2 and develop sustainable small molecule inhibitors that will target the virus for the long-term.

Acquisitions

The **Proteintech Group** from Rosemont in Illinois, USA, has acquired the Martinsried-based company **ChromoTek**, a leading manufacturer of so-called nanobodies in late 2020. Through the merger, the two companies aim to meet the growing research market and the challenges of their customers even better.

MorphoSys has acquired Constellation Pharmaceuticals for a total equity value of EUR 1.4 billion. The takeover was enabled by MorphoSys' long-term strategic financing partnership with Royalty Pharma. Following the closing of the transaction, MorphoSys will retain its headquarters in Munich, Germany, and maintain a commercial and R&D presence in Boston, Massachusetts.

Planegg-based **Sirion Biotech**, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies, has been acquired by the U.S. company PerkinElmer.

The diagnostics company **Mikrogen** from Neuried has acquired **Lophius Biosciences** from BioPark Regensburg to enter the future market for T cell-based tests.

Company Highlights

Swiss Pharma Giant **Roche** is celebrating its 125th anniversary in 2021. Founded in Basel in 1896 by Fritz Hoffman-La Roche, the company has evolved over the course of its history from one of the first industrial drug manufacturers to one of the world's leading healthcare companies. Since 1972, the company has also been based in Bavaria with its site in Penzberg near Munich and, with a total of over 6,000 employees, is one of the largest and most important employers in the region. Most of the employees work in the Diagnostics division. Roche is also an enormous attraction for highly qualified specialists from all over the world and employs people from around 55 different nations in Penzberg.

Financing Life Science Innovation

TVM Capital Life Science

TVM Life Science Management GmbH, TVM Capital GmbH, Munich
TVM Life Science Management Inc., Montréal

www.tvm-lifescience.com



Creating future cell therapy miracles together




MINARIS

REGENERATIVE MEDICINE

- Leading contract development and manufacturing organisation
- Experts in clinical and commercial manufacturing of cell and gene therapies
- More than 20 years' experience in all relevant cell types
- More than 30 clean rooms across our expanding global sites



PATIENT SAFETY MUST BE GUARANTEED

64%



4SC researches and develops targeted therapies for the treatment of cancer. What impact has the coronavirus pandemic had on conducting clinical trials? What problems, but also opportunities, are resulting from the crisis, and what lessons can we learn from it?

DR. SUSANNE DANHAUSER-RIEDL
CMO at the Martinsried-based biotechnology company 4SC AG



© 4SC AG

BioM: Conducting clinical trials is part of the development and marketing of cancer drugs. How has the pandemic affected the performance of these trials? Has there been an impact?

Dr. Susanne Danhauser-Riedl: I must say very clearly: Yes, the pandemic has affected the performance of clinical trials and continues to do so. The pandemic is not over. At 4SC, we experienced that first-hand. In February 2020, we had to think about whether our patients were safe in the trials and whether they might be infected. The main concern is always to guarantee the patients' safety. We considered whether it would be safe to keep the patients in the trials and we came to the conclusion that the benefit-risk assessment was still favorable. In fact, we did not enroll any new patients in trials from March to May 2020. Not because we didn't want to, but because the patients themselves did not want to expose themselves to the risk and didn't come to the clinic.

Besides, clinical trials had to be interrupted during the pandemic. What were the reasons for that?

There is a variety of reasons for this. One reason was that the staff was otherwise occupied and had no more time for the study patients. In addition, the patients shied away from the risk of coming to the study centers. We also had the issue of logistics. For example, blood samples have to be brought to central laboratories in the case of international studies from different countries. These transport routes were, of course, restricted, so logistically we had to consider very carefully how to proceed. After all, in the end, patient safety must be guaranteed, and the data must also be clean, conclusive, and meet the quality standards. Otherwise, the effort of conducting the trial and the contributions of the patients who voluntarily chose to participate would be for nothing. Thus, it is ethically imperative to collect the data very sensibly and to be able to analyze it well in the end.

The approval of cancer drugs is very extensive in terms of time and expense, although, compared to vaccines, the active ingredients are developed for the seriously ill and not healthy patients, and here certain side effects are also accepted. Where do you see the differences?

There is, of course, a difference between the development of vaccines and cancer drugs. With

patients who are seriously ill and almost hopeless, one can accept side effect profiles that would not be acceptable with vaccines, for example, which are administered to healthy subjects for disease prevention. That is already indicated in the respective regulations. You have to meet different development requirements if you want to have a vaccine approved than if you want to have a cancer drug approved. That has already been taken into account by the regulatory guidelines. However, safety and efficacy has to be demonstrated for any drug, regardless if it is a cancer drug or a vaccine.

Do we even need phase III trials?

That is a very interesting question. Phase III trials are there to really confirm the efficacy of a drug. It depends very much on what the phase III trials look like and how many patients they include, how big they have to be, and how long they last. That depends very much on the indication. In the end, 40,000 patients were included in the COVID-19 vaccine trials, which is really a lot and in a very, very short time. The patients were recruited in approximately four months, which is tremendous. You get data from these studies very quickly because the immune response to the vaccine, which is what needs to be recorded, takes place in a few weeks. You can also see whether the patient can be protected from the disease especially well during a pandemic because you can very quickly see whether the patients get infected or not. This is obviously different with cancer drugs. There we are often in the range of several hundred to maybe a thousand patients with phase III trials. Those are much, much smaller numbers. That shows that other standards are applied in life threatening diseases. Of course, an acceptable safety profile has to be ensured, but it is often tested in fewer patients than it is the case, for instance, with vaccines given for disease prevention in healthy subjects or also pain pills or diabetes medications, which are taken daily for years or decades. In addition, the relevant outcome with cancer drugs is often survival. You want to know whether a patient survives longer with treatment A than treatment B or the standard treatment. Thankfully, these patients often survive another year, two years, or five years. You have to wait for that data. That means the time it takes to get the results is very different than with vaccines, for instance, where you see the results very quickly. Time and scale are the factors that make things costly and time-consuming in the end. And it takes time before these drugs are available and can be approved.

The general public is currently learning a lot about clinical trials and drug development. Are you experiencing a certain change in acceptance and the willingness to participate in clinical trials?

I don't know if the population is really learning that much about clinical trials right now. There is, of course, constant media coverage about the vaccines. But only a small portion of the population has a basic understanding of how drug development works. There are always different groups. Some are very enthusiastic about innovation and research, who would also participate in clinical trials and are very interested in the subject. Then there is a large group in the middle who pay attention but do not really concern themselves with it personally. And then there are

always the skeptics, who are also very skeptical in clinical trials.

How could we increase that willingness?

I don't believe that can be done easily and quickly. One would have to educate people starting broadly, for example deal with this topic early in biology classes in schools and try to dispel this skepticism that people have by serious communication of drug development and clinical trials in the media.

Can speed in the approval of new active ingredients only come at the cost of safety, or what factors need to be adjusted to bring drugs to the market quickly and safely?

That is a very exciting question, and it entails many factors, in my opinion. I would divide this into different phases of development. First, there is the development phase of a candidate drug until it has really been tested in the clinical trial to the point where it has met the approval requirements. That is, of course, the longest and most expensive phase. Then, comes the approval process. Here you can see on the basis of the vaccines that with the so-called rolling review - in which data can be submitted permanently by the companies and the authority looks at these ongoing - the speed could be improved. There are already faster approval processes for cancer drugs. These usually last six to twelve months. Here there is not as much leeway as in other areas. A more important point is also how long it takes for the drug to actually come onto the market after approval. There are huge country-specific differences here. We are fast here in Germany. It usually takes from about one to a few months. In other countries, it can take years because even more regulatory and healthcare system-mandated steps are required.

So the accelerated speed we have just witnessed with the development of the SARS-CoV-2 vaccine will never become the standard?

I don't believe that will become the standard for all kind of drugs. In addition, the COVID-19 vaccine development did not start from scratch; rather, a new antigen was used on a fully established platform. Knowledge and experience had already been acquired in advance and the time to read-out is generally fast for vaccine trials. So I don't think that can become a standard procedure.

What is your vision for future trial models? What is needed so that innovative and more effective drugs and treatments reach the patients more quickly and also more safely?

I don't even believe that the trial models need to change. The models are relatively mature. Maybe at one point or another you could still save time or costs. But in principle, testing first the safety, then the correct dosage, and then the efficacy is a very well-established model, in my opinion. What we should really value, however, is the excellent fundamental research to identify which patients might particularly benefit from a treatment. Moving even further away from the scat-

tershot approach and much more toward truly personalized approaches. This could lead to real improvement. We have also seen the importance of resource allocation and the social mandate in the development of the vaccine. If something is important to society, it can be done faster. I believe the social dialogue should be spurred toward things that are really needed by society so we can move them forward quickly. There are, of course, technologies like artificial intelligence which could improve or accelerate some things. There are approaches, even when it comes to such subjective things as pain or itching, which are hard to measure. We considered this ourselves in one trial. For example, one could imagine using wristbands that record movement. You would see if a patient itched themselves five times throughout the day, or three times, or not at all. Such things will bring innovations. But overall, I think the models are very good so far.


How do you rate the interdisciplinary interaction now, in the pandemic?

The exchange was already taking place because, originally, this RNA fractionation came out of the field of cancer research. The idea was to use RNA from tumors to generate an immune response. This is what made it possible to pivot to development so quickly. I think the exchange is good, and it should continue like this. The scientists work well together.

Listen to the interview with
Dr. Susanne Danhauser-Riedl from our
Bio^M podcast series *Biotech Talk aus
Bayern* in German under:

[www.bio-m.org/Podcast/Interview_
Danhauser-Riedl_DE](http://www.bio-m.org/Podcast/Interview_Danhauser-Riedl_DE)





Integrated drug and medical device solutions to help you advance your **development project every leg of the journey**

KLIFO is a **leading European drug development consultancy** built on expertise and deep experience in helping biotech and pharmaceutical companies advance their drug and medical device development projects.

We offer a range of **consulting and operational services** and work closely with you to deliver **customised solutions to fit your project.**

**CMC
DEVELOPMENT
SOLUTIONS**

**REGULATORY
AFFAIRS
SOLUTIONS**

**DRUG
DEVELOPMENT
CONSULTING**

**CLINICAL
OPERATIONS
SOLUTIONS**

**CLINICAL
TRIAL SUPPLY
SOLUTIONS**

**QUALITY
ASSURANCE
SOLUTIONS**

**PHARMACOVIGILANCE
SOLUTIONS**



OFFICES IN FOUR
EUROPEAN LIFE
SCIENCE HUBS

25+



25+ YEARS
OF EXPERIENCE



MORE THAN 150
HIGHLY QUALIFIED STAFF

 **KLIFO**

KLIFO GmbH
Heimeranstr. 35
80339 München
Deutschland
T: +49 (0)89 89 52 86-0
F: +49 89 89 52 86 66

klifo.com

BOOM IN BIOTECH DUE TO COVID-19?

Hardly any industry has received as much attention due to the coronavirus pandemic as biotechnology. Yet, will the industry be able to profit from this in the long term? Despite a record level of financing in 2020, funding opportunities for the German biotech industry remain critical.



**MICHAEL
MOTSCHMANN**

General Partner and Board
Member of MIG Capital AG
as well as early investor at
BioNTech

© MIG Capital AG

Bio^M: Mr. Motschmann, you're a General Partner and Board Chairman at MIG Capital AG. Through various MIG funds you provide financing to entrepreneurs and young companies at different stages of their development. What must a start-up have – besides excellent scientific data – to win over you as an investor?

Michael Motschmann: First and foremost, like an entrepreneur, you have to think with the end goal in mind. This means I'm looking for a sophisticated and attractive business model, a comprehensible business plan up to realization of this business model, and – as you have rightly pointed out – enthusiastic yet modest managers who want to and can implement this plan. At least in our view.

BioNTech, which is actually a biotech company that develops personalized cancer treatments, has achieved worldwide renown over for its coronavirus vaccine. You recognized the Mainz-based company's potential very early on. As early as 2008, BioNTech received investments from the Strüngmann brothers and from three MIG funds that you manage. What was it about BioNTech's mRNA technology that convinced you at the time?

In this case we have to look at the broader context. Our involvement with BioNTech actually began two years prior, in 2006, when I met the two founders Özlem Türeci and Uğur Şahin through their very first company, Ganymed. Ganymed Pharmaceuticals was an antibody company in which we invested in 2007 and which we successfully sold to Astellas in 2016. It was in this context that I got the Strüngmann family involved in this investment in Ganymed. Then, getting to know Uğur Şahin and his visions, I felt more and more fascination over the coming months to implement further things. This resulted in BioNTech being founded in 2008. I found it fascinating how all decisions were based on and then made subordinate to this long-term goal. Of course, Uğur Şahin and Özlem Türeci are impressive people in their own right: highly intelligent, modest, ever curious, and able to learn. I really think they're a great team, so I quickly decided to become a founding investor in the company.

The coronavirus pandemic provided a major impetus not just to BioNTech and other vaccine manufacturers, but also to the entire biotech industry. Do you think that, in the future, companies in this sector will have an easier time finding parties interested in making considerably sized investments?

Well, if the companies take the right approach, then yes. Even the investors who thought biotechnology was a very risky billion-dollar grave have woken up. Now some of them are willing to invest in biotechnology. It's more widely understood that these industry risks are more manageable than they were, say, 20 years ago. We're seeing the start of the second wave or generation of biotechnology entrepreneurs: People who have seen their projects collapse and now have a better idea on how to succeed. And it's not a negative thing to fail at something and then get back up on your feet. People need to be given the chance to get back on their feet.

In your opinion, how long will the pandemic-fuelled boost in the biotech industry last?

I think it depends on whether, and to what extent, the industry learns from the BioNTech success stories. In my opinion, a strong emphasis on the product and its market is crucial, along with far-reaching vision for the necessary resources. By that I mean, for example at BioNTech, big data, data analytics, artificial intelligence, machine learning, robotics, automation – all of these are relevant within the industry. Always staying agnostic when it comes to the technology, as I mentioned earlier. No vanity concerning the origin of these technologies, quick decisions, and actually making decisions. It's better to be incorrect, correct yourself, and then take the right path. That's what it means to make a decision. Clarity and acceptance that it can and will take a long time. And all of us who have worked in biotechnology for years know that it will always ultimately be a little more expensive.

BioNTech originated with funding under the GO-Bio initiative from the German Federal Ministry of Education and Research, which funds entrepreneurial researchers with innovative ideas from the life sciences. This program was put on hold in 2018. What does BioNTech's success say about the suspension of this funding program?

GO-Bio was an outstanding program that was managed very, very well. From early on, it showed founders the high standards that professional investors hold and gave rise to excellent teams because of its selection process. Personally, I find it regrettable that this program isn't around anymore, and in my view, consideration should be given to reinstating it.

To what extent should policy support and promote innovation?

To the greatest extent possible. That's a rather bold and generic statement, of course. But here's what I mean by that. If Germany wants to play

a serious role as an international leader in technology, our government must reach a broad consensus, regardless of the party leading the way. It's a matter that concerns society as a whole. Only if innovation – including outside of biotechnology – is explicitly seen as a pillar of our future economy can the funding be provided by lower-level bodies, both large and small. It's really about achieving a general social consensus. One good example in which you can see the potential that this holds is ESG, which concerns matters of sustainability such as climate protection. It illustrates what can be achieved when you really strive for something. And to return to the issue of COVID-19, the development of the Comirnaty vaccine from BioNTech shows what can be achieved in our society when everybody shares a common goal. Nobody would have thought that within ten months, the most successful and perhaps the best vaccine in the world would come from Germany, in the form of a technology lacking validation among products already on the market.

As is often the case in fundamental research, a research grant does not usually cover the typically later, cost-intensive phase of pharmaceutical development. How can the conditions for growth financing in Germany be improved so that investors can invest more money in biotech firms?

It's a very broad field, of course. For example, the tax recognition of investments through immediate write-offs, entirely or partially – i.e. taxation only in the event of success – is one possible fiscal approach to this. The second request is for bailouts on tax losses carried forward when owners are changed. That's an important topic, I believe we've been discussing it for decades. I think the taxation of ESOPs, meaning the stock option programs these young companies set up, is an important point. They should be taxed as capital gains and not as income, i.e. at a different tax rate. And one final point that's very important to me is a possible change to stock corporation law, such that stock options can also be given to supervisory boards in large biotechnology companies because it is the only way they can attract the members necessary for those boards. At some point the risk people take has to be proportionate to the upside that they thus stand to gain.

Why is it so much easier for investors from the US than it is for German investors to invest large sums of venture capital in young companies?

This response could be summed up under the term "ecosystem." The USA has a completely different ecosystem. There's more money in the market, such as in pension funds, hedge funds, crossover investors, foundations. It boasts a functioning capital market with a considerably higher share quota than in Germany. In Germany, our problem is that private investors have too few shares in their portfolios. When it comes to the economy, a higher share quota is an important point that I would like to address here – and not just for this reason. I think that, with regard to our retirement planning, a higher share quota and trust in our own economy is crucial. Of course, they are more willing to take risks over there. This openness to risks has developed over time because they have more experience. So it's easier to assess the risk. And the investment banks have outstanding, highly qualified analysts. That's something that


we in Germany – just think of the years 2000 and beyond – have lost, unfortunately, because all the banks' equity capital market departments and analyst teams were downsized. After there were fewer initial public offerings on German trading floors, the banks took action. Just as they expanded drastically in the late '90s, they drastically drew back in the early 2000s. And so there's a whole other approach to biotechnology, or young technology. That doesn't apply only to biotechnology, but also extends to many, many fields of technology. This is a challenge to us all. What I mean is: the challenge of giving this technology a crucial position with regard to future technologies is one for us all. You cannot forget that humanity's greatest challenge after the war – which the pandemic certainly is – was resolved by science, and specifically biotechnology. When you look at the opportunities we have in Germany and how little arose from these chances in the past 20 years, it's a shame on the one hand, and on the other hand a logical approach to changing course and daring to have more faith in our technology and our entrepreneurs. This will pay off in the end, and ultimately it's about transforming our economy.

Read the full interview with
Michael Motschmann from our Bio^M
podcast series *Biotech Talk aus
Bayern* under:

www.bio-m.org/Podcast/Interview_Motschmann_EN



Committed to delivering breakthrough therapies.



MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. More information at www.morphosys.com.

morphosys
Engineering the Medicines of Tomorrow



BAVARIA'S STRENGTH AGAINST COVID-19

Success in Diagnostics, Vaccines and Drug Development

Biotechnology is on the front lines in the fight against the coronavirus pandemic. From the very first day, numerous Bavarian companies and research teams have been driving innovative research in the development of testing systems and vaccine candidates as well as drug development, with positive results.

World-Class Testing

The Munich start-up **GeneSurge** was the only company from continental Europe to reach the finals in the international XPRIZE Rapid Covid Testing competition with a prize fund of USD six million.

To successfully contain and manage the spread of infection, it is crucial to have not only general evidence of a SARS-CoV-2 infection but also the genetic analysis of the virus strain. This is especially relevant with regard to the spread of significantly more infectious virus variants. That's where the new analysis technique from the company **baseclick** in Neuried comes in. It provides a precise genomic classification of emerging new mutations as well as an assessment of the frequency of new mutations in the population.

Bavarian companies have also been active since the beginning of the pandemic in the detection of antibodies that are formed as a reaction to a SARS-CoV-2 infection. After the presentation of its RT-PCR tests as proof of an acute SARS-CoV-2 infection in March 2020, **Mikrogen**, Bavaria's oldest biotechnology company, was able to launch a highly-specific serological antibody test to identify antibodies against the SARS-CoV-2 virus in April 2020. The company has also developed a PCR test to monitor mutations or so-called "variants of concern."

The antibody test RACORDIAX from the Munich company **BacTrace BioTec** provides a sophisticated analysis system that determines the current status of an infection or the subsequent immune status of the test person in detail.

In 2020, **Roche Diagnostics** launched a SARS-CoV-2-antibody test as well as an antigen rapid test and expanded its portfolio in 2021 with a PCR test for SARS-CoV-2 mutations and a rapid test for self-testing.

To better monitor the disease progression of COVID-19 patients, especially in home isolation, a team of researchers at the **Technical University of Munich** has developed an ear sensor to monitor the patients' condition. Similar to a hearing aid worn in the ear canal, it records important data such as temperature, heart rate, breathing, and oxygen saturation every 15 minutes. A study of 150 patients demonstrated that COVID-19 risk patients can be effectively monitored by telemedicine, potentially saving resources in future waves of infection.

BayTherapie2020 Funding Program

In addition to innovative analysis measures, there is a wide range of excellent therapeutic developers in Bavaria. However, their projects cannot be implemented without financial support. Twenty-two outstanding Bavarian therapy concepts were submitted as part of the BayTherapie2020 funding measure. The Bavarian funding package offers EUR 50 million to support companies in the development of therapeutics against COVID-19.


The first funding grant under the Bavarian Therapy Strategy went to **Pieris Pharmaceuticals** from Hallbergmoos near Munich. Pieris intends to use the EUR 14.2 million to accelerate the clinical development of its product candidate, an inhalable therapeutic agent for the treatment of SARS-CoV-2-induced lung damage. Other research grants went to Martinsried companies **Formycon**, **ethris**, and **Origenis**. Formycon developed the SARS-CoV-2 blocker FYB207, a promising antiviral drug candidate for the treatment of infections by current and future



© Nanostruct

"Looking back, 2020/21 were exciting and challenging years for NanoStruct, not just due to the pandemic. I think we are on a good track when I consider our highlights: We assembled a highly motivated, skilled and interdisciplinary team, founded our company, were among the top ten of the Science4LifeVenture Cup and even won the North Bavarian Business Plan Competition. The next step is to conclude equity capital financing. Thus, we are currently looking for capital providers to push our innovation forward. And to be honest: I can't wait for what the future might hold for us."

DR. THIEN ANH LE
Co-Founder NanoStruct GmbH



coronaviruses. With ETH47, ethris is developing an inhaled mRNA therapeutic whose mode of action works independent of virus mutations. Origenis is working on the development of a drug that is designed to suppress virus replication in the body.

Triggered by the funding measures of the Free State of Bavaria, the federal government shortly followed suit with a EUR 50 million funding program. **Eisbach Bio** from Martinsried and **Explicit Pharma** from Hohenbrunn are now being funded with nearly EUR 8 million and EUR 4.2 million, respectively, by the Federal Ministry of Education and Research (BMBF). The biotechnology company Eisbach Bio, just founded in 2019, is developing a new class of drugs that inhibit viral replication or interfere with the cells' own mechanisms that can trigger other serious diseases. Explicit Pharma is coordinating trials of its inhalable drug that is intended to prevent severe lung damage from COVID-19.

Professor Horst Domdey, CEO of BioM, says: "Despite the availability of vaccines against COVID-19, the development of effective and safe drugs is of central importance. Bavarian biotechnology has once again demonstrated its innovative power impressively with the funding of outstanding therapy projects."



Hubert Aiwanger, Bavarian State Minister of Economic Affairs (left), hands over the funding notification as part of the Bavarian Therapy Strategy to Dr. Hitto Kaufmann, CSO and Head of the Pieris research and development site. Photo: StMWiE. Neureuther



© Nanion Technologies

"The challenges posed by the pandemic clearly demonstrate the need and importance of drug development, biotechnology and especially new diagnostics. Nanion also had to deal with the new circumstances, but the demand for our analytical instruments for membrane proteins has definitely continued to grow worldwide and has led to corresponding growth for Nanion."

DR. NIELS FERTIG
CEO Nanion Technologies GmbH

Vaccine Development

Over 12,000 variants of the coronavirus were identified in 2020 alone. Therefore, the company **baseclick** from Neuried is already working on second-generation vaccines, which are also highly effective against mutations of the virus. The company **Bavarian Nordic** located in Martinsried is also already in the clinical trials phase with a vaccine candidate. The company **Leukocare**, also located in Martinsried, is developing a new adenoviral, vector-based vaccine against COVID-19 with its partners Univercells (Belgium) and ReiThera (Italy). Leukocare is contributing to the process of pharmaceutical development in this pan-European consortium with a liquid vaccine formulation.

The research and development departments of biotechnology companies are working at full speed on new and, above all, innovative ideas to put a stop to the virus — from Bavaria to the whole world.



© Mikrogen

"The pandemic has sparked a tremendous momentum at our company to provide numerous diagnostic solutions with utmost haste. Many scientific collaborations have arisen, thereby stimulating product development, in fact firing it up."

DR. ERWIN SOUTSCHEK
CEO Mikrogen GmbH



COVID-19 COMPANY SURVEY

How the Pandemic shapes the Bavarian Biotech Landscape – a Snapshot

In early 2020, the SARS-CoV-2 virus was recognized as the cause of the COVID-19 infectious disease. On March 11, 2020, COVID-19 was classified as a pandemic, following the global spread of infections. During this coronavirus pandemic, the biotechnology and pharmaceutical industry, in particular – received new and increased attention from society and politics. The immense impact of the pandemic on almost all areas of life has made people more aware of the industry’s importance. From identifying the virus genome and developing detection methods and therapeutics to delivering the first vaccines at an unprecedented pace, the industry has put tremendous effort into tackling the pandemic.

What pandemic-related challenges do biotech and pharmaceutical corporations in Bavaria need to overcome, and is the heightened level of attention from policymakers and society in general giving rise to additional opportunities? What support does the industry need, and how many companies are even dealing with the various pandemic-related issues? To get answers to these questions (as well as others), BioM conducted an initial survey among companies in the Bavarian biotech cluster in May 2020, and then repeated the survey in 2021. We present the results from the 2021 survey below.

Companies surveyed

The survey reached representatives of all company sizes and sectors of the biotechnology cluster in Bavaria. The responses were composed according to the cluster structure and came mainly from companies in the biotechnology and pharmaceutical sectors - followed by CROs, suppliers and digital health companies.

Overall, 21% of the participating companies expressed concern relating to the coronavirus pandemic and the consequences that it could have for them. This is significantly lower than it was in the previous year, where one-half of the companies surveyed expressed similar concern.

Challenges and Measures

The particular challenges mentioned included bottlenecks in the supply chain and the organization of work processes, home office and childcare, and hygiene measures in the company, as well as the delay of clinical studies. In the 2020 survey, 53% of the companies had already indicated that it was a challenge to organize childcare. However, it is clear that the difficulties due to bottlenecks in the supply chain have become signifi-

cantly worse. Whereas 33% of the participating companies cited this as a challenge in 2020, that number rose to 57% in 2021.

In order to adapt to the new reality brought about by the pandemic – both in the economic environment and due to changes in the political framework requirements – the biotechnology and pharmaceutical companies adopted an exceptionally diverse array of measures. On the one hand, these are related to production, with 25% of the companies responding with an increase in their production output and 2% with a reduction and 25% of the companies changing their supply chains or production routes. On the other hand, staff-related measures were adopted, whereby 20% of the participating companies brought on additional personnel, 8% hired short-time work, and 2% had business-related layoffs.

Sales Development and Financing


When asked how company orders (measured in terms of sales) had been affected since the start of the coronavirus pandemic, 38% of the responding companies reported that they had seen an increase in sales. 31% did not notice any impact, and 33% had to cope with decreases in sales, which in some cases were quite significant.

In light of such, 15% of the companies requested financial assistance from the Free State of Bavaria or the German federal government (or at least plan to do so). All applicants stated that they had received the requested financial aid, but two-thirds did not consider them sufficient to secure their business.

Wishes and Demands of Bavarian Companies in the Coronavirus Pandemic:

- Financial support for projects not related to the coronavirus as well
- More accessible laboratory areas
- Reliable framework requirements
- Improvement of childcare


Business Concern about the Pandemic



79%
of the responding companies are not concerned.

21%
of the responding companies are concerned.

Sales Development




33%
of the responding companies
had declining sales

38%
of the responding companies
had increasing sales

COVID-19 relevant Products/Services


(Multiple answers were possible)



67%
of the responding companies
are involved in COVID-19
product development

Challenges

(Multiple answers were possible)



You can find the entire survey at:

www.bio-m.org/BioM_Company_Survey_COVID-19_2021



PANDEMIC RESEARCH & INFECTION MEDICINE: ROCHE AND FRAUNHOFER IN PENZBERG

A new campus for infection, immune and pandemic research is planned in Penzberg, Germany, south of Munich. The new facility of the Fraunhofer-Gesellschaft wants to investigate the role of the immune system in infectious diseases, in cooperation with Roche and the Ludwig-Maximilians-Universität München.



CLAUS HABERDA
Managing Director of
Roche Diagnostics GmbH

© Roche

Bio^M: At the beginning of 2021, the Fraunhofer-Gesellschaft presented the plans for the project, along with its future partners and political representatives. As one of the largest biotechnology centers in Europe, what role does Roche Penzberg play in setting up this new institute as a strategic partner?

Claus Haberdä: As a strategic partner, we have three roles to play in this constellation. On the one hand, we see ourselves as obstetricians, among many. The original idea of locating a Fraunhofer Institute in Penzberg in the Nonnenwald next to Roche arose on May 4, 2020, when Roche launched a necessary antibody test for COVID-19 in just 4 weeks, after a very, very fast development period, and communicated this to Penzberg. Politicians have become aware of how beneficial it is when important players in the health care system work closely together and cooperate with each other. This led to the birth of this idea. The second role as a strategic partner is, of course, that we are now also getting involved in specific projects, and indeed attempting to answer epidemiological and immunological questions that arise in the context of a pandemic. And the third role is now, actually to get the whole thing going. We are providing space on our campus, infrastructure and laboratory rooms for the first working groups. Fraunhofer will need another year or two before they have really built a new research institute here in the Nonnenwald.

A total of around EUR 80 million is to be invested in the implementation of the concept. The federal government and the state of Bavaria are sharing the costs equally. What goals and opportunities do you see for the Roche Penzberg site and also for the Munich Metropolitan Region?

We are a location with 7,000 employees, but are somewhat isolated from Munich in Penzberg, and anticipate a different level of visibility through the involvement of the Fraunhofer Institute. I believe that we can really position Penzberg as a science location and then contribute to making the existing jobs more attractive, but also future jobs – that we may also serve as a magnet for the settlement of other players such

as startups or other research institutes. I think this simply creates a certain attractiveness, while benefiting the city, the region, and also Roche and Fraunhofer. And then “innovation made in Bavaria”, of course.

As you mentioned it briefly, is there currently a focus on any certain indications?

Our first strategic project with Fraunhofer will now be the identification of new pandemic pathogens. “What might be possible candidates?” is, I believe, an important question if you want to fight pandemics and then also accompany them epidemiologically. Which viruses, which pathogens are next door, so to speak? And for this, we want to develop a toolbox that helps to diagnose and identify the whole thing.

At the presentation, you described the project as a showcase project, both in terms of content and speed. What does the further implementation of the plan look like in concrete terms?

What impressed me at the time and still impresses me today is really the speed with which politicians reacted to the situation and saw this opportunity to establish a Fraunhofer Institute in Penzberg, and how quickly financial resources were made available and how quickly we also made progress in terms of content in describing the first concrete projects. We would now like to maintain this momentum. This is why we are planning the first research activities this year. To support this, the Fraunhofer Institute will set up the first working groups on the Roche Campus, because Fraunhofer will not be able to build its own research building in Penzberg in Nonnenwald that quickly. It just takes three or four years. In this respect, we really want to continue to use the momentum created by the pandemic and start working this year.

What does the alliance with Fraunhofer, but also with the Ludwig-Maximilians-Universität München, mean for Roche? How will the cooperation work in concrete terms?

Specifically, we are looking forward to getting new partners at the Penzberg location. Through the Fraunhofer Institute, we also have access to the Ludwig-Maximilians-Universität München (LMU). They, in turn have a very, very large number of clinical beds, which will then be available for us. This is the so-called “test bed”, with which we can then also work. This is also attractive because modern medical research is also digital research. The data generated there offers enormous added value to accelerate research and development. With 3,000 beds, LMU is really a very important strategic partner in this network of LMU, Fraunhofer and Roche.

The partnership between Fraunhofer and Roche or the LMU is intended to be a seeding mechanism for the settlement of further companies, and thus further cooperation partners. From your point of view, how can the region become such an innovation ecosystem? Do locations such as the Martinsried campus also play a role here?

I really see this as an ecosystem, and ecosystems can also be large-scale. We have now also learned that you can bridge distances and design a lot virtually. Nevertheless, the daily exchanges between researchers on campus and the spontaneous, creative innovation that arises when you run into someone in the hallway is very important to encourage dynamic innovation. In this respect, we should really see this close spatial proximity in Nonnenwald and in Penzberg between Fraunhofer and Roche as a seeding engine for something that can then expand and grow. I see it a bit like the spider in the web. We are now forming the inner spider web here, and then hoping that an ecosystem will develop around it. And Martinsried certainly belongs to this ecosystem, as does LMU. We also cooperate with the Technical University of Munich. We are extremely versatile and have no dogmas about who we work with and who we don't. In the end, it is the cutting-edge science that really counts, which hopefully makes everything meaningful for the patient.

With the concept of the new Fraunhofer Institute for Infection, Immune and Pandemic Research in Penzberg, a forward-looking bundling of therapeutics, diagnostics and digitization is going to take place. Where do you see Roche's strengths and competencies in efficiently connecting these areas?

Here we see ourselves more or less as a natural partner. Roche has been around for 125 years, and the Penzberg site has been around for 50 years. What we do in Penzberg is research, development and production for therapy and diagnosis. We refer to this whole concept using the term personalized medicine and personalized healthcare. These three pillars of research, development, production for diagnosis and therapy is exactly what we need now to be able to fight pandemics. In this respect, we see a huge synergy potential here to further advance something like this with Fraunhofer in Penzberg, because we actually have everything we need at the location.

To what extent will Roche itself invest money in the project?

Clearly, we will also spend money on the project. However, not for the construction of the new Fraunhofer institute building. Fraunhofer will finance this independently – of course supported by state and federal funds. After all, the EUR 80 million is also budgeted for the next five years. But, for example, Roche is of course also financing the joint research projects. We will provide employees, resources and infrastructure, and thus indirectly invest in this joint cooperation.

How do you see the longer-term development of the project, i.e. beyond the next five years?

I hope that this joint cooperation will also attract new fields of work to the location. On the Roche side, we have anchored the topic of gene therapy in Penzberg and will invest EUR 65 million in this over the next two years. Perhaps the cooperation with Fraunhofer and LMU will also raise new questions at the location. This can only help as a nucleus, really like a magnet to bring other institutes, start-ups and stakeholders to the location. In the end, it is of course great for the region, for the Penzberg site, but also for Roche, if cutting-edge research takes place in Penzberg. And imagine when really top-class researchers and developers work in Penzberg, when symposiums and other events take place and other players move into the area. I really see a nucleus of a new science center in Penzberg beginning to germinate here.

Read the full interview with
Claus Haberda from our Bio^M podcast
series *Biotech Talk aus Bayern* under:
www.bio-m.org/Podcast/Interview_Haberda_EN



Mammalian
Bioconjugates
Microbial
mRNA
Licensing
Drug product

Lonza
Biologics

» Active at every stage

With a 30+ year track record of powerful, proven solutions. From late phase discovery to market supply expertise. Let's do this together.


pharma.lonza.com

»
The people **powering** biologics



ARTIFICIAL INTELLIGENCE IN MEDICINE

How can physicians and, especially, patients take advantage of the enormous potential of artificial intelligence? Prof. Daniel Rückert, Technical University of Munich, explains this, and how we can improve data protection and give patients more control over their own data.



**PROF. DR.
DANIEL RÜCKERT**

Alexander von Humboldt
Professor for Artificial
Intelligence at the
Technical University
of Munich



© TU München

Bio^M: Many people probably already know this: after an injury or during an organ examination, magnetic resonance tomography (MRT) and magnetic resonance imaging (MRI) are particularly precise imaging methods for making a diagnosis. You yourself combine computer science with medicine in your research. What exactly does your research involve and what is your vision?

Prof. Dr. Daniel Rückert: Our research involves the use of artificial intelligence, or AI for short, to extract as much information as possible from medical images. We can then make these available to the radiologist in order to make the best possible diagnoses and predictions about the progression of diseases in patients. Our goal is that artificial intelligence becomes one of the most important tools for radiologists to generate as much information as possible from medical data.

In September 2021, you took one of the first two Alexander von Humboldt professorships for Artificial Intelligence in Germany at the Technical University of Munich. The Alexander von Humboldt Foundation wants to attract top scientists to Germany by offering substantial research funding. In addition to the financial resources, what attracted you to accept this professorship?

One of the aspects I found most attractive at the TU in Munich is the opportunity to work in an interdisciplinary manner. An important topic that we deal with is bringing computer scientists together with physicians and jointly researching problems and solutions to these problems. That's only possible if you bring experts from different disciplines together. The Technical University of Munich is one of the leading universities in Germany that has recognized that such collaboration is absolutely critical and has therefore made it possible for me, for example, to be located in both computer science and medicine at Klinikum Rechts der Isar. I found that to be a very attractive opportunity, and I am now looking forward to working with colleagues from IT and medicine here in Munich.

In order to develop an AI, one needs data, often a lot of data. What are the particular challenges in the medical field?

One of the major challenges in medicine or radiology is that we need data that is annotated by experts. This means that we need not only the original image data for radiological data, for example, but also the associated diagnoses. Of course, this can only be created by experts. That is why it is very time-consuming to collect extremely large amounts of data for which you not only have the image data, but also the diagnoses.

In the case of rare diseases, in particular, there is naturally little patient data. How can it still be possible to develop good AI with little data and thereby enable the most personalized treatment possible?

There are two different strategies for doing this, and I'll try to outline both of them briefly. The first strategy is that you can bring together data from different hospitals, for example, and thus build larger data sets. Of course, even at a large university hospital like the Klinikum Rechts der Isar, only a certain number of patients come to the hospital for certain diseases per year. But if we look across Germany at how many patients there are with these diseases, we can bring these data sets together and thereby create larger training data sets for artificial intelligence. That is one strategy: by merging more data, I can train the AI better. The other alternative is to enrich the artificial intelligence by not only using data from patients with a certain disease, but also using data from patients with similar diseases and then training the AI to differentiate between these two different diseases, but can still obtain information from both data sets.

Artificial intelligence has enormous application potential in many areas, but there is also uncertainty or skepticism regarding data protection. How can adequate protection, especially of sensitive health data, be guaranteed? Which ethical aspects play a role here?

The ethical side is an important aspect. Ultimately, the patient must remain in control of their data. We need to always keep that in mind as the basis for many of the projects we do. But there are also technical advances in the field of artificial intelligence that allow us to train models with which we can build our artificial intelligence without having to compile all of the data. Instead of collecting data, we can send the models to the data. In this way, the models are improved on-site, i.e. in the hospital where the data is stored. We can then merge the models and integrate them into one large model. These techniques are often referred to as "federated learning". This distributed machine learning and what you can do with it is a technology with which we could perhaps take better account of data protection and therefore allow the patient more control over the data.

In an international comparison, how do you see the situation with regard to the availability of data, especially in Germany with its relatively strict data protection guidelines?

Germany is a leader in many respects. Data protection is very important, and it is really in everyone's consciousness that data protection is a fundamental right that must be respected. At the same time, however, you have to see that Germany is in a way very conservative and careful with data, perhaps also based on past experiences in recent history. Compared to other countries, there is a gap that should be narrowed if you bear in mind the problems that can really be solved with the data. Especially in times of the coronavirus pandemic, there are of course really important aspects of how data can be used for the common good. You have to weigh the two against each other, the rights of the individual to his data and the right of the general public to use the data sensibly.

What are your specific demands on politics in this case? What do we need to create more trust among the population?

My greatest demand or request to politicians would be to address the issue actively. We can only make progress in this area if we consider people and society as a whole. Therefore, I would ask politicians to address this more and to allow more discussions about it – also with regard to what we can do with the data and how great the improvement of the general welfare can potentially be through the intelligent use of data. If politicians can work out this potential better and can also promote it, I think it would help us all a lot.

Ultimately, the application of AI should reach the physicians in order to facilitate and improve diagnoses and thus also treatments. What will it take so that artificial intelligence can actually be used optimally in medical practices and hospitals, especially in diagnostics?

One of the absolute basic requirements for this is a fundamental digitization of all processes that take place in the hospital. I have been at the Klinikum Rechts der Isar for a few months now, and yet I am often surprised at how much is still communicated in paper form or in other non-digital forms, including faxes. Of course, this is one reason why translating artificial intelligence into clinical practice can also be more difficult. It is really absolutely critical that all processes are digitized as much as possible. There's another point I would like to make: it is also very, very important that the information or the data that one wants to use to bring about improvements through AI is collected in a structured manner. That means you have to define very clearly which data you need, which data should flow into the artificial intelligence. The process of data collection must be standardized and run uniformly in medical practices. This standardization has many advantages, i.e. it also makes it possible to monitor the quality of medical care and perhaps also to measure it in the long term – and this can have many positive aspects not only for the physicians but also for the patients.

Where do you think we will be in terms of the application of artificial intelligence in medicine, in imaging but also in other areas, in five years? And also, looking further ahead, in ten years?

I hope that, in medical imaging, in radiology, we will get closer to the process that we already have in other areas, i.e. when you go to your physician now and have blood drawn. The physician sends the blood to a laboratory, where the blood is analyzed by a laboratory device, and a set of parameters or blood values is obtained that the physician can then interpret. I hope that it will also be the case in radiology that, for example, the images can be acquired, automatically analyzed, and parameters can be extracted through artificial intelligence, through intelligent algorithms. The radiologist can concentrate on the interpretation of this data and no longer sits day in and day out in dark rooms in front of light boxes or at the computer screen to annotate images by hand and measure parameters. My vision for the future is – I don't know whether we will achieve this in five years or maybe in ten years – that this process will be much more automated. And I hope that this will then enable the physician to spend a lot more time with the patient.

Read the full interview with
Prof. Daniel Rückert from our Bio^M
podcast series *Biotech Talk aus
Bayern* under:
[www.bio-m.org/Podcast/Interview_
Rueckert_EN](http://www.bio-m.org/Podcast/Interview_Rueckert_EN)



DIGIMED BAYERN

Data-Driven Personalized Medicine



For implementation of innovative solutions in order to improve healthcare for the population, the generation, compilation, and analysis of healthcare data is prerequisite. Big data analyses can significantly contribute to enhancing early detection, diagnostics, and prevention, as well as to developing personalized and thus more efficient therapy solutions. This is especially relevant in the fight against chronic diseases such as diabetes, coronary heart diseases, cancer or rare diseases, which put major pressure on both the patients concerned and on the health system.

DigiMed Bayern, a Lighthouse Project

The so-called P4 medicine (predictive, preventive, personalized, participatory) allows for personalized prevention and individualized treatment for every patient, with greater and proactive involvement of the patients themselves. Based on high quantities and types of medically relevant data, the DigiMed Bayern project is investigating how molecular, environmental, and behavioral factors influence the development of diseases, and how prevention, detection and treatment can be personalized and optimized. The lighthouse project began at the end of 2018 with a funding volume of EUR 22.5 million by the Bavarian State Ministry of Health and Care. It aims to implement and integrate P4 medicine into everyday clinical practice.

DigiMed Bayern focuses on atherosclerosis, the deadliest disease worldwide. In Germany, cardiovascular diseases cause about 40% of all deaths. The five-year research project DigiMed Bayern combines comprehensive clinical and epidemiological data from patients diagnosed with, for example, coronary heart disease, stroke, or genetic risk factors. State-of-the-art molecular “multi-omics” characterization and health insurance data complement this data set. Thus, in this holistically configured project, data is both generated and analyzed from multiple perspectives, using custom-built IT-infrastructure. Where possible, the resulting findings are transferred to the health system as new state-of-the-art scientific understanding, as new diagnostic biomarkers and drug targets, as adaptations to medical guidelines and best practice, and as new tools.

www.digimed-bayern.de and www.myvroni.de

VRONI Study for Improvement in Hypercholesterolem

An individual’s risk of heart attack and stroke is highly relevant for decisions on prevention and treatment. Familial hypercholesterolemia (FH) is the most common monogenic metabolic disease worldwide. Considerably elevated levels of LDL cholesterol in the blood significantly increase the risk of severe cardiovascular events, even from a young age. With early medication and lifestyle adaptations, however, the disease is treatable. Nevertheless, only under 1% of approximately 270,000 FH carriers in Germany are diagnosed and thus adequately treated. As part of the DigiMed Bayern project, the VRONI study is a Bavaria-wide FH screening of children aged five to 14 years. The study was successfully launched in September 2020 in broad collaboration with pediatricians and cardiologists. VRONI is led by Prof. Dr. med. Heribert Schunkert, Medical Director at the German Heart Centre Munich, and by Dr. med. Veronika Sanin from the same leading cardiology clinic.

The aim is to test up to 50,000 children by the end of 2023 for elevated LDL levels – integrated into their regular visits to pediatricians. If their LDL cholesterol levels are elevated, molecular genetic tests are carried out to identify known and novel causative mutations. Further known and yet unknown causative factors are analyzed. All children with hypercholesterolemia, with and without an identified genetic background, are offered therapy options by pediatricians and pediatric cardiologists, including lifestyle support with a novel psycho-educational training program for the family. Through partnership with a nationwide FH screening study and register, parents and other family members also affected by the hereditary disease can be identified and treated. To date, more than 370 pediatricians with over 5,700 children are participating in the VRONI study. In addition to direct benefits for patients, VRONI aims to provide medical education and serve as a model for FH screening and treatment implementation in the German and in international health systems.

HerzFit App for Cardiovascular Risk Assessment and Management

Health data are increasingly collected and used by patients themselves. The rapid development of mobile devices such as smartwatches, and software applications for health, including fitness, nutrition, and well-being, allows people to take their health management more into their own hands. As an additional benefit, the associated collected “real-world data” have great potential for (applied) health research.

In cooperation with the large patient organizations Deutsche Herzstiftung and Deutsche Hochdruckliga, plus support from the insurance company Techniker Krankenkasse, the app “HerzFit” is being developed in collaboration with DigiMed Bayern. Users receive a tool for risk assessment and are encouraged and guided toward positive behavioral changes. This includes fitness, nutrition, quitting smoking, and stress management. The toolbox enables the setting of personal goals, self-monitoring, individual coaching, and education. Lifestyle changes alone could prevent up to 80% of cardiovascular diseases. The public launch of HerzFit, which will be freely available in the common app stores, is currently planned for early 2022.

A GOOD NETWORK IS ESSENTIAL TO A SUCCESSFUL START-UP

Tubulis develops antibody-drug conjugates (ADCs) for the treatment of cancer.

The start-up was awarded the pre-seed competition m⁴ Award coordinated by Bio^M in 2017. In July 2020, the company successfully closed a series A financing of EUR 10.7 million.

**DR. DOMINIK
SCHUMACHER**

Founder and CEO of the
Martinsried based biotech
start-up Tubulis



**DR. JONAS
HELMA-SMETS**

Founder and CSO of the
Martinsried based biotech
start-up Tubulis



Bio^M: *As a spin-off of the Ludwig-Maximilians-Universität München (LMU) and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin (FMP), Tubulis aims to develop gentler and more efficient forms of therapy in the treatment of cancer. What is the special approach of your technology platform and what does it mean for the treatment of patients?*

Dr. Jonas Helma-Smets: The drug class that we are working on are antibody-drug conjugates (ADCs). ADCs are complex biomolecules consisting of antibodies conjugated to a toxic payload. The function of the antibody is to deliver the payload to the target, the tumor cell, facilitating targeted tumor killing while leaving healthy cells unharmed. The big challenge is to attach this toxic payload safely and stably to the antibody. Here lie the weaknesses of previous approaches, namely that these active ingredients are applied in such a way that they do not remain particularly stable on the antibody while being circulated in the blood, but fly off beforehand, and then of course can cause all sorts of harm in the body. As a result, the targeted effect is lost. However, with our technology, it's possible to attach the active substance to the antibody in a much more stable, secure and firm manner, and thus make the delivery of the active substance to the target cell, i.e. the diseased tumor cell, more effective.

A good network is particularly important at the beginning of a business start-up. How did you find the right contacts for general start-up questions as well as to investors?

Dr. Dominik Schumacher: A good network really is essential. From the beginning, it was totally important to both of us to use and expand our network. To accomplish this, it is key to keep talking to people. In addition to that, one shouldn't be afraid of hearing a negative opinion about his plans or technologies. That's also very important to understand the market and its needs. Very early on, still being at academia, we started building our network. It is a process that takes many years.

Were there any concerns about getting a start-up off the ground?

Dr. Schumacher: Concerns are part of it. I think this is a very important process. I wouldn't go so far as to say that I had doubts about continuing. Our network has always been an essential part for both of us to understand the market and work with potential concerns. Trying to get the appropriate input from the network, an external validation, and going out and asking, is that a good idea or do we still have to fine-tune our concept? We did this very intensively, for example, in 2016, and also through the EIT Health program. This is a Europe-wide network for life science start-ups, supported by the European Union. Many industrial partners and universities are also involved. This program enabled us to speak with over 100 people who are particularly relevant to our idea. At that time, our idea significantly matured from a scientific concept and received market validation. In the end, people really wanted to work with us.

Was there also input from the non-academic side, from the non-start-up area, or from the non-biologist area?

Dr. Schumacher: There was also input from completely different areas. Among other things, we received a lot of input from Bio^M and attended seminars and had training courses. One example is that we have gathered lots of input on how to describe and pitch the company, our technology, and products. At EIT Health, we have been the only biotech company pitching to MedTech folks. We – back then very science focused – thought we were already totally awesome in telling our story and that everybody would understand our pitch – and we were totally wrong. At the beginning they always just looked at us and asked: What do you do? That sounds really exciting, but I don't really understand what you do. It took about two weeks for us to fine-tune and improve our story and in the end everybody understood what we are all about. I would say that this is a process that we're still going through today. Every day we learn how to tell our story a little better. In addition to this, getting validation from external sources is incredibly important for a variety of reasons: Having external feedback, approval or validation helps people or even potential investors to believe in your technology. But it can also support you in early realizing that you are going in a wrong direction and need to change strategy.

Have investors sometimes been amazed at how things are progressing at your company?

Dr. Schumacher: I think they appreciate that we are open to making strategic adjustments when required, do not shy away from these processes. But also to say we still have a gap in the team, in management, and we are filling it now. I think that's one of the reasons we have been successful in the end.

And belief in the idea is of course very important, also from the outside.

Dr. Schumacher: Yes, exactly. This is of course a basic requirement for having a technology that has real potential. But that is not enough. One also needs a convincing concept. How can I use this technology? And how do I want to bring it to market? How do I really want to use this technology to help ensure that, at the end of the day, we have better drugs and can generate added value for patients? These are things one continuously needs to consider. This is also one of our main drivers. That's the reason why we started – the idea that you can create something of your own and transform it to something meaningful for our society.

What was the biggest hurdle so far that you have successfully overcome?

Dr. Schumacher: I don't think there was a single major hurdle. Rather, there are many hurdles, many ups and downs when you want to build a biotech company. For me, it is always important to carefully consider: For example, what just went wrong or why did it go wrong? What could we have done better? How could we have approached it better? But at the end of the day, it has always been the case that one door closes and another opens. That can be exhausting sometimes, I have to admit, but it's also fun.

An academic career is fundamentally different from that of a business founder. How has your life as an entrepreneur changed from that of a scientist in the meantime?

Dr. Helma-Smets: Both career paths are very appealing, yet very different. The entrepreneurial path is probably unique in that the team effort stands out. Trustful collaboration is a necessity to truly achieve success. That, to me, is its biggest appeal.

Dr. Schumacher: The scientist is all about science, research and discovering new things that might not appear relevant to the market at first. Of course, it's a bit different as an entrepreneur. You immediately have the market mindset and think, how do I place my idea or my development? That's a big difference.

Starting your own and, above all, successful business is the dream of many. Looking back, what would you have done differently and what would you do again? What advice would you offer to prospective founders?

Dr. Schumacher: There are really great, excellent programs in Germany that are set up by the government. For example, BioM's m⁴ program, allowing to translate a project from academia and giving the time to develop it to the point that an investor wants to invest. Since

there's a huge gap between the development status of an academic project and a project successfully funded in a company, I would advise anyone to take advantage of all the unique opportunities we have here in Germany and try to fill this gap. What would I do differently? I would have started asking people what they thought about the idea much earlier.

Dr. Helma-Smets: I would like to point out to future founders that it is important to establish a healthy mix of stubbornness on the one hand, but at the same time also flexibility and the ability to integrate external input and know-how.

Listen to the interview with
**Dr. Dominik Schumacher and
Dr. Jonas Helma-Smets** from our
**Bio^M podcast series *Biotech Talk aus
Bayern*** in German under:
[www.bio-m.org/Podcast/Interview_
Tubulis_DE](http://www.bio-m.org/Podcast/Interview_Tubulis_DE)



Bio^M inQlab

we guide you from idea to success

virtual incubator for the future of medicine



Startup Coaching

get hands-on support



BioEntrepreneur Lounge

join the community



Mentor Circle

inspired by experience



BioAngels

find the right investor



Pitch Doctor

how to convince investors



m⁴ Award

create the future of medicine



BioEntrepreneur Bootcamp

validate your business idea



BioEntrepreneurship Summit

connecting the ecosystem



INTERNATIONAL AFFAIRS

Bio^M takes Gold again



In April 2021, Bio^M Biotech Cluster Development GmbH received the GOLD label of the European Cluster Excellence Initiative (ECEI) for the second time. This award confirms that Bio^M is one of the leading cluster management organizations in Europe.

Overall, Bio^M looks back on more than 20 years of successful innovation support and cluster development. Supported by a strong and long-term commitment of the Bavarian State Government, Bio^M is able to offer an excellent portfolio of services for biotechnology companies of all sizes, especially for start-ups.

The Bio^M cluster was first awarded the ECEI GOLD label in 2013, although at that time the evaluation was focused on a narrower group of cluster stakeholders within the m4 leading-edge cluster on personalized medicine. The evaluation of Bio^M in spring 2021 was conducted for the management of the entire biomedical cluster in the Greater Munich area. The pleasing result: Bio^M received the ECEI GOLD label for the second time.

Excellent performance in many areas

Some aspects of the cluster management were highlighted by the experts with special recognition for the improvements and successes achieved since the first GOLD label. In addition, Bio^M was certified as having “excellent performance” in 21 of the total 31 test indicators.

Contributing factors to the excellence label included the qualifications and experience of the stable cluster management team, with well-addressed staff development and a wide range of training activities. The cluster management team is optimally positioned in terms of size, stability and expertise for the extensive and also complex cluster.

In terms of work structure, the numerous bi-directional contacts between the cluster management team and the cluster stakeholders stand out positively - a very personal feedback mechanism that feeds into the cluster’s strategic decisions.

The cluster itself is characterized by a high level of interactions between cluster actors, with Bio^M being well integrated into the regional innovation system. The systematic analyses regarding trends in the addressed sector and benchmarking with other cluster management organizations are carried out on an international level. The lively exchange process on cross-cluster topics and the coordination of programs between the Munich Bio^M cluster (red biotechnology) and the Erlangen Medical Valley EMN e.V. (MedTech) also received positive recognition.

In addition, the clear and consistent mindset of the cluster management was highlighted, which stands out due to the clear focus of the cluster strategy and its specific fields of action: support for regional and international business development of the companies in the cluster, entrepreneurship and location development (e.g. person-

alized medicine, digital health), in competence building in human resources and in location marketing. In the latter, the cluster’s high profile in publications, the press and the media scored particularly well, especially at the international level.

Continuous Improvement as a Goal

“We are extremely pleased about this recognition, which confirms our work and commitment,” says Dr. Stephanie Wehnelt, manager responsible for the GOLD Label process at Bio^M. “For us, however, being amongst Europe’s top cluster organizations also means continuing to improve and expand our activities and performance. Only in this way we can optimally leverage the innovation potential provided by the local biotech network of industry and science.”

The Cluster Management Excellence Guidelines are internationally recognized. Even for established, mature clusters, professional cluster management makes an important difference in cluster development.

An internationally valid standard for cluster excellence is provided by the European Secretariat for Cluster Analysis (ESCA) in close cooperation with the European Commission. The European Cluster Excellence Label (ECEI) GOLD/SILVER/BRONZE not only provides orientation on how well cluster management is positioned, it also helps to stimulate optimization measures in favor of sustainable cluster growth.

Currently, fewer than 50 cluster management organizations in Europe have been awarded the GOLD label.



DR. STEPHANIE WEHNELT

responsible manager for the Gold Label process at Bio^M

European Clusters joining Forces

Bio^M is a member of CEBR, the Council of European BioRegions. It is a unique network bringing together the managers of health-focused clusters and related life science ecosystems across Europe for the benefit of their regional economies. Together, CEBR represents and supports a critical mass of European SMEs, and hundreds of universities and research centers. Its vision is to strengthen the transfer of knowledge and collaboration between cluster managers, and with this support a sustainable growth for SMEs, creating a competitive Europe in the global economy.

CEBR's mission is to

- create a European platform for cluster network development & collaboration,
- increase the visibility of bioregions,
- highlight the importance of cluster management organizations and their contribution to the sustainable growth of European ecosystems,
- initiate joint activities with the final aim to support SME development.

Bio^M was one of the founders of CEBR and has been an active member since 2013. Being part of larger European networks is an important tool for a cluster management organization to gather valuable knowledge, to optimize one's services, and to achieve a critical mass for lobbying and funding activities.

After a longer time of changes in the leadership and management of the network, CEBR focused on consolidating itself from 2017 to 2019 under the presidency of Dr. Stephanie Wehnelt from Bio^M. During this time, vision, mission and activities were redefined, and the membership grew steadily. Today the network counts 40 clusters across Europe, being a strong base for many joint activities benefiting both, the cluster managers and the companies and entities belonging to their regions. The intensive exchanges between members lead to the formation of new pan-European projects such as the Open Innovation Platform SAFEnmt. SAFEnmt is an open testbed for nano-enabled medical technologies, in which CEBR works closely with key stakeholders in the field. Companies and laboratories offer their capabilities,

knowhow, networks, and services required for the development, testing, assessment, upscaling, and market exploitation of nanotechnology-based medical and diagnostic devices. CEBR also re-launched its Special Interest Groups, in such areas as Internationalization, Digitalization and SME Cascade Funding Schemes, with the aim to optimize the work of cluster management organizations.

In 2020, the focus was set to increase the visibility of CEBR and the important work of cluster management organizations in Europe, especially towards the European Commission. In response to the current pandemic challenge, CEBR also took a very active role in supporting the development of a series of COVID-19 related projects and initiatives, aiming to improve the connection between companies and institutions from the member regions. CEBR co-organizes matchmaking events in cooperation with the European Clusters Alliance and DG Grow to further connect companies across Europe, enabling them to work together in up-scaling vaccines production, as well as for the development of therapeutics.

CEBR has also started a partnership with EIT Health and EIT manufacturing in order to landscape the biomanufacturing capacities throughout Europe. The full map will be made available in the second half of 2021. This will constitute a great step towards working with the clusters and companies across Europe, showcasing the sector's great potential.

The members of CEBR will continue to connect with each other, investigating new opportunities to optimize their own management and on how they best support their ecosystems. Current activities offer sector-relevant information on green transition, new EU funding schemes, soft landing opportunities in key markets, and much more!

Further information on the activities of CEBR can be found on www.cebr.net.





LIFE SCIENCE CENTERS IN BAVARIA

Regional Networks

In Bavaria, a lively and successful biotech scene has established at five locations. Munich, Regensburg, Würzburg, Straubing and the Nuremberg metropolitan region are among the leading locations in the biotech sector in Germany. The neighbourhood of scientific institutions, providers, technology parks and support by cluster organizations creates perfect environments for attracting and founding biotech companies.

The cluster organizations are building a network of companies, universities, research facilities, university hospitals, chambers and associations, investors, funding authorities, advisers, and other players in the clusters.



Würzburg

The Innovation and Start-up Center close to the Julius-Maximilians-University offers lab space and has developed a comprehensive program for promoting start-up activities in the region. Cluster organization: Innovation- and Start-up Center (IGZ) Würzburg
Incubator: IGZ Würzburg (> 5000 sqm)
www.igz.wuerzburg.de

Regensburg

The Innovation center and Start-up Center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services. Cluster organization: BioPark Regensburg for BioRegio Regensburg / Healthcare Regensburg managed by BioPark
Incubator: BioPark Regensburg (>18,000 sqm)
www.bioregio-regensburg.de



Munich

The cluster organization Bio^M is the central point of contact for the biotechnology sector in Munich and Bavaria and is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personalized medicine. Bio^M offers a wide range of services and events and has developed the comprehensive incubation program "inQlab" for company founders in the field of biotechnology.
www.bio-m.org



Industrial Biotechnology in Bavaria

Managed by Industrielle Biotechnologie Bayern Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes and industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint projects in Industrial Biotechnology and sustainable economy.
www.ibbnetzwerk-gmbh.com





Erlangen and Nuremberg

The European Metropolitan Region Nuremberg is an internationally leading location for medical technology. Cluster organization: Medical Valley Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm) www.medical-valley-emn.de

Straubing

The BioCampus in the port of Straubing focuses on creating value from biobased resources, biomass logistics and start-up management. In close vicinity to the TUM Campus Straubing for sustainability and biotechnology, it offers lab space, offices, start-up and business support and industrial plots. Cluster Organization: BioCampus Straubing GmbH Incubator: TGZ Straubing (4.000 sqm) www.hafen-straubing.de



IZB Martinsried and Freising

The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on life sciences) has developed into one of the top biotechnology centers in the world and offers young biotech start-ups 26,000 sqm of modern building infrastructure for biotechnology. www.izb-online.de

EUROPEAN METROPOLITAN REGION MUNICH

An excellent and successful Biotechnology Site

The European Metropolitan Region Munich (EMM) is one of the outstanding locations for the biotechnology and pharmaceutical industry in Germany. The innovative industry makes a significant contribution to the region's economic performance. 21% of the biotechnology companies based in Germany are located in the EMM.

On behalf of the Department of Labor and Economic Development of the City of Munich, Bio^M 2021 prepared the study *Biotechnology and Pharmaceutical Industry in the Munich Metropolitan Region* for the fourth time in order to analyze this important sector of the region's economy and to determine its needs.

While the number of companies is almost the same as it was in 2013, the sector's success is visible in the clear rise in employment numbers and projects in the pipeline.

The majority of companies are optimistic about the future, with 80% expecting their business prospects to improve in the next three-to-five years. When it comes to international markets, 98% of the companies are active in the EU, 63% in the USA, 35% in Japan and 34% in China. These countries are also leaders in other markets of interest to the companies.



© Tourismus Pressestelle München

EMM Success Factors

One focal point of biotechnology and pharmaceutical companies in the EMM is the development of drugs and diagnostics. The majority of substances in clinical development relate to cancer therapy, followed by therapies against autoimmune diseases. As throughout Germany, the product pipeline in the EMM is dominated by biopharmaceuticals and here by the drug class of recombinant antibodies.

Excellent Research Landscape

Generating and sharing knowledge for future innovations is key to a region's success. A number of excellent and renowned universities are based in the EMM, including the Ludwig-Maximilians-Universität München (LMU), the Technical University of Munich (TUM), the Catholic University of Eichstaett-Ingolstadt, and the University of Augsburg. The region has a total of almost 170,000 students, along with scientists at 16 research institutions.

Start-ups

The Munich Metropolitan Region offers entrepreneurs in the biotechnology industry ideal conditions for doing business and is one of Germany's start-up hotspots. 56 biotechnology companies have been founded in the EMM since 2015, and the curve is continuously rising. In addition, seven existing companies have set up branches in the region.

Partnerships

When it comes to cooperation within the biotechnology sector in the EMM, what particularly stood out in the Bio^M survey was cooperation between companies and research institutes based in the region. A large number (around 27%) of those surveyed said they had benefited enormously from the cooperation between industry, research institutions, and universities.

The Appeal of the EMM

The companies clearly feel comfortable at the location: In the current survey, 81% of the companies rated the Munich region as a very good or good biotechnology and pharmaceutical location.

Whether companies settle and remain in a region depends on a variety of factors beyond economic ones. Collaboration between companies, proximity to top-class research and a vibrant network thus make EMM an attractive location for both established companies and the innovative start-up scene. This mix of already successful and new companies, scientific institutions and networks within the EMM forms a reliable, future-oriented foundation for its successful international development as a biotechnology and pharmaceutical location. In addition,



there is the excellent geographical location in the center of Europe. With one of the largest international airports and a high recreational value, the region offers ideal business connections and attracts top international talents as well as local talents.

Challenges

However, biotechnology and pharmaceutical companies in the EMM face various challenges. International pressure from competitors and the difficult German investment climate are two equally prominent examples. There is a shortage of laboratory and office space on a regional level. Bureaucratic obstacles such as the German Foreign Trade and Payments Act have also increased pressure on the industry.

Trends

Its many areas of application and potential for innovation make biotechnology a key cross-sector technology of the 21st century. Nevertheless, the survey showed a clear trend towards personalized medicine, cell and gene therapy, and the use of artificial intelligence and Big Data and digitization in general. Other clear trends included the development of vaccines and immunotherapies.

You can find the entire study in German here:
www.bio-m.org/EMM_BiotechPharma_2021

A detailed summary of the study in English can be found here: www.bio-m.org/EMM_BiotechPharma_2021_Summary_EN



Ihr Hightech-Unternehmen sucht Eigenkapital?

Bayern Kapital bietet:

- Eigenkapital für Seedphase, F&E, Markteinführung und Wachstum
- Co-Investments mit Partnern
- Langjährige Finanzierungserfahrung
- Zugang zu einem starken Netzwerk

**Von der EIB auf
165 Mio. EUR erhöht:
Wachstumsfonds
Bayern**



WWW.BAYERNKAPITAL.DE

Bayern Kapital GmbH | Ländgasse 135 a | 84028 Landshut
Telefon 0871 92325-0 | info@bayernkapital.de



MY REGENSBURG

A Guest Contribution from Dr. Thomas Diefenthal

In 2019 BioPark Regensburg celebrated its 20th anniversary. During this time, the company from the City of Regensburg has supported 64 start-up teams from the life sciences (biotech, pharma, medtech diagnostics). EUR 661 million, including EUR 154 million in venture capital, EUR 326 million in equity and EUR 180 million in funding, were invested in the development – EUR 42 million alone in the three laboratory buildings of the BioPark with a total area of 18,000 sqm. There are currently 35 leaseholders with 718 employees working here. The BioRegion Regensburg Cluster with 61 companies and 4093 employees in Eastern Bavaria is managed from here. Via the Healthcare Regensburg Initiative, the BioPark links the health industry with over five hospitals and over 20,000 employees at the site.



© Bauer.com, Hans Bauer

The secret of success of the boomtown Regensburg with over 150,000 inhabitants has many layers of complexity. On the one hand, there are the two young universities, the University of Regensburg, founded in 1962, and the East Bavarian Technical University of Regensburg, founded in 1971. The 33,000 students not only enliven the cathedral city, which was founded by the Romans and has been a UNESCO World Heritage Site since 2006, but also contribute with their research to the innovation potential of the location. On the other hand, the consistent, cross-party economic development of the City of Regensburg has settled high-tech industries here over the past 25 years and pursued a pioneering cluster policy.

European Clusters, Business Incubators and Tech Campuses

Of the ten municipal cluster initiatives set up here, five have already been certified by the European Cluster Initiative. The city operates two start-up centers with over 30,000 sqm with more than 100 innovative leaseholders on the university campus. A former barracks area right next to it has been successfully converted into a tech campus, where high-tech SMEs have successfully settled.

Life Sciences and AI as focal Points

The location is just the right size to promote interdisciplinary potential between the industries. With several location analyses, BioPark Regensburg GmbH has taken the initiative right from the start. In addition to the life sciences, new cluster initiatives in the areas of sensor technology and healthcare were launched. Most recently, the city used the cross-cluster approach AIR Regensburg (Artificial Intelligence Regensburg) to link the topic of artificial intelligence across industries and clusters.

Start-up Network established

Sandwiched between the top clusters in Munich and Erlangen-Nuremberg, the location has built up its own considerable start-up network. The “Startup Guide Regensburg” published by the BioPark lists 16 institutions and contacts alone. In the BioPark with the experienced Brain 8 Network personalities, mostly former founders and old-hands, are available in-house. With BioPark Jump, an accelerator program has been brought to life to create the best possible start-up conditions for selected teams. Start-up weekends and investor evenings are organized together with the subsidiary company R-tech GmbH at TechBase. The Digital Startup Offensive Upper Palatinate (DGO) is located at TechBase, an initiative funded nationwide by the Bavarian Ministry of Economic Affairs. This has also supported many activities in the BioPark and is an essential reason for the success of the founding State of Bavaria.

Conclusion

I am often asked why successful companies do not move to Munich or abroad. The spirit of the city is deeply rooted. Anyone who has spent a relaxing night in Regensburg’s old town or on the Danube appreciates the manageable, not so large and culturally not too small northernmost city to Italy. If possible, stay true to the location, even if more money could be earned elsewhere.

www.bio regio-regensburg.de



© BioPark Regensburg GmbH, Elisabeth Wiesner

DR. THOMAS DIEFENTHAL

is Managing Director of BioPark Regensburg GmbH and Managing Director of the German Association of Innovation, Technology and Business Incubation Centres (BVI) in Berlin.



THE SUCCESSFUL INNOVATION CENTRE

MADE IN REGENSBURG



Health Industry of Regensburg

- 2.7 billion Euro turnover
- 21.600 employees

Cluster BioRegio Regensburg

- 61 companies
- 4.093 employees

BioPark Regensburg

- 18.000 sqm area
- 35 companies, 718 employees
- 67 start-ups since 1999
- flexible leasehold concept & single offices
- direct motorway connection
- located on the University Campus
- own day-care facility
- conference rooms and theatre

A company of the City of Regensburg



Am BioPark 13 | D-93053 Regensburg | Phone: +49 941 92046-0 | Fax: +49 941 92046-24 | Email: info@biopark-regensburg.de | www.biopark-regensburg.de

GROWTH FACTOR & JOB MOTOR



RESEARCH

2 Universities | Cell therapy
Immunology | Oncology



DEVELOPMENT

50 Companies | Biotech
Medtech | Health IT



HEALTHCARE

Over 20,000 employees
2.7 billion Euro turnover



MAIN FOCUS

Digitalization & AI | Innovation in Nursing
Hygiene and Infection Prevention

The Top Region for **excellence** in science and **innovative** companies:



Profit from the **Healthcare Network** with over 50 companies, five hospitals and two universities.



WÜRZBURG – LIFE SCIENCE & START-UP HUB IN NORTHERN BAVARIA

A Guest Contribution from Dr. Gerhard Frank

With almost 36,000 students, Würzburg (population 130,000) is a young and dynamic city that offers strong potential in the fields of healthcare, biomedicine, and biotechnology, as well as medicine and medical technology. The IGZ Würzburg, the only life science start-up center in Northern Bavaria, and a lively and nationally supra-regionally very well networked start-up ecosystem pave the way for innovative start-ups.

Dynamic economic and scientific Region of international Importance

The medical and healthcare industry is one of the most important growth and key sectors in the economic and scientific region of Würzburg. The presence of two universities and their respective research centers, other non-university research institutions, the strong regional hospital landscape, and innovative medium-sized biotechnology and medical technology companies, as well as their corresponding suppliers, cover almost all stages of the life sciences value chain from the idea to the finished product.

Excellent Scientific Basis in Life Sciences Research

Würzburg's Julius-Maximilians-Universität (JMU), with its research centers, research groups and graduate programs in medicine and the natural and life sciences, is one of the most successful universities in Germany and the world. This is reflected in its current ranking as top 5 university in Germany and top 104 worldwide. First-class research institutions form the basis for the development of new diagnostic and therapeutic procedures. These include the Rudolf Virchow Center for Experimental Biomedicine, where research on key proteins in cancer, cardiovascular, autoimmune and inflammatory diseases is conducted, the German Center for Heart Failure, an integrated research and treatment center for cardiovascular diseases, and the Comprehensive Cancer Center (CCC), an oncological center of excellence. Since 2020, Würzburg, with its partner cities Erlangen, Regensburg, and Augsburg, has been the new location of the National Center for Tumor Diseases. The excellent university research is complemented by the non-university research institutes of the Helmholtz, Max Planck, or Fraunhofer Societies in the fields of regenerative therapies for cancer and musculoskeletal diseases, systems immunology, or RNA-based infection research. It is precisely this area that has gained importance due to the coronavirus pandemic in terms of research into new strategies for the diagnosis and treatment of SARS-CoV-2.

Würzburg as the Start-up Hotspot of Northern Bavaria

Würzburg offers an ideal environment for start-ups from a wide variety of categories and industries, from small graphic design offices to full-blown biotech start-ups. The IGZ Würzburg and its "sister centers," the Technology and Start-up Center (TGZ) Würzburg and the Center for Digital Innovations (ZDI) Mainfranken, are central drivers of the lively start-up support ecosystem (Gründen@Würzburg),

which plays a decisive role. Through a wide range of space, qualification, coaching, and networking opportunities, every founding team will find the right support. Over the past 20 years, Würzburg has developed into the startup hotspot of Northern Bavaria based on the excellent scientific and economic environment, combined with many ideal support structures for founders and start-ups.

20 Years of IGZ Würzburg – Catalyst of the local Life Sciences Start-up Scene

The IGZ Würzburg – the only life science startup center in Northern Bavaria – is celebrating its 20th anniversary this year. As a location partner of the Bavarian Biotechnology Cluster, as well as integrated supra-regional organizations, such as BayStartUP, Bavaria Innovative or the Medical Valley EMN e.V., the IGZ Würzburg offers the regional life sciences teams access to a Bavaria-wide financing and support network. sAs a catalyst of the local life sciences start-up scene, the IGZ Würzburg has accompanied many start-ups since its inception. These include Vaso-pharm, Corimmun, Patrys, TheraMAB, Gilyos, CoBaLT implants, CatalYm, TCUR-X, Cherry Biolabs, DyeNA Genetics and NanoStruct. The latter is still a very young life science company that develops highly sensitive biosensors for Raman spectroscopy and won Phase 3 of the Business Plan Competition Northern Bavaria in July 2021.

www.igz.wuerzburg.de



© IGZ Würzburg

DR. GERHARD FRANK

has been working as a project manager and start-up consultant at the Innovation and Start-up Center (IGZ) Würzburg since 2012. The IGZ Würzburg is the largest start-up center in Lower Franconia with a focus on life sciences.

Die drei Gründerzentren in Würzburg



Life Science



Robotik/
Automatisierung



Digitale
Geschäftsmodelle

Hier entstehen aus Ideen erfolgreiche Unternehmen

www.gruenderzentren-wuerzburg.de



20 Jahre Erfahrung in Innovation





Company Profiles

www.bio-m.org/company-database



Kreillerstrasse 210
D-81825 München
Phone: +49 (0) 163 874 79 75
E-Mail: peter.bristot@21dx.de
Internet: www.21dx.de



Am BioPark 11, BioPark II
D-93053 Regensburg
Phone: +49 (0) 941 20000890
E-Mail: info@2bind.de
Internet: www.2bind.de



Fraunhoferstraße 22
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
E-Mail: public@4sc.com
Internet: www.4sc.com

21Dx GmbH

LIFE SCIENCE / TECHNOLOGY TRANSFER

Keywords: Infectious Diseases, Molecular Diagnostics, Vaccines

21Dx GmbH is a pioneer helping to fight the pandemic with high-quality test and vaccination offers in Germany. Entrepreneurship and experience enable a combination of a fast and custom-fit implementation of all available technologies and end-to-end quality managed processes. We will continue to develop and provide future pandemic solutions, but also strive to deploy our assets and capabilities in the health care systems where they are needed the most.

2bind GmbH

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Small Molecules, Molecular Diagnostics, Peptide/Protein, Bioanalytics, Drug Development, R&D Service

2bind is a provider for biophysical services in early drug development (hit ID, hit validation and characterization) and antibody characterization based on the core technologies MST, Dianthus, nanoDSF, BLI and ITC. Our Biotech and Pharma customers benefit from a strong expertise in biophysical methods (certified by NanoTemper for MST, Dianthus and nanoDSF), from customized milestone-based projects with clear timelines and reliable cost structures. Be smart work with the experts!

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rare Disease, Orphan Drug, Drug Development, Small Molecules, Oncology

4SC is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical need. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat. 4SC had 44 employees as of 31 December 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

ABF GmbH

CRO

Keywords: Metabolomics, Analytical Chemistry, Biomarker Discovery & Development

ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and application in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS(/MS). Since end of 2001, ABF provides its services to corresponding industry, academic and governmental institutions.

abf diagnostics GmbH

PHARMA SUPPLIER & TRADE

abf diagnostics develops, manufactures and markets products and solutions for the collection, storage and onsite analysis of biological traces and samples. Our strategic focus lies on innovations in pre-analytics and decentralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces.

Actarmo Medical GmbH

CRO

Keywords: Respiratory Diseases, Devices, Drug Delivery, Drug Development, Laboratory

Actarmo is a technology focused Contract Research Organisation supporting small to mid size pharmaceutical, biopharmaceutical and device companies in development of respiratory products. With our highly experienced team we offer GMP laboratories as well as consultancy activities.

adivo GmbH

PHARMA ANIMAL HEALTH

Keywords: Pain, Oncology, Inflammation, Antibody, Drug Development

adivo is a German biotech company generating species-specific therapeutic antibodies for companion animals. The adivo team aims to initially address high medical needs in dogs including chronic inflammation and cancer, with the potential of expanding activities into the development of therapeutics for other species in the future. Using its fully canine-based antibody library, adivo, either alone or with partners, intends to generate therapeutics for dogs that are well tolerated and efficacious.



Semmelweisstraße 5
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 535395
E-Mail: max.scherer@abf-lab.com
Internet: www.abf-lab.com



Gewerbepark 14
D-85402 Kranzberg
Phone: +49 (0) 8166 9986 130
E-Mail: info@abfdiagnostics.com
Internet: www.abfdiagnostics.com



Robert-Koch-Allee 29
D-82131 Gauting
Phone: + 49 (0) 89 614233 0
Internet: www.actarmo.com



Am Klopferspitz 19
c/o IZB
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 - 588 08 84 71
E-Mail: info@adivo.vet
Internet: www.adivo.vet



Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 2000 204-10
E-Mail: info@advancecor.com
Internet: www.advancecor.com



advanced biolab service
Gesellschaft für Laborgeräte, Beratung und Support mbH

Stäblistraße 10
D-81477 München
Phone: +49 (0) 89 45470050
E-Mail: info@advancedbiolabservice.com
Internet: www.advancedbiolabservice.com



Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
E-Mail: info@advitos.com
Internet: www.advitos.com



Berger Straße 8 - 10
D-82319 Starnberg
Phone: +49 (0) 8151 9987-001
E-Mail: info@aenova.de
Internet: www.aenova-group.com

advanceCOR GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a biotech company focusing on personalized medicine in cardiovascular diseases. Revacept, a biological drug (lesion specific inhibitor of atherothrombosis) has completed a phase II trial in patients with stroke and cerebral vascular syndromes. A phase II clinical trial for the treatment of coronary artery disease has completed patient recruitment. Further preclinical candidates are under development. advanceCOR is financed by MIG AG, KfW, Bayernkapital, HTGF, Occident and Bio^M AG.

advanced biolab service Gesellschaft für Laborgeräte, Beratung und Support mbH

DEVICES

advanced biolab service GmbH based in Munich provides maintenance, repair and troubleshooting service for capillary electrophoresis sequencers, Real Time and standard PCR instruments ABI 377, ABI 310, ABI 3100(-Avant), ABI 3130(xl), ABI 3500(xl), ABI 3730(xl), ABI 7300, ABI 7500(Fast), ABI 2700, ABI 2720 and GeneAmp 9700. Remanufactured instruments, service contracts or individual repairs, software and computer upgrades, user training and reagents offered by a small and highly professional team.

ADVITOS GmbH

MEDTECH

Keywords: Multi organ failure, Respiratory Diseases, Hepatology, Devices

ADVITOS has developed the CE-marked & globally patented ADVOS technology (ADVanced Organ Support) the only therapy worldwide offering multi-organ support integrated in one single device, supporting all 3 main detoxification organs simultaneously: liver, lung and kidney. ADVITOS was founded near Munich in 2005 by renowned nephrology & multi-organ support expert Dr. Bernhard Kreymann who was instrumental in establishing the previous gold standard of organ support by single-pass albumin dialysis.

Aenova Holding GmbH

BIOTECH & PHARMA PRODUCTION, CMO

Keywords: Laboratory, Regulatory Affairs, R&D Service

The Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The groups portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. Aenova operates 15 manufacturing facilities located within Europe and the United States. More than 4300 employees contribute to the group's success.

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Bioanalytics, Laboratory

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular-genetic diagnostics). Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies.



Larezhausen 3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
E-Mail: info@agrobiogen.de
Internet: www.agrobiogen.de

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services.



Cauerstr. 4
D-91058 Erlangen
Phone: +49 (0) 9131 85-29452
E-Mail: info@agrolytix.com
Internet: www.agrolytix.com

Alexion Pharma Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world. Alexion operates a branch office in Germany to support patients locally. Further information about Alexion can be found at www.alexion.com or at www.alexion.de.



Landsberger Straße 300
D-80687 München
Phone: +49 (0) 89 45 70 91 300
Internet: www.alexion.de

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Infectious Diseases, Oncology, Autoimmune Diseases

Algora offers a broad range of services for phase II-IV clinical trials as well as for observational studies in Germany, with key competencies in study start-up, clinical monitoring, data management, and statistical analysis. Experienced in oncology and infectious diseases since the first days of the company in 1989, we later gained additional expertise in immunology and entered the field of nutritional studies while we continued to cultivate strong relations with the medical community.



Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
E-Mail: cro@algora.de
Internet: www.algora.de



Rupert-Mayer-Str. 46
D-81379 München
Phone: +49 (0) 89 724805-90
E-Mail: info@altmann-analytik.de
Internet: www.analytics-shop.com



Riesstraße 24
D-80992 München
Phone: +49 (0) 89 149096-0
E-Mail: corinna.jacob@amgen.com
Internet: www.amgen.de



Research GmbH

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
E-Mail: susanne.sporer@amgen.com
Internet: www.amgen.de

Altmann Analytik GmbH & Co. KG

PHARMA SUPPLIER AND TRADE

Keywords: Laboratory, Fine Chemicals/Reagents, Devices, Analytical Chemistry

Specialized distributor for chromatography & lab supply. We provide consumables for HPLC & GC, Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps) as well as chemicals and products for dairy and food industry. On www.analytics-shop.com you can find more than 200,000 lab supply products from high-quality manufacturers, such as Agilent, Chiral Technologies, Grace, Hamilton, Macherey-Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC.

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nephrology, Bone/Joint Diseases, Oncology

Amgen is one of the worlds leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history. Worldwide, millions of patients with serious or rare diseases benefit from our therapies every year. Our drugs are used in nephrology, cardiology, hematology, oncology, bone health and chronic inflammatory diseases. In addition to original products, our portfolio also includes biosimilars. We have a diverse pipeline. Amgen GmbH in Munich was founded in 1989. Today, almost 650 employees work here with a focus on clinical research, regulatory affairs and the distribution of pharmaceuticals.

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Amgen Research (Munich) GmbH (formerly Micromet GmbH) located in Munich, Germany has been part of Amgen since March 2012 and is Amgen's largest R&D site outside of the U.S. The site has about 200 employees and is specialized in the development of the "Bispecific T cell Engager" (BiTE[®]) antibody constructs for innovative cancer therapies. Amgen is one of the world's leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history.

AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, In-Vitro-Diagnostics, Molecular Diagnostics, Clinical Diagnostics, PCR

Founded 2002, AmplexDiagnostics is one of the first suppliers for CE IVD diagnostics based on a real-time isothermal amplification technique in a portable device (GENIE II) using lyophilized test reagents for a maximum on user-friendliness and a minimum of hands-on time. With the new eazyplex[®] system you identify pathogenic bacteria within 15 min, screen swabs for multi-resistant bacteria within 20 min or realise Meningitis diagnostics directly from CSF in 30 min.

AMS Advanced Medical Services

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service, Regulatory Affairs, Data Management, Pharmacovigilance

AMS specialises in Global Drug Development, are market leaders in Health Economics and Public Health Benefit Assessments of pharmaceuticals, as well as HTAs and Relative Effectiveness Assessments for medical devices. AMS can provide market access programs in Europe and field force services in German speaking countries. The comprehensive suite of AMS services also include ePRO solutions, strategic consultancy and staff development training.

AMSilk GmbH

BIOTECH NEW MATERIALS AND COMPOUNDS

Keywords: New Materials, Industrial Biotechnology

AMSilk GmbH is the world's first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers combine the advantages of natural products with the possibility of large scale, industrial production processes. AMSilk's high-performance biopolymers are distributed in the form of Biosteel[®] fibers or as a coating solution for medical devices.



Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-80
E-Mail: info@amplexdiagnostics.de
Internet: www.eazyplex.com



Rosa-Bavarese-Str. 5
D-80639 München
Phone: +49 (0) 89 2000074-100
E-Mail: Medical.Science@ams-europe.com
Internet: www.ams-europe.com



Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 579 5393-0
E-Mail: info@amsilk.com
Internet: www.amsilk.com

amYmed

Vinzenz-Schlüpfer-Straße 20a
D-81475 München
Phone: +49 (0) 89 745 022 73
E-Mail: linke@amymed.de
Internet: www.amymed.de



Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 151 50516119
E-Mail: info@afin-ts.de
Internet: www.afin-ts.de



Münchner Straße 47e
D-83607 Holzkirchen
Phone: +49 (0) 8024 4686 652
E-Mail: info@anteris-medical.com
Internet: www.anteris-medical.com

amYmed GmbH Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians. We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

Analytisches Forschungsinstitut für Non-Target Screening GmbH

LIFE SCIENCE / CHEMICAL INDUSTRY

Keywords: Bioanalytics, R&D Service, Laboratory, Analytical Chemistry, Metabolomics, Natural Compounds, Small Molecules

AFIN-TS was founded in 2018 as spin-off from TUM and provides research as well as important services and consulting around MS based non-target screening (NTS). Drug production processes as well as drug production origins/sources can be monitored by NTS. Thus, NTS can be used to characterize unknown/unexpected organic compounds in these or to track changes in the chemical composition (e.g. impurities, fake compounds, etc.) along treatment processes. R&D for (plant) metabolomics offered in own lab.

anteris medical GmbH

CRO CONSULTANTS

Keywords: Regulatory Affairs, R&D Service, In-Vitro-Diagnostics, Clinical Diagnostics, Molecular Diagnostics, Devices, Drug Delivery

anteris medical supports Pharma and Biotech companies with the development, quality control and approval of their products. Our expertise in the fields of requirements management, quality control and risks management, usability engineering, Alliance Management as well as approval accompanies the products through the entire product life cycle. anteris medical brings together the experience of its founders and employees with medical products, combination products and in vitro diagnostics under one roof.

Assay.Works GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Tissue Engineering/Cell Culture, Automation, Small Molecules, Laboratory, Pharmacology, R&D Service, Drug Development

Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.



Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 2000 1240
Fax: +49 (0) 941 2000 1241
E-Mail: contact@assay.works
Internet: www.assay.works

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to changing tomorrow by improving the health of people around the world. We focus on oncology, anti-infectives, urology and transplantation as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies and modalities. The German headquarters are based in Munich. Located here are sales, marketing and medical.



Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1057
E-Mail: info@de.astellas.com
Internet: www.astellas.de

ASPHALION, S.L., Zweigniederlassung München

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing

ASPHALION is a Scientific and Regulatory Affairs consultancy firm with offices in Barcelona, Madrid, Munich and London. Founded in 2000, ASPHALION now consists of a team of over 100 professionals offering services to Pharma and Biotech companies in Drug Development, Regulatory Strategy, Medical and CMC Writing, Regulatory Submissions, eSubmission, Pharmacovigilance and Training. ASPHALION operates in a global environment with regulatory submission expertise mostly in EU and North America.



Leopoldstrasse 244
D-80807 München
Phone: +49 (0) 89 208 039 280
E-Mail: munich@asphalion.com
Internet: www.asphalion.com

ATRES engineering biogas

BIOGAS

Keywords: Bioprocessing, Agrobiotechnology

Our top products for the top performance of your biogas plant! Stable biogas production, high effectiveness, high availability of the plant.



Hansjakobstr. 127a
D-81825 München
Phone: +49 (0) 89 45 21 60 8-0
E-Mail: lab@atres-group.com
Internet: www.atres-group.com



Planegger Str. 9a
D-81241 München
Phone: +49 (0) 89 780 720 010
E-Mail: info@aurigon.de
Internet: www.aurigon.de



Am Klopferspitz 19
D-82152 Martinsried
Internet: www.avergen.com



Birkerfeld 11
D-83627 Warngau
Phone: +49 (0) 8024 470999 0
Internet: www.a-m-w.eu



Fritz-Hornschuch-Str. 9
D-95326 Kulmbach
Phone: +49 (0) 9221 82762-0
E-Mail: info@axolabs.com
Internet: www.axolabs.com

Aurigon GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Toxicology, Pharmacokinetics, ELISA/EIA, Bioanalytics, Drug Development, R&D Service

AURIGON is an independent CRO offering a full range of in vivo and in vitro non-clinical services. These services include, but are not limited to: PK/PD, ADME, bioanalytics, toxicology and safety pharmacology in all species used in toxicity testing. We're big enough to provide a full service, but small enough to fully adapt to your needs. AURIGON operates offices in Munich and state-of-the-art GLP- and GMP-compliant facilities at its ATRC Aurigon Toxicological Research Center near Budapest.

Avergen Pharmaceutical GmbH (APG)

BIOTECH THERAPEUTICS & DIAGNOSTICS

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated on its core competences in neurodegenerative disease and oncology research. The location of the company in Munich enables the access to experienced experts in R&D, as well as business development and commercialization.

AMW GmbH, Arzneimittelwerk Warngau

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery

Intelligent Pharmaceuticals AMW GmbH is an innovative, and steadily growing pharmaceutical company situated nearby Munich, the capital of the Free State of Bavaria in Germany. The base of our technology is to provide a prolonged therapeutic effect with the benefit of having lesser side effects and lower consumption of the active pharmaceutical ingredients. One example from our portfolio is a biodegradable implant, that will be applied subcutaneously by an applicator with an automatic needle-retraction mechanism.

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Pharmacology, Bioinformatics, Bioanalytics, Aptamer Technology, Pharmacokinetics

Axolabs is the leading preclinical research organization for oligonucleotide therapeutics and nucleic acid medicines. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 20 years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs.

BAP Pharma

PHARMA & CHEMICAL INDUSTRY

BAP Pharma are specialists in the clinical trial supply of comparator drugs, with a global reach. We have extensive experience both in Europe and worldwide. With over 50 years in the industry we are well-placed to understand your clinical trial supply needs. With the newly founded site in Höchstädt, Bavaria, BAP Pharma is even closer to serve customers of the pharma and biotechnology communities.



An der Kohlplatte 23
D-89420 Höchstädt a.d.Donau
Internet: www.bappharma.com

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Nanobiotechnology, Chip/Array Technology,

Baseclick GmbH was founded in 2008 as a spin out of the LMU in Munich by Prof. Dr. Thomas Carell. Baseclick utilizes the "click chemistry", discovered by the Nobel laureate Prof. Dr. Barry Sharpless, and developed a wide range of nucleic acid modification products, e.g. EdU proliferation kits, labeling of nucleotides and preparation kits for "Next Generation Sequencing" (NGS) and for the development of RNA-based drugs. baseclick GmbH out-licensed this technology to leading companies worldwide.



Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 9699 3401
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu

Basilea Pharmaceutica Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich.



Elsenheimerstraße 7
D-80687 München
Phone: +49 (0) 89 7857674-0
E-Mail: basilea.info@basilea.com
Internet: www.basilea.com

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology

Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox and monkeypox vaccines. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. BN was founded in 1994 and is headquartered in Denmark. The company has more than 500 employees in Europe and USA and is listed on the Copenhagen Stock Exchange.



Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 255446-030
E-mail: hho@bavarian-nordic.com
Internet: www.bavarian-nordic.com

Baxter

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
E-Mail: info_de@baxter.com
Internet: www.baxter.de



Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
E-Mail: info@beckmancoulter.de
Internet: www.beckmancoulter.de

Bencard Allergie

Wir denken weiter.

Leopoldstraße 175
D-80804 München
E-Mail: info@bencard.com
Internet: www.bencard.de



Herterichstraße 1
D-81479 München
Phone: +49 (0) 89 74987-0
E-Mail: contact@bene-arzneimittel.de
Internet: www.bene-arzneimittel.de

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.

Bencard Allergie GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Allergy

Bencard Allergie GmbH is the Munich based, German subsidiary of Allergy Therapeutics plc. (Worthing/UK). As a global company, we specialize in the research and development of allergy treatments since 1934. We constantly aim to improve the quality of life of people suffering from allergies. Our strong portfolio offers specific immunotherapies to treat allergies such as pollen, pets, wasps or bees. Additionally we provide prick-tests for diagnostic purposes and OTC products (e.g. immunoBON®).

bene-Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for our most important goal: human health!

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.



Bernina Plus

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388-740
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de

betapharm Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m.

beta pharm

Kobelweg 95
D-86153 Augsburg
Phone: +49 (0) 821 74881-0
E-Mail: info@betapharm.de
Internet: www.betapharm.de

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Natural Compounds, Nutraceuticals, Medicinal Chemistry, Oncology, R&D Service, Agrobiotechnology, Small Molecules

Bicoll is a company in the field of plant small molecules backed up by a strong medicinal chemistry competence. Bicoll delivers breakthrough solutions in pharmaceuticals, cosmetics, nutraceuticals, and agriculture. Bicoll strengthens the synergies inherent in two operating segments drug discovery from small molecules natural products and medicinal chemistry. Furthermore, Bicoll can process tons of crude material as well as handle +10 steps of multi-kilogram synthesis routes.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 820106-30
E-Mail: contact@bicoll-group.com
Internet: www.bicoll-group.com

Bind-X GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Agrobiotechnology, R&D Service, Industrial Biotechnology

Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. Bind-X products are capable of solidifying almost any permeable material and providing additional functional properties. Foremost they always increase the sustainability of Bind-X clients in the worldwide mining, agriculture and construction industry.



Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 2620344-0
E-Mail: info@bind-x.com
Internet: www.bind-x.com



Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-0
E-Mail: biobank@blutspendedienst.com
Internet: www.biobank.de



Landsberger Str. 290
D-80687 München
Phone: +49 (0) 89 202 444 97-0
Internet: www.bioclinica.com



Riedenburger Straße 7
D-81677 München
Phone: +49 (0) 89 99617-0
Internet: www.biogen.de

BIOBANK der Blutspender Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research. With a collection of more than 4 Mio plasma samples and a large pool of more than 400,000 active blood donors we are one of the largest blood donor based biobank. The serial, pre-diagnostic blood samples of several thousands of diseased BIOBANK participants per year are a unique resource for investigating markers associated with the onset and progression of diseases.

BioClinica GmbH

CRO

Keywords: Drug Development, Oncology, Neurology, Cardiovascular Diseases, Imaging, Metabolic Diseases, CNS

Bioclinica is the global leader in medical imaging core lab services, providing life-science companies with clinical trial support for all phases and across all major indications. Our commitment to service and scientific excellence is focused on advancing our clients' drug development process. Bioclinica's services create a unique and scalable platform and include Medical Imaging, Cardiac Safety Services, Clinical Event Adjudication Services, Software Solutions, and Drug Safety Solutions.

Biogen GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development

Biogen's mission is clear: We are pioneers in neuroscience. Founded in 1978 as one of the first biotechnology companies, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in MS, neuroimmunology, Alzheimer's disease, neuromuscular and movement disorders and ophthalmology. Biogen German is located in Munich.

Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organizations (e.g. CDC, USA), several armed forces and other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Biogents also offers a fee-for-service business for insect repellents and attractants.



Weißenburgstr. 22
D-93055 Regensburg
Phone: +49 (0) 941 5699 6947
E-Mail: biogents@biogents.com
Internet: www.biogents.com

BioLink Informationstechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Laboratory

The BioLink GmbH, an information-technology company, was founded in 1997 to serve as High Security Internet Provider and as Software Developer for Laboratory-Information-Management-Systems (LIMS). It was specifically the software-developing business which evolved over the last years. Based on the concept to design and develop personalized LIMS solutions, BioLink put forth a number of softwares aimed to support laboratory processing as well as certain aspects of genetic engineering.



Lochhamer Straße 9
D-82152 Martinsried
Phone: +49 (0) 89 741595-0
E-Mail: info@biolink.de
Internet: www.biolink.de

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, Industrial Biotechnology, Data Management, Personalized Medicine, Agrobiotechnology, Informatics, Data Management and Biostatistics

Biomax Informatics provides software solutions for knowledge management in the life science markets: AILANI is a semantic search platform that catalyzes digital change and accelerates the innovation cycle. NeuroXM is the one-stop-shop to decipher brain physiology. The Clinical Integration System ensures access to real world evidence data, which is critical to train Artificial Intelligence to support clinical decisions at the point of care. Biomax is certified according to ISO 9001 and ISO 27001.



Robert-Koch-Str. 2
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
E-Mail: info@biomax.com
Internet: www.biomax.com



Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
E-Mail: info@biomed.de
Internet: www.biomed.de



Im Gewerbepark B49
D-93059 Regensburg
Phone: +49 (0) 941 454 41
E-Mail: info@biometric-gmbh.de
Internet: www.biometric-gmbh.de



Kerschensteinerstr. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 231-90
E-Mail: info@bionorica.de
Internet: www.bionorica.de



Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 8188802-0
Internet: www.biontech.de

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: In-Vitro-Diagnostics, Bioanalytics

BIOMED has been known for decades as a reliable manufacturer for lab diagnostics. Our core competences are diagnostic products, staining solutions and staining devices for routine and special laboratories for the detection and prevention of diseases. Whether immunology, infectiology, cytology, haematology, safe screening methods or the automation of staining for your different sample materials we offer solutions for many clinical and laboratory challenges.

Biometric GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Analytical Chemistry

Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.

BIONORICA SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Neurology, Pain, Respiratory Diseases, Oncology, Analytical Chemistry, Drug Development

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders. Phytonearing combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficient and safe preparations.

BioNTech Small Molecules GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Oncology, Medicinal Chemistry, Analytical Chemistry, Small Molecules, 3D-Structural Analysis, Molecular Modelling

BioNTech Small Molecules is a 100% subsidiary of BioNTech SE (Mainz, Germany) focusing on discovery and preclinical development of small molecule drugs in immuno-oncology. BNT411, the most advanced compound, is expected to enter clinical development by mid-2020. The research pipeline ranges from hit identification via in silico screening through hit-to-lead and lead optimization to preclinical development. We are offering services in virtual High Throughput Screening and Analytical Chemistry.

Biontex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents

Biontex Laboratories GmbH is an innovative biotech company with focus on transfection technology, covering the introduction of genetic material and proteins into eukaryotic cells by synthetically produced carrier systems. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects.



Landsberger Str. 234
D-80687 München
Phone: +49 (0) 89 324799-50
E-Mail: contact@biontex.com
Internet: www.biontex.com

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service

Bio-Rad was founded in 1952. The headquarter is in Hercules, California. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms and classrooms around the world. Bio-Rad's key competencies incl. separation, purification and analysis. The company is a leader in electrophoresis, protein assays, gel image analysis, quality controls, diabetes monitoring, autoimmune testing, blood typing and BSE.



Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-0
E-Mail: info@bio-rad.de
Internet: www.bio-rad.com

Biosepar Ges. für Medizin- und Labortechnik mbH

PHARMA ANIMAL HEALTH

BIOSEPAR is driving excellence in sample preparation for parasitologic diagnostics since 1987. With the vision to make parasitologists' life easier, BIOSEPAR has revolutionized parasitological stool diagnostics with standardized, hygienic, ready-to use kits and non-toxic, environmentally friendly reagents in both, human and veterinary medicine. The flagship product ParasiTrap[®] was followed by FixSepar[®] ECO and while increasing its global reach the company continues driving innovation.



Am Industriepark 2A
D-84453 Mühldorf
E-Mail: mail@biosepar.de
Internet: www.biosepar.de

Biophyll GmbH

PHARMA SUPPLIER AND TRADE

Biophyll has over 25 years of experience in sourcing and manufacturing of biological products of animal, human, and plant origin. We assess the specific needs of our customers to provide tailored product solutions for pharmaceutical, diagnostic, and scientific purposes. - Access to new and rare biological products sourced worldwide - Supply of quality and traceability documentation - Regulatory support in import, export, and registration matters - Individually designed transport logistics concepts.



Winkl 4
D-84378 Dietersburg
Phone: +49 (0) 8565 964961
Internet: www.biophyll.com



Konnersreuther Straße 6g
D-95652 Waldsassen
Phone: +49 (0) 9632 9248325
E-Mail: josef.scheiber@biovariance.com
Internet: www.biovariance.com



Obere Hauptstr. 10 b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
E-Mail: info@biozol.de
Internet: www.biozol.de



Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
E-Mail: info-bms-germany@bms.com
Internet: www.bms.com/de

bioVariance GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics, Bioinformatics, Personalized Medicine, Biomarker Discovery & Development, Informatics, Pharmacogenomics, NGS

BioVariance GmbH offers biomedical data analyses and related software development in the area of precision medicine for the healthcare, pharma and biotech sector. To accelerate the data analytics, we use special algorithms and machine learning to automate complex analytical processes in a customized software pipeline and to develop prediction models. We develop user-friendly interfaces including mobile apps to simplify data collection, processing, visualization and research.

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Rheumatoid Arthritis, Hematology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease and rheumatoid arthritis.

BSL BIOSERVICE

Scientific Laboratories Munich GmbH

CRO

Keywords: Toxicology, Pharmacology

BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering biological testing services for Pharmaceuticals, Chemicals and Medical Devices. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A experienced team guarantees acceptance by authorities and supports customers from research until finalization. BSL is certified in accordance with GLP/GMP. We are listed by the WHO and been audited by the FDA.

Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Imaging, Molecular Diagnostics, Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture, Toxicology, Genomics

ZEISS Research Microscopy Solutions is the world's only one-stop manufacturer of light, electron, X-ray and ion microscope systems and offers solutions for correlative microscopy. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical practice. The unit is headquartered in Jena. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.

CASCAT GmbH

INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY

CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus.

CatalYm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Oncology

CatalYm is developing innovative immunotherapies to transform cancer patients lives by effectively engaging their own immune systems to combat this malignant disease. Targeting novel mechanisms that lead to a potent and sustained activation of the immune system within the tumor microenvironment, CatalYms goal is to rapidly bring its next-generation immuno-oncology products to patients in need.



Behringstr. 6 / 8
D-82152 Planegg-Martinsried
E-Mail: info@bioservice.com
Internet: www.bioservice.com



Seeing beyond

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
E-Mail: microscopy@zeiss.com
Internet: www.zeiss.com/microscopy



Europaring 4
D-94315 Straubing
Phone: +49 (0) 9421 7855 20
Internet: www.cascad.de



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 2000 664-40
E-Mail: info@catalym.com
Internet: www.catalym.com



Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
E-Mail: info@celgene.de
Internet: www.celgene.de

cellasys

Illerstrasse 14
D-87758 Kronburg
Phone: +49 (0) 8394 257929
E-Mail: info@cellasys.com
Internet: www.cellasys.com



Lindemannstraße 13
D-82327 Tutzing
Phone: +49 (0) 8158 9064010
E-Mail: info-celltool@celltool.de
Internet: www.celltool.de



Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 7243-00
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com

Celgene GmbH - a BMS company

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: R&D Service, Bioanalytics, Laboratory, In-Vitro-Diagnostics, Biochips, Devices, Toxicology

cellasys delivers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance. Furthermore we offer consulting services in the area of application development, data analysis and data interpretation. Our microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO₂) and morphology (impedance).

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Devices

CellTool is a company that develops, manufactures and distributes Raman laser microscopes for single cell analysis in suspension, tissue and organoids, 2D and 3D. Multi-omics read out from functional genomics to functional metabolomics (DNA, proteins, lipids, sugars, small molecules).

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Analytical Chemistry, Medicinal Chemistry, In-Vitro-Diagnostics, Clinical Diagnostics

Centronic GmbH is a German manufacturer and distributor of a big range of high qualitative clinical chemistry and immunoturbidimetric reagents for the medical diagnosis of enzymes, electrolytes, substrates, lipids and specific proteins. The portfolio is completed with corresponding controls, calibrators, Latex and Salmonella reagents and cleaning solutions for many analysers. Our Quality Management System is certified according EN ISO 13485:2016 by the TÜV.

Cfm Oskar Tropitzsch GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, AntibodyDrugConjugate ADC, Antibiotics, Natural Compounds, Drug Development, Drug Delivery, Fine Chemicals/Reagents

Cfm Oskar Tropitzsch is your reliable and GDP-Certified partner for: Small scale (API) manufacturing (nonGMP/cGMP), Contract synthesis (nonGMP/GMP), Small molecules (> 700 substances), Phytochemicals (> 1000 substances), Phyto-Reference Substances, Pharmaceutical raw materials, Excipients, HPAPIs - Cytotoxins - Payloads for ADCs, Sourcing of APIs. Cfm Oskar Tropitzsch GmbH assists the pharmaceutical and biotech industry in sourcing and producing APIs and Excipients.



Oskar Tropitzsch

Adalbert-Zoellner-Str. 1
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
E-Mail: info@cfmot.de
Internet: www.cfmot.de

Charles River Laboratories, Research Models and Services, Deutschland GmbH

CRO

Keywords: Drug Delivery

At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - biosecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future.



Sandhofer Weg 7
D-97633 Sulzfeld
Phone: +49 (0) 9761 406 0
Fax: +49 (0) 9761 406 60
E-Mail: dbestell@de.crl.com
Internet: www.criver.com

Cherry Biolabs GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Cherry Biolabs GmbH has developed a novel antibody-based platform technology for the treatment of cancers, not amenable by current immune therapies. This is achieved by the combination of two complementary antibody fragments (hemibodies) that assemble on target and thus specifically tag tumor cells for lysis by the patients killer T cells. While distinct hemibody-combinations against certain tumor types have already been identified, the platform is continuously expanded.



Friedrich-Bergius-Ring 15
97076 Würzburg
Phone: +49 (0) 931 201 444 23
E-Mail: info@cherrybiolabs.com
Internet: www.cherrybiolabs.com



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 124 148 8 - 0
E-Mail: info@chromotek.com
Internet: www.chromotek.com



Inselkammerstraße 4
D-82008 Unterhaching
Phone: +49 (0) 89 6242208 10
E-Mail: europe@cipla.com
Internet: www.cipla.com



Semmelweisstraße 1
D-82152 Planegg b. München
Phone: +49 (0) 89 710 661-0
E-Mail: biotech@clariant.com
Internet: www.clariant.com

ChromoTek GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Antibody](#), [Proteomics](#), [Imaging](#), [Laboratory](#)

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of Nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proud contributing to breakthrough research discoveries around the world. In October 2020 ChromoTek was acquired by Proteintech Group. The combined companies will better address the industry's growing opportunities. Founded in 2008, ChromoTek continues to grow its business in Martinsried.

Cipla Europe NV

PHARMA & CHEMICAL INDUSTRY

Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe.

Cipla offers a range of products in Europe —Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products.

Clariant Produkte (Deutschland) GmbH, Group Biotechnology

PHARMA & CHEMICAL INDUSTRY

Keywords: [New Materials](#), [Agrobiotechnology](#)

Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth. The main focus of Clariant Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.

Climedo Health GmbH

BIOTECH BIOINFORMATICS

Keywords: Automation, Cell Therapy, Oncology, Clinical Trial Management and Monitoring, Devices, Regulatory Affairs, Data Management

Climedos mission is to bring the best treatment to every patient by empowering healthcare professionals with intelligent software solutions. Together with Europes leading hospitals, they have developed a cloud-based platform for cutting-edge clinical validation and post-market surveillance of medical devices and pharmaceutical products. By digitally connecting all stakeholders (medical device manufacturers, pharma companies, CROs, hospitals and patients), Climedo allows for increased performance, better cost-efficiencies - and ultimately - accelerated medical innovation.

Clinipace GmbH

CRO

Keywords: Drug Development, Regulatory Affairs, Medical Writing, Orphan Drug, Oncology, Clinical Trial Management and Monitoring, Data Management and Biostatistics

Clinipace is a global, mid-size contract research organisation (CRO) providing a comprehensive suite of services, technology, and people. We have the global reach and cutting-edge systems of a large CRO, but the agility and speed of a smaller organisation. Clinipace understands the complexities involved in clinical development and we take a personal and consultative approach through our knowledgeable staff who can navigate both the operational and regulatory challenges that may arise.

Clinrex GmbH

CRO

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the of areas GCP, Quality Management and Project Management for clinical trials. GCP/Quality Management Consulting - GCP gap analyses - Inspection readiness/Audits - SOP development/streamlining - Interface sponsor/CRO - Investigator Initiated Trials (IITs) Training (Smart Training® or customised in-house training) - GCP for Sponsors, CROs or On-site Personnel - Project Management/Working with CROs - NIS.



Schellingstr. 109a
D-80798 München
Phone: +49 (0) 89 32209394 0
E-Mail: info@climedo.de
Internet: www.climedo.de



Helfmann-Park 10
D-65760 Eschborn
Phone: +49 (0) 6196 7009 - 0
E-Mail: contact@clinipace.com
Internet: www.clinipace.com



Clinrex GmbH
your clinical research experts

PF 1223
D-85572 Neubiberg
Phone: +49 (0) 89 9292 87-0
E-Mail: info@clinrex.com
Internet: www.clinrex.com



Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 8355
E-Mail: germany@clintec.com
Internet: www.clintec.com

COLORIMETRIX

Oskar-von-Miller-Ring 20
D-80333 München
E-Mail: contact@colorimetrix.com
Internet: www.colorimetrix.com



Kolpingring 8
D-82041 Oberhaching
Phone: +49 (0) 89 673 4688 10
E-Mail: info@comphass.de
Internet: www.comphass.de



Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
E-Mail: info@conreso.com
Internet: www.conreso.com

ClinTec GmbH

CRO

Keywords: Regulatory Affairs, Drug Development, Oncology, Medical Writing, Data Management and Biostatistics

Covering over 80 countries, we have a strong presence in Europe, USA and Asia-PAC as well as unique markets in Middle East & Africa, providing the global footprint to performing global trials. Clintec has a wealth of experience in conducting clinical trials in oncology and rare disease as well as other therapeutic areas. We use industry leading e-clinical technologies to support our focused, flexible and forward-thinking approach, ensuring excellence at every stage of the trial, everywhere in the world.

COLORIMETRIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Colorimetrix GmbH - The lab in your pocket - We turn any smartphone into a portable laboratory using its camera to read diagnostic tests at home. No hardware needed, iOS and Android compatible, very competitive pricing, cloud analytics, trends, insights on the measurements, etc. Check out our first products: <https://pearlfertility.app> and <https://covidrapidtest.app> - happy to discuss opportunities, info@colorimetrix.com.

Compass GmbH

PHARMA SUPPLIER AND TRADE

Keywords: Logistics

Compass GmbH and Pharmapack Stade GmbH offer a wide range of services in the secondary packaging sector. Our focus is blistering and packaging of capsules and tablets. But we also offer secondary packaging of bottles, cans and special packaging. We are specialized in the packaging of small to medium batch sizes. Certifications according to EU-GMP and manufacturing authorization according to §13 AMG are available.

Conreso GmbH

CRO

Keywords: Vaccines, Data Management and Biostatistics, veterinary clinical trials, Devices, Oncology, Infectious Diseases, Clinical Trial Management and Monitoring

Conreso, established in 1990, BVMA member, offers a wide range of clinical development services from phase II to late phase clinical trials, non-interventional and epidemiological studies for pharmaceuticals, vaccines and medical devices. Your need for temporary insourcing can be met with the permanent permission to temporarily lend staff. Since 2008 the Conreso Department of Veterinary Medicine provides also veterinary (field-) studies. We serve as Legal Representative for non-EU sponsors.

Coriolis Pharma Research GmbH

CRO

Keywords: Peptide/Protein, Antisense/Nucleotides, Vaccines, Antibody, Viruses, Drug Development, R&D Service

Coriolis is a globally operating and world-leading contract research organization in formulation development of (bio)pharmaceutical drugs and vaccines, including proteins, peptides, antibodies, RNA/DNA, VLPs, virus-based ATMPs and GMOs (up to BSL-2). Coriolis is highly experienced in biopharmaceutical characterization by using innovative and state of the art analytical technologies to support trouble-shooting, higher order structure characterization, particle identification and GMP release. .

Covance Clinical Development GmbH

CRO

Keywords: Regulatory Affairs, Oncology, Pharmacology, Medical Writing, Laboratory, Clinical Trial Management and Monitoring, Drug Development

Covance Inc. is the worlds most comprehensive drug development company. We are dedicated to advancing healthcare and delivering Solutions Made Real[®] by providing high-quality nonclinical, preclinical, clinical & commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and deep knowledge, we are in a unique position to provide insights to our client partners that go above and beyond testing.

CRELUX GmbH - a WuXi AppTec company

BIOTECH PRECLINICAL SERVICES

Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis

CRELUX is part of HitS platform of WuXi AppTec and provides one-stop solutions for clients seeking premium drug discovery services. We enable early drug discovery, which starts by providing high quality protein and continues with target validation, hit finding (fragment or DNA encoded library screenings) and hit confirmation (biophysics, biochemistry). Importantly, our clients can obtain structural elucidation of their target at atomic precision from X-ray crystallography, Cryo-EM or NMR.



Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 41 77 60-0
E-Mail: contact@coriolis-pharma.com
Internet: www.coriolis-pharma.com



Carl-Wery-Str. 42
D-81739 München
Phone: +49 (0) 89 9210930
E-Mail: wolfgang.schlaeger@covance.com
Internet: www.covance.com



Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700760-0
E-Mail: crelux_office@wuxiapptec.com
Internet: www.crelux.com



Arnulfstraße 19
D-80335 München
Phone: +49 (0) 89 9901649-0
E-Mail: info@cri-muc.eu
Internet: www.cri-muc.eu



Zeppelinstr. 71-73
D-81669 München
Phone: +49 (0) 89 45835 508
E-Mail: jorge.garcia@cromsource.com
Internet: www.cromsource.com



Schlosserstr. 4
80336 München
Phone: +49 (0) 89 / 540435-72
E-Mail: info@cryondo.de
Internet: www.cryondo.de

CRI – The Clinical Research Institute GmbH

CRO

Keywords: Devices, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Pharmacovigilance, Regulatory Affairs

We are a full-service Contract Research Organization for clinical studies - controlled trials and observational studies - in all medical indications. We perform clinical projects primarily within Europe with currently >500 contracted hospitals in about 25 countries. The special competence of our 50+ team is large-scaled non-commercial trials, studies with medical devices, and supportive IT solutions like App-based follow-up of patients or data exchange with remote clinical monitoring services.

CROMSOURCE GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Medical Writing, Devices, Drug Development, Clinical Trial Management and Monitoring, Data Management and Biostatistics

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.

Cryondo GmbH

OTHER SERVICES

Keywords: Logistics

CRYONDO offers the (back-up) storage of biological/medical samples, reagents and retained samples. The samples can be stored at temperatures from -196 °C to room temperature, secured by a 3D security concept. Cryondo is certified according to DIN EN ISO 9001 and has the permits to store for instance samples of genetically modified organisms or samples that are subject to infection protection. In addition, Cryondo offers various services, logistics and products around cryo storage.

CryoShop

OTHER SERVICES

Keywords: Logistics

SUPPLIER FOR LIQUID NITROGEN EQUIPMENT CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. CryoShop is offering value added cryogenic solutions. Our portfolio allows us to provide products and solutions along the cryopreservation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/automated thawing devices. Furthermore we are offering special cryogenic personal protective equipment.



WerkStadt Sendling / Haus 2
Flößergasse 4
D-81369 München
Phone: +49 (0) 89 63 899 012
Fax: +49 (0) 89 892 94 31
E-Mail: einfachcool@cryoshop.de
Internet: www.cryoshop.de

CSO Pharma Consulting GmbH

CRO

Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigilance, Medical Writing, Laboratory

CSO Pharma provides reliable pharmacovigilance services, professional medical affairs support and successful QM/GDP consulting. We run our own quality management system and offer our customers reliable services and processes based on international standards. You can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements.



Bachbauernstrasse 1
D-81241 München
Phone: +49 (0) 89 20335359
E-Mail: info@cso-pharma.eu
Internet: www.cso-pharma.eu

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer.




Merianstraße 26
D-90409 Nürnberg
Phone: +49 (0) 700 - 1447 1447
E-Mail: info@curadis.eu
Internet: www.curadis.eu

Cytophorics GbR

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, Devices, Chip/Array Technology, In-Vitro-Diagnostics

The Cytophorics technology enables a variety of applications in the pharmaceutical industry, clinical diagnostics and basic research. Wherever a living cell sample is in interest of investigation, the patented sensor-equipped multi-well plate is able to capture high quality, relevant vital data in real time. The integrated fluidic system allows long-term studies for all kind of cell based assays. The main areas of interest are in personalized medicine in drug developing and in research to investigate basic cell mechanisms.



Am der Rehwiese 20
D-81375 München
Phone: +49 (0) 89 30725921
E-Mail: info@cytophorics.com
Internet: www.cytophorics.de



Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
E-Mail: info@cytox.de
Internet: www.cytox.de

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.



Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Oncology, AntibodyDrugConjugate ADC

Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical therapies. In addition to a strong portfolio of medicines for cardiovascular diseases, the Group's 2025 vision is to become a Global Pharma Innovator with Competitive Advantage in Oncology. Our European headquarters are in Munich, Germany and we have affiliates in 13 European countries.



Neuhauserstraße 25
D-80331 München
E-Mail: info@dm-matrix.com
Internet: www.dm-matrix.com

Data Matrix GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing

Data MATRIX was established in 2014. With its high-quality software products and professional team Data MATRIX has already successfully completed over 200 projects. Our products automate the processes of clinical trials, and users manage and monitor its progress online. We adjust and validate our software before the project starts in order to do it in the best way. With Data MATRIX products, 6 out of 10 TOP Big Pharma companies reduced their R&D costs by 15%.



Roentgenstr. 3
D-93055 Regensburg
Phone: +49 (0) 941 948 228
E-Mail: info@dabio.de
Internet: www.davids-bio.de

Davids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA/EIA, Tissue Engineering/Cell Culture, Antibody Production Service

Davids Biotechnologie is a German custom manufacturer for antibodies since 1996. Polyclonal antibodies and monoclonal antibodies. Antibodies and other proteins are produced in HEK and CHO cells after transient transfection as well as in standard E.coli cells. Chromatographic and affinity purification services for purification of protein without a tag and with a tag. Cell based natural killer cell assays for detection of active molecules and for control of human therapies.

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest focussed on family relationship testing and has an ISO/IEC17025 accreditation. Additional services are paternity tests and genetic tests for dogs, as well as some antibody tests for humans and dogs. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.



Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
E-Mail: info@delphitest.de
Internet: www.delphitest.de

Denk Pharma GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany.

Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally operating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948.



Prinzregentenstraße 79
D-81675 München
Phone: +49 (0) 89 2300 29-0
E-Mail: mathias.seidel@denkpharma.de
Internet: www.denkpharma.de

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.



Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 8036-05
E-Mail: contact@diaserve.de
Internet: www.diaserve.de

Dojindo EU GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals/Reagents

Dojindo produces over 500 well-known products used by research organizations in the world. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for offering state-of-the-art products because our creative researchers are working continuously to meet tomorrow's research needs.



Leopoldstr. 254
D-80807 München
Phone: +49 (0) 89 3540-4805
E-Mail: info@dojindo.eu.com
Internet: www.dojindo.eu.com



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
E-Mail: info@donatur.de
Internet: www.donatur.de



Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de



Dr.-Robert-Pflieger-Str. 12
D-96045 Bamberg
Phone: +49 (0) 951 6043-0
E-Mail: info@dr-pfleger.de
Internet: www.dr-pfleger.de



Lochhamerstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 897 4544-0
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Medical Writing, Pharmacology, Devices, Drug Development

We provide a complete pharmacovigilance full-service solution: - 24-hours availability - Literature screening and -review - Data entry and MedDRA coding - Scientific assessment by experienced physicians - Authority reporting - SUSAR reporting - Periodic reports: ASR, DSUR, PSUR - Risk management plans - Implementation of pharmacovigilance systems - Audits and guidance through inspection.

Dr. Pflieger Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Drug Delivery

Dr. Pflieger Arzneimittel GmbH is a medium-sized pharmaceutical company with over 390 employees and a sales turnover of nearly 100 million EUR in 2019. Dr. Pflieger markets over 60 non-prescription and prescription medicines for indications in urology, gynecology, dermatology and areas of self-medication in Germany and selected territories world-wide. The financial surpluses generated by the company are passed onto the Doktor Robert Pflieger-Stiftung.

Dynamic Biosensors GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody, Proteomics, Small Molecules, Peptide/Protein, Chip/Array Technology, Drug Development, Devices

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. The company commercializes the switchSENSE[®] technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE[®] technology is protected worldwide and only available through Dynamic Biosensors. Further information at www.dynamic-biosensors.com

Ebenbuild GmbH

DIGITAL HEALTH

Keywords: Personalized Medicine, Respiratory Diseases, Pneumology, Biomarker Discovery & Development, Informatics, Imaging, R&D Service

Every year, six million patients worldwide are mechanically ventilated due to Acute Respiratory Distress Syndrome (ARDS), e.g. caused by Corona. Two million die. Ebenbuilds deep-tech software harnesses cutting-edge physics simulation and computer vision to generate unprecedented data of the patients lung. A first of a kind precision tool, it will enable physicians to provide better, personalized protective ventilation therapy for ARDS, improving the patients odds of survival and recovery.

Eisbach Bio GmbH

BIOTECH DEVICES & REAGENTS

Eisbach develops medicines that target chromatin regulatory mechanisms essential to tumors. Our novel targets and best-in-class drug discovery allow us to develop a pipeline of impactful medicines. Since a tumors genome constantly evolves, cancers can be difficult to target. We identified the engines that drive all genome rearrangements. Our unique screening platform has generated first-in-class inhibitors that target the key vulnerability in genetically- defined tumors.

Electrochaea GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Electrochaea delivers innovative, patented technology to produce high-quality, renewable methane that can be stored and used through the existing gas grid. Industrial-scale pilot plants have been operated in the U.S., Switzerland and Denmark. The company is planning to produce more than 15bn cft per year of renewable methane by 2025. The technology has been awarded the Swiss Watt d'Or energy prize and listed by FOCUS magazine as one of the most important technologies for climate and environment.

ELLA Biotech GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip/Array Technology, PCR, In-Vitro-Diagnostics

Our expertise is the synthesis of special oligoribonucleotides for random mutagenesis, in-vitro diagnostics, epigenetic sequencing, Aptamer technology and many more following quality standards which you would appreciate and expect in your own lab. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.

EBENBUILD

Schinkelstraße 44
c/o Dr. Kei Müller
D-80805 München
Phone: +49 (0) 89 289 15265
E-Mail: info@ebenbuild.com
Internet: www.ebenbuild.com/index.html



Am Klopferspitz 19
D-82152 Martinsried
Internet: www.eisbach.bio



Semmelweisstraße 3
D-82152 Planegg
Phone: +49 (0) 89 3249 3670
E-Mail: info@electrochaea.com
Internet: www.electrochaea.com



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7093 9316
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com



Am Morgenroth 6
D-97246 Eibelstadt
Phone: +49 (0) 9303 984 964
E-Mail: service@emfret.com
Internet: www.emfret.com



Straussenlettenstrasse 7b
D-85053 Ingolstadt
Phone: +49 (0) 841 3796013
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com

EPIGENE

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigenene.de



Großhaderner Str. 9
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 2153 5730
E-Mail: info@epiqmax.de
Internet: www.epiqmax.com

EMFRET Analytics GmbH & Co. KG

BIOTECH DEVICES & REAGENTS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Biomarker Discovery & Development, R&D Service

EMP Genetech is a CDMO in the field of recombinant protein production. Recombinant proteins are expressed from mammalian cells. We develop stable high producer cell lines mainly of human (HEK293 EBNA) origin cells. Protein production is conducted by bioreactor driven high cell cultivation up to 10 L scale with serum free conditions. Gene cloning and single cell clone selection as well as downstream processing are well established methods in our lab. We work successfully since 2000.

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiQMAX GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Clinical Diagnostics, Molecular Diagnostics, Proteomics, Personalized Medicine

Since 2018, EpiQMAX is a partner for the development of epidrugs and biomarker research in the epigenetic and proteomic field. Headquartered nearby Munich, we operate a state-of-the-art mass spectrometer to facilitate epigenetic screenings into clinical applications. Our technology platform comprises a kit for quick sample preparation, a mass spectrometer for a unique quantitative analysis of modifications and software programs for intuitive and visual reporting of the results.

essentim GmbH

BIOTECH DEVICES & REAGENTS

essentim lab pursues the goal to improve process, workflow and documentation in laboratories of today and tomorrow. As our first product essentim lab kit optimises the documentation of procedures and simplifies the effort for continuous quality control. The scope is meant as mobile wearable device transmitting data in real time being visualized by our lab application. Location and process documentation is easier, more detailed and accomplished with more satisfaction.

essentim 

Grillparzerstr. 12
D-81675 München
Phone: +49 (0) 89 999 50696
E-Mail: info@essentim.com
Internet: www.essentim.com

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.

ethris

Semmelweisstrasse 3
D-82152 Planegg
Phone: +49 (0) 89 8955 788-0
E-Mail: info@ethris.com
Internet: www.ethris.com

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy

Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute) and extensive testing by highly qualified personnel.

eticur) 
GESUNDHEITSVORSORGE FÜR'S BABY

Landsberger Str. 406
D-81241 München
Phone: +49 (0) 89 12 59 81-0
E-Mail: info@eticur.de
Internet: www.eticur.de



Behringstr. 6/8
D-82152 Martinsried
Phone: +49 (0) 89 899650-0
E-Mail: info-munich@eurofins.com
Internet: www.eurofins.de

Eurofins BioPharma Product Testing Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Small Molecules, Bioanalytics, Laboratory, Medicinal Chemistry, Toxicology

Eurofins BioPharma Product Testing Munich is part of the world's largest network of testing laboratories providing comprehensive laboratory services to pharmaceutical, biopharmaceutical and medical device companies. Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, medical devices, chemicals and cosmetics. The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at Planegg near Munich.



Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
E-Mail: info-eu@eurofins.com
Internet: www.eurofinsgenomics.com

Eurofins Genomics Germany GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins Genomics is an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis.



Am Biopark 13
D-93053 Regensburg
E-Mail: kontakt@evanium.de
Internet: www.evanium.de/

Evanium Healthcare GmbH

PHARMA & CHEMICAL INDUSTRY

Alcohol consumption and the associated health-risks as well as the Hangover are common problems with a negative impact on the consumer as well as the society. Evanium Healthcare is active in alcohol research, with the company pursuing a dietary approach. By the means of custom galenic formulation of the key ingredients Evanium Healthcare could develop tablets for oral consumption and produce them on a pilot system. Wide-ranging patent applications protect the product from imitation and enable a strong market position.



Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 4524465-0
E-Mail: info@evotec.com
Internet: www.evotec.com

Evotec (München) GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Cell Therapy, Metabolomics, Biomarker Discovery & Development, Bioinformatics, Small Molecules, Proteomics, Genomics

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with a broad range of partners. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. Evotec (München) GmbH is the Company's centre of excellence for proteomics, biomarker and metabolomics services.

ExB Health GmbH

IT, DIGITAL HEALTH

ExB Health is a subsidiary of the ExB Labs GmbH, a Germany based technology incubator and research company in the field of unstructured big data, natural language processing, Cognitive Computing and deep learning. Exb Health draws on the labs mature developments and adapts them for the use in lifescience and healthcare. The knowledge discovery and decision support systems help pharma and healthcare industries to lower costs, speed up the drug-development cycle and improve patient outcomes.

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH & Co. KG has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Focused towards high containment manufacturing Excella supplies products to the generic industry and big pharma but also develops processes for innovative API's and novel solid dosage forms. Services offered from our globally registered and approved site range from early product development through registration support to state-of-the-art manufacturing.

Exosome Diagnostics GmbH, a Bio-Techne company

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, R&D Service, In-Vitro-Diagnostics, NGS, Biomarker Discovery & Development, Oncology

Exosome Diagnostics is developing and commercializing biofluid-based diagnostic tests using proprietary technology. The company also offers biopharma services for exploration of exosomal RNA, cell-free DNA, and proteins to identify and validate biomarkers without tissue. The urine-based ExoDx Prostate test is included in the 2019 NCCN Guidelines and will soon be offered as CE-IVD in Europe. Exosome has clinical laboratories in Waltham (US) and Munich (DE) and was acquired by Bio-Techne in 2018.

F-Select GmbH

PHARMA & CHEMICAL INDUSTRY

The element fluorine plays an increasingly important role in the field of high-performance materials and pharmaceuticals. The production of the necessary chemical substances remains a challenge and F-Select has the solution. F-Select offers selected fluorinating agents as well as a comprehensive know-how in the handling and production of fluorinating agents. The methods developed by F-Select provide resource-saving methods for the production of pharmacological building blocks.



St.-Martin-Str. 63
D-81669 München
Phone: +49 (0) 89 55067340
E-Mail: contact@exb.de
Internet: www.exb-health.com/



Nürnberger Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 404-0
E-Mail: info@excella-pharma-source.de
Internet: www.excella-pharma-source.de



Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 416172-70
E-Mail: munich@exosomedx.com
Internet: www.exosomedx.com



Semmelweisstrasse 5
D-82152 Planegg
Phone: +49 (0) 89 74032330
E-Mail: info@f-select.de
Internet: www.f-select.de



Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893 119-0
E-Mail: info@fgk-cro.com
Internet: www.fgk-cro.com



Heimeranstraße 35
D-80339 München
Phone: +49 (0) 89 893 119-0
E-Mail: info@fgk-pv.com
Internet: www.fgk-pv.com



Fürstenstraße 15
D-80333 München
Phone: +49 89 71690877
E-Mail: connect@fluics.com
Internet: www.fluics.com



Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 74776-30
E-Mail: info@foodchainid.de
Internet: www.foodchainid.com/de

FGK Clinical Research GmbH

CRO

Keywords: CRO/CMO, Drug Development, Cell Therapy, Regulatory Affairs, Devices, Data Management and Biostatistics, Clinical Trial Management and Monitoring

FGK is a Europe-based CRO with offices in DE (HQ), PL, CZ and HU, offering full service for all phases of clinical trials. Our international client base includes biotech, medical device and pharma companies. With extensive experience in all major therapeutic areas and 150+ highly qualified medical, scientific and regulatory experts we can guide you through the clinical development process, from planning and approval up until the final report.

FGK Pharmacovigilance GmbH

CRO

Keywords: CRO/CMO, Medical Writing, Clinical Trial Management and Monitoring, Drug Development, Pharmacovigilance, Data Management and Biostatistics

FGK Pharmacovigilance GmbH is a service provider offering vigilance services in support to pharmaceutical, biotech, and medical device companies' obligations in managing risk-benefit profile of their products. Services can be added to existing vigilance system of a client on a modular basis or comprise a stand-alone center of product vigilance on national, international or global level.

FLUICS GmbH

BIOTECH DEVICES & REAGENTS

Keywords: sample tracking, inventory management, QR code printing, IoT, mobile app development

FLUICS CONNECT is a mobile solution that helps innovative research labs to improve efficiency and reproducibility by keeping their sample inventory up to date. With our mobile app and an internet-ready printer connected to an online database we offer a convenient solution to print and track smear proof, QR-coded cryo labels. Watch our 1 min video to see how it works: go.fluics.com/teaser.

FoodChain ID Testing GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Agrobiotechnology, NGS

FoodChain ID Testing GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, genotyping, custom contract assay development) and immunological detection of allergens in food and feed.

Formycon AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Dermatology, Ophthalmology, Drug Development

Formycon is a leading, independent developer of high-quality follow-on products for biopharmaceutical medicines known as biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval.



Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 864667-100
E-Mail: info@formycon.com
Internet: www.formycon.com

Freeline Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Gene Therapy, Industrial Biotechnology, Drug Development

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.



Fraunhoferstraße 9b
D-82152 Planegg
E-Mail: infode@freeline.life
Internet: www.freeline.life



YOUR CRO: FLEXIBLE EXPERTS AND RELIABLE SOLUTIONS.

- ▶ Customized conduct of clinical trials for biotech and medical device companies
- ▶ Highest quality standards, accompanied by frequent and clear communication
- ▶ Combined know-how in all major indications through our 180+ in-house experts in Europe

fgk-cro.com

New Branch Office Berlin

Owned and managed by:

Dipl.-Stat. Martin Krauss
+49 89 893 119-25
martin.krauss@fgk-cro.com

Dr. med. Edgar J. Fenzl
+49 89 893 119-22
edgar.fenzl@fgk-cro.com

Heimeranstrasse 35 · 80339 Munich · Germany

Delivering Reliability





Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 7244 09-25
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de



Galapagos

Luise-Ullrich-Straße 8
c/o Design Offices NOVE
D-80636 München
Phone: +49 (0) 89 26201309
E-Mail: deutschland@glpg.com
Internet: www.glpg.com/deutschland/



DNA NANOTECHNOLOGIES

Am Schlosshof 8
D-91355 Hiltpoltstein
Phone: +49 (0) 9192 243 99 44
E-Mail: info@gattaquant.com
Internet: www.gattaquant.com



Fraunhoferstraße 11a
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 899229-0
E-Mail: info@gba-pharma.com
Internet: www.gba-pharma.com

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, PCR, Infectious Diseases, Chip/Array Technology, In-Vitro-Diagnostics, Clinical Diagnostics, Devices

We provide novel, disruptive and fastest quality molecular diagnostics with special emphasis on near-patient applications which require as little laboratory equipment and training as possible. Our two unique patented technology platforms Lab-direct-RT-PCR and Cycle® Diagnostics cover both microbiological and viral applications for clinical diagnostics as well as for R&D.

Galapagos Biopharma Deutschland GmbH

LIFE SCIENCE / BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis, Inflammation, Small Molecules

Galapagos is a pioneering biotech with a pipeline of innovative therapies to address unmet medical needs. We built an innovative, integrated model that takes us from target discovery, through the discovery of molecules addressing targets, all the way to the development of those molecules into potential medicines, helping people worldwide with severe diseases, including inflammation and fibrosis.

GATTAquant GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy

The worldwide first commercial DNA origami application: The key innovation behind our nanorulers is the application of an elaborate nanotechnology method, which serves as a breadboard to position dye-molecules on the nanometer scale. The used technique, where DNA is folded into predefined shapes, is called DNA origami and allows to attach dye-molecules at will.

GBA PHARMA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: R&D Service, Regulatory Affairs, Laboratory, Analytical Chemistry

GBA Pharma Labs run three GMP-certified and FDA-inspected sites in Germany with more than 160 highly qualified employees and over 4,500 m² of lab space. Our locations for analytical services support domestic and international customers, whether from the private industry or research institutions, with scientific and technical solutions for the development, approval process, and quality control throughout every step of the product lifecycle. Additionally we offer regulatory affairs services.

GBN Systems GmbH

BIOTECH & MEDTECH DEVICES & REAGENTS

For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conductor industry and automation technology. Our product range: From customized components to complete assemblies and machines from initial vision to serial end production. The Facilities are centrally located near Bavarian capital and airport of Munich. Key competencies in: Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics.



Performing Mechatronics
Made in Bavaria

Fellnerstrasse 2
D-85656 Buch am Buchrain
Phone: +49 (0) 8124 5310-0
E-Mail: info@gbn-systems.com
Internet: www.gbn-systems.com

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).



Fürstenrieder Straße 281
D-81377 München
Phone: +49 (0) 89 4581901-0
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services. Another area is DNA genealogy and antropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation).



Candidplatz 13
D-81543 München
Phone: +49 (0) 89 543448-0
E-Mail: info@genedia.de
Internet: www.genedia.de

GeneSurge GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

GeneSurge is your access to individualized diagnostics. Even though we classify tumors according to their place of origin and appearance, each one remains somewhat different at the molecular level. And that is exactly what makes each cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specific to the individual patient. We provide 3 tests to reach your individual profile.



Ottostr. 3
D-80333 München
Internet: www.genesurge.com



Lise-Meitner-Str. 30
c/o IZB
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 8068186
E-Mail: info@genidee.eu
Internet: www.genidee.eu/



Staffelseestraße 6
D-81477 München
Phone: +49 (0) 89 780 179 40
E-Mail: info@gen-plus.de
Internet: www.gen-plus.de



Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com



Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
E-Mail: info@gilyos.com
Internet: www.gilyos.com

GENidee

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Molecular Diagnostics, PCR

GENidee is a young and innovative biotech company specialized in the development, production and sales of molecular biological diagnostic kits for the rapid detection of food-borne pathogens in food. Fast and reliable real-time PCR diagnostics is guaranteed by simultaneous analytics suited to the individual customer requirements. GENidee offers DNA-based detection systems of highest quality. Using our kits directly in the production facilities enables the results of molecular food analytics to be supplied much sooner than by conventional diagnostics.

Gen-Plus GmbH & Co. KG

CRO

Keywords: Laboratory, R&D Service, Drug Development

Gen-Plus GmbH & Co.KG provides solutions for challenging needs in pharmaceutical development and is a state-of-the-art CRDO. We develop tailor-made formulation and technology concepts (NCE, value-added-Generics, OTC) for solid/semisolids, non-steril liquids, patches and thin films from early idea to IMP production under GMP. Further in-house capabilities: narcotics & high potent handling (isolators), 2D&3D API printing, high-tech analytics incl. skin permeation.

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com.

GILYOS GmbH

CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

GILYOS is a contract development solution provider with more than 20 years of experience in pharmaceutical freeze drying. GILYOS` key business is consultancy and hands-on development services. Typical services include formulation development of small molecules and proteins, process optimization and analytical characterization. Further, GILYOS has a very strong expertise in scale-up and technical transfer of freeze drying cycles, including troubleshooting of established products (scale down).

gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie

BIOTECH BIOINFORMATICS

Keywords: Automation, Data Management

Gimbio GmbH offers innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses.

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring

GKM Gesellschaft für Therapieforschung is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for non-interventional studies. GKM also provides services for early benefit analyses (AMNOG), vigilance, and medical writing. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible, cost-effective services with expert knowledge and dedication to your projects.

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology

GSK is a science-led, globally operating healthcare company with a special purpose: to help people do more, feel better, live longer. Our goal is to be one of the worlds most innovative, best performing and trusted healthcare companies. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines, respiratory and additionally in Oncology. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV.



Weihenstephaner Berg 4
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 986 4480
E-Mail: info@gimbio.de
Internet: www.gimbio.de



Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
E-Mail: mail@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de



Prinzregentenplatz 9
D-81675 München
Phone: +49 (0) 89 360 440
E-Mail: service.info@gsk.com
Internet: www.de.gsk.com



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 998 207-180
E-Mail: info@gna-bio.com
Internet: www.gna-bio.com



430 East 29th Street
Alexandria Center for Life Science,
Suite 1435E
USA-NY 10016 New York
E-Mail: bzech@gothamtx.com
Internet: www.gothamtx.com



Gollierstr. 70
D-80339 München
Phone: +49 (0) 89 7264960-0
E-Mail: info@gwk-munich.com
Internet: www.gwk-munich.de



Passauerstraße 35
D-81369 München
Phone: +49 (0) 152 05390057
E-Mail: info@hellsicht.ai
Internet: www.hellsicht.ai

GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, In-Vitro-Diagnostics, Bioanalytics, Molecular Diagnostics, Devices, New Materials, Other Diagnostics

GNA Biosolutions GmbH was founded in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich. The company employs 40 people today. GNA develops instruments, consumables and tests for fast molecular diagnostics, based on its proprietary technology, Pulse Controlled Amplification (PCA). PCA can transform molecular diagnostics by enabling the development of testing platforms that can be used outside of the traditional laboratory setting.

Gotham Therapeutics, NY/Munich

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, Gotham aims to develop new treatment options for patients suffering from cancers, autoimmune and neurodegenerative diseases. The team is applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field.

GWK Präzisionstechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Regulatory Affairs, In-Vitro-Diagnostics, Microscopy, Chip/Array Technology, Automation

GWK Precision Technology offers development and manufacturing of laboratory equipment and medical devices. Being a team of 20 specialists, we serve industry and scientific institutions since 1991. We provide special know-how in technical fields as well as the certification of equipment and production systems following ISO 13485. For the detection of Covid and Legionella we offer a differential diagnostic system using microarray-chip-technology, also see www.LegioTyper.de.

Hellsicht GmbH

BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, Imaging, Data Management, Informatics

We build deep learning software to improve medical diagnosis by combining human expertise with machine intelligence in a unique hybrid approach.

Hematrix Wound Care GmbH

MEDETECH

Keywords: Devices

Hematrix Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.



Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
E-Mail: bertsch@hematrix.de
Internet: www.hematrix.de

HWI regulatory services GmbH

CRO

Keywords: Drug Development, Analytical Chemistry, Medical Writing, Pharmacology, Toxicology, Devices, Regulatory Affairs

HWI regulatory services GmbH (former i.DRAS) provides regulatory services for drug substances and products. For medical devices and drug-device combination products we offer clinical evaluation, biological safety assessments and technical documentation writing for certification. Together with HWI group's services in analytics, development, reference standards, life-cycle management, vigilance and quality we are the one-stop shop for the pharmaceutical, medtech and biotech industries.



Fraunhoferstr. 9
D-82152 Martinsried
Phone: +49 (0) 89 200 0203-50
E-Mail: s.oettl@hwi-group.de
Internet: www.hwi-group.de

HMNC Brain Health GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development

HMNC is a biopharma company developing novel treatments for depression and anxiety: Proprietary gene-based companion tests support the decision which drugs optimize treatment effects. Our portfolio includes investigational drugs targeting stress systems in the brain. A novel formulation of ketamine holds promise to become prime option for treatment resistant depression. The myGeneCode1-test informs whether a given antidepressant passes the blood-brain barrier. The test is already on the market.



Wilhelm-Wagenfeld-Str. 20
D-80807 München
Phone: +49 (0) 89 36090200
E-Mail: info@hmnc.de
Internet: www.hmnc.de



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 520 59694
E-Mail: info@htcr-services.com
Internet: www.htcr-services.com



Am Forst 6
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
E-Mail: info@hti-automation.com
Internet: www.hti-automation.com



Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
E-Mail: info@hyglos.de
Internet: www.hyglos.de



Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 4612531
E-Mail: stefan.miller@hyperthermics.com
Internet: www.hyperthermics.com

Human Tissue and Cell Research-Services (HTCR) GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Biomarker Discovery & Development, Bioprocessing, Tissue Engineering/Cell Culture, Toxicology

HTCR-Services (HSG) develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used for prognosing metabolism of novel drugs and for in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products, HSG provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extend.

HTI Automation GmbH

BIOTECH DEVICES & REAGENTS

Keywords: In-Vitro-Diagnostics, Laboratory, Clinical Diagnostics, Devices, Automation

For more than 20 years we have regularly challenged ourselves always in the service of our customers. With our engineering services and our solutions for laboratory and production automation, we are the strategic partner for your continued success.

Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Proteomics, Infectious Diseases, Peptide/Protein, Clinical Diagnostics

Hyglos is BioMérieux's Endotoxin Center of Excellence based in Bernried, Germany. Our ENDONEXT(TM) range of recombinant Factor C assays and our ENDOXPERS(TM) services provide innovative solutions for endotoxin detection. We aim at revolutionizing the endotoxin detection market through the replacement of historical animal-source based methods by modern, sustainable and ecological techniques, leveraging significant advantages such as accuracy, sensitivity, lot-to-lot consistency, and easy automation.

Hyperthermics Regensburg GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hyperthermics Regensburg GmbH is a biotechnology company developing applications of hyperthermophilic organisms in renewable energy solutions and in industrial processes. In these applications hyperthermophilic microorganisms are the "software". In the initial phase we are focusing on developing applications together with international industrial partners. In an operational phase we will focus our research activities towards "software development and update".

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

The ibidi product lines includes micro-Dishes, -Slides, and -Plates for the cultivation and high-resolution microscopy of cells, and also cell-based assays for investigating angiogenesis, chemotaxis, wound healing, and cells under flow. ibidi also specializes in instruments, such as stage top incubators for live cell imaging under physiological conditions, plus a unique perfusion system for the simulation of blood vessels. The company also offers reagents and cell lines for live cell imaging.



Lochhamer Schlag 11
D-82166 Gräfelfing
Phone: +49 (0) 89 520 46 17-0
E-Mail: info@ibidi.de
Internet: www.ibidi.de

ImevaX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Industrial Biotechnology, In-Vitro-Diagnostics, Clinical Diagnostics, Biomarker Discovery & Development

ImevaX GmbH, founded in 2013, is a Munich based life science company focussed on novel infection diagnosis. Current product in development is an innovative H. pylori rapid test that combines unprecedented sensitivity, specificity and speed. It determines the presence of two specific antibodies to H. pylori, FliD and CagA, that allow a risk-stratification into low- and high-risk groups for development of gastric cancer. ImevaX owns the global patent for the detection of antibody marker FliD.



Sendlinger Str. 60
D-80331 München
Phone: +49 (0) 89 4140 2477
E-Mail: info@imevax.com
Internet: www.imevax.com

IMGM Laboratories GmbH

BIOTECH & PHARMA PRODUCTION

Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics, Pharmacogenomics

IMGM Laboratories are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover biomarker discovery, pharmacogenetics, metagenomics and biodistribution studies of nucleic acid compounds. In close collaboration to our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification.



Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 452 4667-0
E-Mail: info@imgm.com
Internet: www.imgm.com



immatics

Machtlfinger Straße 11
D-81379 München
Phone: +49 (0) 89 540415-0
E-Mail: info@immatics.com
Internet: www.immatics.com



Karlstrasse 46
D-80333 München
Phone: +49 (0) 89 5432177-89
E-Mail: info@immumed.de
Internet: www.immumed.de



Lochhamer Schlag 21
82166 Gräfelfing
Phone: +49 89 2080 477 61
E-Mail: info@imux.com
Internet: www.imux.com

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Cell Therapy, Personalized Medicine, Immune Therapy, Oncology, Genomics, Proteomic

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells - unlocking new avenues for patients in their fight against cancer.

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology - Testing Services We offer testing services for scientific samples: - Analysis of cytokines, chemokines and hormones - Cell-characterization - Cytotoxicity. Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform many applications for flow-cytometry analysis, for example cell phenotyping or cytotoxicity assays, as well as a broad range of metabolic and aging parameters.

Immunic AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Autoimmune Diseases, Inflammation, Drug Development, Immune Therapy

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Gräfelfing/Munich, Germany, where the company's research and development activities are conducted.

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH, established in 1997, is a privately owned antibody manufacturer. Full service custom antibody services are supplemented by epitope mapping (single amino acid precision) and recombinant antibody technologies in cooperation with different partners. A special focus is on antibodies to posttranslational modifications (PTM), such as combinations of different (de)phosphorylation states of neighboring sites, neo-epitopes (e.g. cleavage sites), isoforms, variants, and point mutations.



Rudolf-Diesel-Str. 8a
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.



Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
E-Mail: info@implen.de
Internet: www.implen.de

Independent Data Lab

BIOTECH BIOINFORMATICS

Genomic data has become an essential part of almost every project in molecular biology and medicine. Unfortunately, high rate of rotation of personnel in academic environment has made it difficult to maintain collaborations for projects that often can last for years. At IDL we are committed to making sure every dataset receives the most thorough attention, and makes it's contribution to the progression of science.



Josef-Frankl-Straße 5A
D-80995 München
E-Mail: info@independentdatalab.com
Internet: www.independentdatalab.com

INCYTON GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, Drug Development, Toxicology, R&D Service, In-Vitro-Diagnostics, Imaging, Bioanalytics

INCYTON multi-sensor systems monitor different cellular key parameters simultaneously, in real time and label free. Our technology records each event, giving the user full control at every time-point without the need to be constantly present. A highly automated testing process reduces the time spent carrying out even the most complex assays. INCYTON smart technologies are combined in one housing creating a global environment control and reducing the risk of contamination and variations.



Am Klopferspitz 19a
D-82152 Planegg-Martinsried
E-Mail: info@incyton.com
Internet: www.incyton.com

INFORS HT

Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com



Sonnenstraße 24-26
D-80331 München
E-Mail: contact@ingeneron.com
Internet: www.ingeneron.com



Balanstr. 6
D-81669 München
Phone: +49 (0) 89 48777-4
E-Mail: info@I-A-Z-zellkultur.de
Internet: www.I-A-Z-zellkultur.de



virion\serion

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, shaker incubators and bioprocess software. We offer the right solutions for the cultivation of microorganisms and cell cultures: Customer specific bioreactors and incubation shakers including qualification, parallel bioprocesses, and integration of all your bioprocesses in one software platform. Close customer relationships, high quality, innovation and flexibility are our greatest strengths.

InGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service, Tissue Engineering/Cell Culture

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases, Automation

Institut Virion\Serion GmbH is an in-vitro diagnostic company. Our product portfolio for the diagnosis of infectious diseases contains SERION ELISA classic tests for quantified antibody detection in human serum, plasma, and against various viral, bacterial and parasitic infections. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt allow simultaneous antibody detection against multiple antigens using flow cytometry.

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, R&D Service

Intana Bioscience GmbH is a privately owned service provider company. We contribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candidates, and by supporting drug discovery and development efforts from target validation to clinical testing. Our services cover target validation, assay development, screening, support of PK/PD studies and target occupancy measurements.



Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 895 572-80
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

inveox GmbH

IT, DIGITAL HEALTH

Keywords: Other Diagnostics, Data Management, Devices, Clinical Diagnostics, Laboratory, Imaging, Tissue Engineering/Cell Culture

inveox has the goal of making cancer diagnosis faster, safer, and more reliable. In today's labs, tissue samples (biopsies) are at risk of being mixed-up, contaminated or lost. But our products are designed to work as a cohesive unit to make this a thing of the past. We help patients and doctors. In addition, we create the lab of the future by bringing big data, artificial intelligence, and machine learning to labs. This provides better research data for scientists so they can eradicate cancer.



Lichtenbergstraße 8
D-85748 Garching bei München
Phone: +49 (0) 89 57847601
E-Mail: info@inveox.com
Internet: www.inveox.com

Invitrocue Europe AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, 3D-Structural Analysis, Other Diagnostics, Tissue Engineering/Cell Culture, Laboratory

Invitrocue Europe AG is an innovative leading healthcare bio-analytic company, that specialises in ex-vivo 3D cell culture models such as PDOs as well as in-vivo models by producing HiMice™ as promising tools for personalized cancer treatment. IVQ imparts to the industry valuable knowledge in creating better, faster and more affordable disease treatments.



Hildegardstr. 9
D-80539 München
Phone: +49 (0) 89 998209483
E-Mail: contact.de@invitrocue.com
Internet: www.invitrocue.com

Intercept Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, Intercept now has operations in the United States, Europe, Canada, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the 'liver community'.



Rosenheimer Str. 52
D-81669 München
Phone: +49 (0) 89 4111 124 11
E-Mail: info-DE@interceptpharma.com
Internet: www.interceptpharma.com/about/germany



Fraunhoferstraße 13
D-82152 Planegg-Martinsried
Internet: www.iomx.de



Einsteinstraße 174
D-81677 München
Phone: +49 (0) 89 262036100
E-Mail: contact.ipсен.germany@ipсен.com
Internet: www.ipсен.com/germany



Adalbert-Zoellner-Straße 1
D-95615 Marktredwitz
Phone: +49 (0) 9231 97121-15
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de

IRUBIS

Schillerstraße 40b
D-80336 München
E-Mail: info@irubis.com
Internet: www.irubis.com

iOmx Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Immune Therapy

iOmx Therapeutics is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune-checkpoints hijacked by cancer cells. Using the foundational iOTarg discovery platform, iOmx has identified several new tumor-associated immune-checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. For more details, please visit www.iomx.com.

Ipsen Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Ipsen Pharma GmbH, subsidiary of the Ipsen Group for Germany, Austria and Switzerland, has been commercializing various drugs in the fields of oncology, neuroscience and rare diseases in Germany for more than 40 years. In 2019, the company relocated its headquarters to the competence center Munich. Ipsen would like to utilize the vibrant research landscape, with its numerous universities and clinics, to further promote the innovative spirit and the biotech mindset of within the company.

Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Starting materials for peptide synthesis, peptidomimetic and medicinal chemistry: protected amino acids, coupling reagents, linkers and resins, natural and unusual amino acids and natural compounds with physiological properties. 2. Technologies for Drug Delivery: more than 900 different carriers used in polymer therapeutics products (PEGylating reagents, Poly(amino acid)s and Poly(2-oxazoline)s. 3. Custom synthesis in all areas above, especially compounds with one or several chiral centers.

IRUBIS GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Drug Development, Bioanalytics, Bioprocessing, Peptide/Protein, Devices, Analytical Chemistry, Tissue Engineering/Cell Culture

IRUBIS offers an innovative analytical device for online monitoring of upstream and downstream processing in the production of biopharmaceutical drugs. Applications are in metabolite monitoring and control, as well as in downstream bioprocessing to aid in aggregation studies, contaminant detection or monitoring of target proteins and excipients.

ISAR Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Neuro-Degeneration, Cell Therapy, Industrial Biotechnology, Biomarker Discovery & Development, Drug Development, Tissue Engineering/Cell Culture, Nutraceuticals

ISAR Bioscience GmbH is a translational research company. We overcome current limitations of stem cell research in order to advance development of novel therapeutics and industrial biotechnology products. We use human iPSC and genome editing technologies to build the next generation of disease models and cell-based models for biotechnology applications. ISAR forges strategic partnerships with industry partners and translates academic achievements and ideas into industrial solutions and products.

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, "MSOT" = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

ITM Isotope Technologies Munich SE

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology

ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. ITMs main objectives are to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies.

ISAR Bioscience



Semmelweisstr. 5
D-82152 Planegg
Phone: +49 (89) 3564 754-00
E-Mail: info@isarbioscience.de
Internet: www.isarbioscience.de

iTheraMedical

Listening to Molecules

Zielstattstr. 13
D-81379 München
Phone: +49 (0) 89 700 7449-0
E-Mail: info@ithera-medical.com
Internet: www.ithera-medical.com



Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 329 8986 600
E-Mail: info@itm-radiopharma.com
Internet: www.itm-radiopharma.com



Elisabeth-Selbert-Weg 4
D-93055 Regensburg
Phone: +49 (0) 941 30798265
E-Mail: kalbitzer-innovations@t-online.de
Internet: www.kalbitzer-innovations.de

KANTAR

Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600 1005
E-Mail: info@kantarhealth.com
Internet: www.kantarhealth.com



Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 895286-0
E-Mail: info-de@klifo.com
Internet: www.klifo.com

Kalbitzer Innovations UG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3D-Structural Analysis, Bioinformatics, Bioanalytics, Drug Development, Oncology

Kalbitzer Innovations is a spin-off from the Institute of Biophysics and Physical Biochemistry (University of Regensburg) that provides novel experimental as well computational methods. It is focused on the application of high pressures on proteins in drug design, drug screening and protein refolding/renaturation. Kalbitzer Innovations develops software for specific application in NMR-based analytics as AUREMOL, a software package for automated protein structure determination.

Kantar GmbH

CRO

Keywords: Logistics, Pharmacovigilance, Oncology, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

Kantar GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmaco-economic studies. Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, data management, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.

KLIFO GmbH

CRO

Keywords: Medical Writing, Devices, Drug Development, Regulatory Affairs, Clinical Trial Management and Monitoring, Pharmacovigilance, Data Management and Biostatistics

KLIFO owns significant experience in partnering with biotech and pharma companies providing end-to-end expert capabilities. At KLIFO, we offer multidisciplinary consulting and operational solutions across all areas of clinical research, clinical trial supply, QA, CMC development, regulatory affairs, PV and the development of pharmaceutical/biotech products and medical devices. KLIFO has offices in Denmark, Sweden, Germany and The Netherlands and employs more than 150 highly skilled employees.

KLIFOVET AG

CRO

Keywords: Data Management and Biostatistics, Drug Development, Regulatory Affairs, Pharmacovigilance, Clinical Trial Management and Monitoring

KLIFOVET AG is a full service veterinary CRO and Regulatory Consultancy and provides the following services: evaluation of research projects, Regulatory Consultancy, Life Cycle Management & PhV, Preclinical and Clinical Studies, Quality Assurance, Data Management and more. Experienced in all species, we manage the development of VMPs & Feed/ Feed Additives in every step. Multiple Animal Pharm Awards in 2006, 2015 and "Best Service Company for 2019 show our long term commitment to our customers.



Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580 082-0
E-Mail: info@klifovet.com
Internet: www.klifovet.com

Precisely for me.

With patient benefit as the driving principle for all we do, we provide the most precise cancer radiotherapeutics and diagnostics to fight hard-to-treat tumors.

We are leveraging our radioisotope leadership to advance a broad pipeline of Targeted Radionuclide Therapies enabling nuclear medicine to reach its full potential.

www.itm-radiopharma.com

itm
PASSION FOR PRECISION



Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 8161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de



LABOR FÜR KLINISCHE DIAGNOSTIK GMBH & CO. KG

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971 7202-0
E-Mail: mueller@laboklin.de
Internet: www.laboklin.com



Von-Heyden-Str. 11
D-93105 Tegernheim
Phone: +49 (0) 9403 967 98-0
E-Mail: info@labor-friedle.de
Internet: www.labor-friedle.de



Mangelsfeld 4, 5, 6
D-97708 Bad Bocklet
Phone: +49 (0) 9708 9100-0
E-Mail: service@labor-ls.de
Internet: www.labor-ls.de

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs care for organismic studies e.g. in Wildlife Biology, Phylogeny, Taxonomy, and Conservation Biology to clear up specimens' identities by means of DNA analyses (sample preparation, PCR, DNA sequencing) for purposes like identifying species, detecting animal pre-/absence, delimiting species boundaries, resolving species relations a.s.o. Off the lab, mapping species inventories or searching for organisms including electro fishing is our business.

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

Labor Friedle GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy

Labor Friedle GmbH is an internationally active residue analysis laboratory based in Tegernheim near Regensburg. It focuses on chemical, chemical-physical, microbiological and mycological analyses of food samples, especially fruits and vegetables. Consumer goods, cosmetics, pharmaceuticals, cleaning products and animal feed (pet food) as well as environmental medical issues from human biological matrices are also examined.

Labor L+S AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry

The Labor LS is one of the leading European CROs for analytics and consulting for pharmaceuticals and medical devices. More than 1000 customers trust in the company's experience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials and on finished products. In addition, services in industrial hygiene and clinical-microbiological diagnostic are offered.

LabPMM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics

LabPMM (an Invivoscribe® company) is your partner of choice for diagnostic, research, and clinical trial services. Our network of laboratories located in the USA, Europe and Asia specialize in internationally harmonized molecular testing and collectively have CLIA and ISO15189 certifications via CAP and DAkkS. We offer an ever expanding menu of molecular assays, including NGS gene and MRD panels, FLT3 and NPM1 mutation assays, and B- and T-cell clonality and MRD assessment.

Lead Discovery Center GmbH, LDC - Abteilung Antikörper

BIOTECH PRECLINICAL SERVICES

The lead discovery center GmbH was founded in 2008 by the Max Planck Society in order to exploit the potential of the excellent basic research for the development of new, urgently needed drugs. The Lead Discovery Center collects promising academic research projects and develops them further into pharmaceutical lead structures (Proof-of-concept in model systems). In close collaboration with leading academic and industrial partners the Lead Discovery Center develops an extensive project portfolio in the fields of small molecules (Dortmund) and therapeutic antibodies (Planegg) with high medical and commercial potential.

leon-nanodrugs GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, R&D Service, Liposomes, Small Molecules, Peptide/Protein

LEON utilises its proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles (ranging from surface stabilised polymeric through to lipid nanoparticles (LNP's) and liposomes). Working with world class industry partners for both process and product development, leon is focused on process engineering solutions and combining with development and formulation expertise we expedite APIs small and large molecules, NCE or generics to deliver improved solutions.

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics. Our technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products. They provide manifold benefits as improved shelf-life, terminal sterilization and significant production cost savings. LEUKOCARE provides development services based on fee for service during implementation of its technologies.

LabPMM GmbH
an invivoscribe company

Zeppelinstr. 1
D-85399 Halbergmoos
Phone: +49 (0) 89 899 480 780
E-Mail: szorbas-seifried@labpmm.de
Internet: www.invivoscribe.com/clinical-service



Semmelweisstr. 5
D-82152 Planegg
Phone: +49 (0) 231 97 42 70 00
E-Mail: info@lead-discovery.de
Internet: www.lead-discovery.de



Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 4142 4889-0
E-Mail: info@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com

LEUKOCARE

Am Klopferspitz 19
D-82152 Martinsried/Munich
Phone: +49 (0) 89 7801665-0
E-Mail: info@leukocare.com
Internet: www.leukocare.com



Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 942 898 0
E-Mail: info@lifespın.de
Internet: www.lifespın.de



Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700 766 24
Internet: www.lindisbiotech.com



Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 28096-208
E-Mail: info@lisando.com
Internet: www.lysando.com



Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
E-Mail: info@livimplant.de
Internet: www.livimplant.de

lifespın GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: In-Vitro-Diagnostics, R&D Service, Analytical Chemistry, Agrobiotechnology, Laboratory, Bioanalytics, Biomarker Discovery & Development

Digitize the metabolism - we measure biological processes in medicine and biotechnology: fast, precise, cost-efficient. lifespın offers diagnostic/analytical NMR-services, software solutions and databases, for R&D, routine industrial use, diagnostics and QC in medical research, the pharmaceutical industry, plant research and biotechnology. The portfolio ranges from standardized multiparameter quantification, metabolomics-based classification, to the integration of big data approaches.

LINDIS Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

LINDIS Biotech was founded to develop ektomun[®], an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options. The company is managed by Horst Lindhofer, inventor of the underlying trifunctional antibody technology and CEO of TRION Pharma.

Lysando Innovations Lab GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

LYSANDO AG is the world leading company for the development of antimicrobial proteins to combat Gram-positive and Gram-negative pathogens. In a wide range of fields including hygiene, agriculture, domestic and livestock husbandry, medical devices, veterinary and human pharma, LYSANDO AG provides a solution that is right for every customer. LYSANDO AG has been certified by the quality management standards of EN ISO 13485.

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Ludwig-Maximilians-University of Munich and a close collaboration with the Veterinary Clinic of the University of Giessen, LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA/EIA

LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Immune Therapy, Infectious Diseases

Lophius mission is to transform treatment paradigms and patient management with novel molecular diagnostic solutions for life threatening infectious diseases. The core program addresses an unmet clinical need in tuberculosis (TB) with a proprietary blood-based multi-marker solution to improve TB infection detection and enable differential diagnosis. Lophius also markets a clinically validated CE-marked IVD to individualize transplant patient management by personalized CMV risk stratification.

LRE Medical GmbH

MEDTECH

Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics

LRE Medical is a leading provider of contract engineering and manufacturing of complex, highly integrated instrumentation for IVD, MedTech and Life Sciences. The spectrum of instruments ranges from PoC, field-testing systems through analyzers based on a variety of technologies including solutions for molecular diagnostics. LRE offers one-stop shop solutions from feasibility, product development, manufacturing, after-safer-sales service to lifetime support. 60 years of expertise and continuity.

Luye Pharma AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Luye Pharma AG Miesbach is one of the largest independent manufacturers of transdermal delivery systems in Europe with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone treatments. Luye Pharma AG also acts as the EU hub for Luye Pharma Groups development efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards.

LOEWE®

Mühlweg 2 a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com

lophius

biosciences

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 6309 197-0
E-Mail: request@lophius.com
Internet: www.lophius.com



Georg-Brauchle-Ring 89
D-80992 München
Phone: +49 (0) 89 354803-47
E-Mail: info@lre.de
Internet: www.lre.de



Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
E-Mail: info@luyepharma.eu
Internet: www.luyepharma.eu



Lilienthalstrasse 4
D-82205 Gilching
Phone: +49 (0) 8105 7783 30
E-Mail: pr@mdservices.de
Internet: www.mdservices.de

medigene

Lochhamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 2000 33-0
E-Mail: medigene@medigene.com
Internet: www.medigene.com



Keltenring 15
D-82041 Oberhaching
Phone: +49 (0) 89 12 11 26 36
E-Mail: info@medizone.com
Internet: www.medizone.com



Theresienhöhe 30
D-80339 München
Phone: +49 (0) 89 895 5718-0
E-Mail: info.de@medpace.com
Internet: www.medpace.com

Medical Device Services GmbH

PHARMA & CHEMICAL INDUSTRY

Biological Safety of Medical Devices: Our test laboratories at Medical Device Services have been synonymous with success for medical device manufacturers for 20 years.

Medigene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Immune Therapy, Gene Therapy

Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

Medizone Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Clinical Trial Management and Monitoring, Logistics, R&D Service

Medizone Germany is your trusted and reliable partner regarding sourcing of comparator products for clinical trials and analytical samples for biosimilar development. We are authorized to import comparators into the EU with proper certification through our Qualified Person. With an extensive network of well-established approved suppliers, Medizone prides itself with meticulous quality standards when providing global sourcing services.

Medpace Germany GmbH

CRO

Keywords: Oncology, Metabolic Diseases, Cardiovascular Diseases, Imaging, Pharmacovigilance, Drug Development, Regulatory Affairs

Medpace is a global, full-service clinical CRO providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpaces mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, endocrinology, central nervous system and anti-viral.

MedPharmTec GmbH

CRO

Keywords: Medical Writing, Pharmacovigilance, Regulatory Affairs

MedPharmTec is a service provider for pharmaceutical medicine. Our customers: pharmaceutical industry and companies in the biotechnology, medical technology and food industries. Our services: Proofreading of special and product information // Creation/maintenance of drug information // Authorization maintenance (e.g. creation of PSURs) // Consulting for pharmacovigilance and Clinical Trials/NIS // Preparation/Submission of Ethical Applications and official registrations.

metabion

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics

metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Metabion offers production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs as well as the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time.

Metabolon GmbH

LIFE SCIENCE / BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Agrobiotechnology, Nutraceuticals, Metabolomics, Drug Development

Metabolomics in the heart of Europe. Where other „omics“ technologies reach their limits, Metabolon's strength begins. With results close to the phenotype, we open doors that other technologies cannot. We welcome you at any time in our International HQ in Hallbergmoos.

MetaHeps GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development

MetaHeps® is an innovative service provider specialized to identify or exclude drug-induced liver injury (DILI) in an individual patient using a blood sample. MetaHeps tackles DILI in clinical trials or postmarketing as a major cause of drug attrition: As a diagnosis of exclusion, DILI suspicion may be incorrect in up to 50% of cases. Now, the MetaHeps technology allows to clear a drug from DILI suspicion, or - in case DILI is confirmed - biomarker development using the cell- and databank.



Neuhauser Str. 47 / IV
D-80331 München
Phone: +49 (0) 89 354 998-0
E-Mail: office@medpharmtec.de
Internet: www.MedPharmTec.de



Semmelweisstr. 3
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
E-Mail: info@mymetabion.com
Internet: www.metabion.com



Zeppelinstraße 3
D-85399 Hallbergmoos
Phone: +49 (0) 89 99017752
E-Mail: rpfister@metabolon.com
Internet: www.metabolon.com



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 89 7007 6614
E-Mail: info@metaheps.com
Internet: www.metaheps.com

METRONOMIA

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
E-Mail: info@metronomia.net
Internet: www.metronomia.net

Metronomia Clinical Research GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

Metronomia is a specialized CRO for biostatistical consulting, biostatistics, clinical data management and medical writing in Munich. Experience: > 600 projects since foundation in 1990, proven track record in all major therapeutic areas and all clinical phases / NIS. Customers: Biotech-, pharma- and medical device companies, universities, CROs. Commitment: High-quality and reliability of our data, outstanding flexibility and personal service through stable teams, competitive cost-benefit ratio.

To ensure that ingenious solutions receive their rightful protection,

we are there by your side - 230 dedicated team players at the cutting edge between law and science. We devote all our energy to supporting our clients: with our expertise in 23 practice areas. With our ideal blend of specialist legal knowledge, economic ingenuity and technical know-how. With the competence of 80 patent attorneys and lawyers. And above all: with the personal passion for our clients' interests.

MGZ Medizinisch Genetisches Zentrum

CRO

Keywords: Personalized Medicine, Oncology, Bioinformatics, Genomics, Laboratory, Clinical Diagnostics

The MGZ, Medical Genetics Center is one of the leading laboratories for human genetics in Europe and combines interdisciplinary medical expertise with a cutting-edge, accredited (DIN EN ISO 15189) laboratory. With a team of physicians, scientists and bio-informaticians as well as a broad spectrum of methods such as short- and long-read sequencing, array, conventional cytogenetics, molecular combing, polygenic risk scores and liquid biopsy, the MGZ serves patients, physicians and pharmaceutical companies.



Bayerstraße 3-5
D-80335 München
Phone: +49 (0) 89 30 90 886-0
E-Mail: info@mgz-muenchen.de
Internet: www.mgz-muenchen.de

Microcoat Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: In-Vitro-Diagnostics, Bioanalytics, PCR, Laboratory, Pharmacokinetics, ELISA/EIA

Custom Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits. Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating. Biomarker Services, PK/PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, GLP, GC(L)P, cGMP.



Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
E-Mail: info@microcoat.de
Internet: www.microcoat.de

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: PCR, Clinical Diagnostics, ELISA/EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip/Array Technology

MIKROGEN is a global provider of system solutions for medical laboratory diagnostics. We combine excellent genetic engineering know-how with scientific background and consistent customer orientation. The extensive and efficient evaluation of system solutions in collaboration with scientific experts and institutes is the basis for reliable diagnoses. MIKROGEN offers a wide range of system solutions for the indirect detection (antibodies) and direct detection (PCR) of pathogen.



Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
E-Mail: meyer@mikrogen.de
Internet: www.mikrogen.de



Haidgraben 5
D-85521 Ottobrunn
Phone: +49 (0) 89 700 9608-0
E-Mail: contact@rm.minaris.de
Internet: www.rm.minaris.com



Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-664
E-Mail: csimmet@minitube.de
Internet: www.minitube.de



Fallstrasse 9
D-81369 München
Phone: +49 (0) 160 777 0880
E-Mail: info@mk2.bio
Internet: www.mk2.bio



Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 990 17-0
E-Mail: info@mll.com
Internet: www.mll.com

Minaris Regenerative Medicine GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Gene Therapy, Cell Therapy, R&D Service, Gene Transfer

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years experience providing outstanding quality and reliability. Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies.

MINITÜB GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Minitüb is an international established system supplier for assisted reproduction of domestic animals, notably in the areas of A.I., cryobiology and E.T. Through its participation in MWM Biomodels GmbH, a spin-off company of LMU Munich, Minitüb is also engaged in the development and characterization of transgenic large animal models for biomedical research. Current projects focus on genetically modified pigs for xenotransplantation, transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency.

mk2 Biotechnologies GmbH

LIFE SCIENCE / BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Industrial Biotechnology, Bioanalytics, R&D Service

mk2 Biotechnologies develops, produces and investigates peptides at highest purity and quality standards using a revolutionary synthesis technology. We are able to synthesize any kind of peptide, regardless of its physical or chemical properties. We are strongly convinced, that our process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Laboratory, Oncology, Hematology, PCR, Genomics

MLL Munich Leukemia Laboratory is a leading institution for leukemia diagnostics and research. An interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis and includes: cytomorphology, chromosome analysis, immunophenotyping, cytogenetics, FISH, and molecular genetics. MLL performs also WGS. Several workflows are already supported by AI. This combination gives medical professionals an essential foundation to ensure ideal patient care.

Molecular Machines & Industries GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Molecular Diagnostics, Devices

MMI Microdissection, Micromanipulation and Imaging MMI is the leading provider of unique technologies for microdissection, micromanipulation, and imaging with a wide range of clinical and research applications. I.e. Capillary-based selective isolation of single cells (CellEctor), Pico-cut laser microdissection to isolate cells in tissue (CellCut), Microscopy-integrated Whole Slide Imaging (CellScan), Optical tweezers to quantify biological forces (CellManipulator).



Molecular Machines & Industries

Breslauer Strasse 2
D-85386 Eching
Phone: +49 (0) 89 319 048 40
E-Mail: info@molecular-machines.com
Internet: www.molecular-machines.com

Molecular Networks GmbH - Computerchemie

BIOTECH BIOINFORMATICS

Keywords: Molecular Modelling, Toxicology, Small Molecules

Molecular Networks and Altamira (MN-AM) offer innovative approaches and solutions for chemoinformatics, computational toxicology and safety/risk assessment of chemical compounds. The ChemTunes-ToxGPS® software platform provides a unique combination of expert-reviewed toxicity databases, MoA-based in silico predictions for human health endpoints and workflows to support, e.g., Read-Across and ICH M7 GTI studies. A rigorous decision theory approach delivers weight of evidence-based final outcomes.



Neumeyerstraße 28
D-90411 Nürnberg
Phone: +49 (0) 911 597 424 00
E-Mail: info@mn-am.com
Internet: www.mn-am.com

Molekula GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibiotics, Analytical Chemistry, New Materials, Medicinal Chemistry, Peptide/Protein, Fine Chemicals/Reagents

Molekula is a leading chemical supplier offering research chemicals and biochemicals sourced from production sites across the globe. Our clients ranging from university labs to big industrial players. With offices in the UK, USA, China, Germany and Italy, our global insight into the market keeps us firmly at the forefront of this industry. We hold over 8000 ex-stock products and also have in-house production of tailor-made gases in solutions and Grignard reagents.



Landshuter Allee 12
D-80637 München
Phone: +49 (0) 89 360 900 900
E-Mail: dinfo@molekula.com
Internet: www.molekula.com



Semmelweisstraße 7
D-82152 Planegg
Phone: +49 (0) 89 89927-0
E-Mail: info@morphosys.com
Internet: www.morphosys.com



Lichtenbergstraße 8
D-85748 Garching b. München
Phone: +49 (0) 89 215 366 18
Fax: +49 (0) 89 215 366 19
E-Mail: info@msaid.de
Internet: www.msaid.de



Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 800 673 673 673
E-Mail: infocenter@msd.de
Internet: www.msd.de

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Small Molecules, Nephrology, Oncology, Antibody

MorphoSys is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. In July 2020, the FDA granted accelerated approval of the company's first proprietary product Monjuvi® for patients with a certain type of lymphoma. MorphoSys Group is headquartered near Munich, Germany, and includes the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc.

MSAID GmbH

LIFE SCIENCE / BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Informatics, Bioanalytics, Data Management and Biostatistics, Bioinformatics

MSAID transforms the way scientists analyze proteomics data. The company was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. Our ambition is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper and more reliable way of interrogating proteomic data.

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Infectious Diseases, Oncology, Diabetics, Cardiovascular Diseases, Antibiotics, Vaccines

MSD Merck & Co., Inc., in the USA and Canada, with headquarters in Kenilworth, NJ, USA is a leading global healthcare company. MSD's core business is the discovery, development, production and distribution of prescription medicines, vaccines, biologic therapies and animal health products. In 2017, the company generated sales of approximately 40.1 billion US dollars with approximately 69,000 employees in more than 140 countries. The company has its German headquarters in Haar near Munich.
Twitter: @MSD_Deutschland

multi-service-monitoring

CRO

Keywords: Regulatory Affairs, Devices, Autoimmune Diseases, Clinical Trial Management and Monitoring, Oncology, , Drug Development

multi-service-monitoring CRO (founded in 2003) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and "DIN ISO 14155".



Ahornweg 8
DE-93176 Beratzhausen
Phone: +49 (0) 9493 95 92 966
E-Mail: info@multi-service-monitoring.de
Internet: www.multi-service-monitoring.de

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Imaging, Antibody, Oncology, Immune Therapy, Drug Development, Personalized Medicine, Cell Therapy

multimmune GmbH is a clinical stage biopharmaceutical company delivering new theranostics for tumours expressing surface-bound Hsp70, a tumor-specific marker which is present on about 70% of all cancer entities. Current pipelines include: activated autologous Natural Killer (NK) cells (Phase II for lung cancer), monoclonal antibody-based therapeutics and imaging (preclinical) and inducing tumor-specific apoptosis using recombinant human serine protease (preclinical).



Kirchenstrasse 82
D-81675 München
E-Mail: graham.pockley@multimmune.com
Internet: www.multimmune.com

MVZ Martinsried GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Genomics, Bioinformatics, Oncology, Personalized Medicine, Laboratory

The Center for Human Genetics and Laboratory Diagnostics in Martinsried continues to broaden its expertise and competencies. The interdisciplinary collaboration between five medical specialist areas - Human genetics, Laboratory Medicine, Microbiology/Virology, Transfusion Medicine, Molecular Oncology/Pathology - enables diagnostic questions to be more efficiently, comprehensively and accurately resolved. Accredited according to DIN EN ISO/IEC 17025 and ISO 15189.



Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
E-Mail: info@medizinische-genetik.de
Internet: www.medizinische-genetik.de



Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-0
E-Mail: csimmet@minitube.de
Internet: www.mwm-biomodels.com



Ganghoferstraße 70a
D-80339 München
Phone: +49 (0) 89 2190 95-0
E-Mail: info@nanion.de
Internet: www.nanion.de



Würmstraße 4
D-82319 Starnberg
Phone: +49 (0) 8151 959022-0
E-Mail: info@nanosaar.com
Internet: www.nanosaar.com



Flößergasse 4
D-81369 München
Phone: +49 (0) 89 4522 895-0
E-Mail: info@nanotemper.de
Internet: www.nanotempertech.com

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies is a world leading provider of Automated Patch Clamp (APC) electrophysiology systems, with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS). Founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), Nanion's product range includes in vitro systems for membrane pump/transporter, and bilayer recordings, and confluency and contractility measurements from cells monolayers (impedance/EFP).

nanoSaar AG

NANOTECHNOLOGY

Keywords: Nanobiotechnology

THE POWER OF NANO! nanoSaar AG is a leading provider of tailor-made nanotechnology solutions that give a wide range of partners from the chemical industry a competitive advantage. - Very homogeneous, superior product quality - Continuous, cost-effective production process - Fast, simple scale-up for industrial chemical production - Business opportunities with license or joint venture models - You can find out more at: www.nanosaar.com

NanoTemper Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Devices, Bioanalytics, Drug Development, Bioprocessing, Vaccines

NanoTemper provides biophysical instruments, kits & software. We have a strong customer focus and stand for strong commitment to quality, ease of use and high precision instrumentation. Our globally operating team of experts strongly focuses on the users benefits by ensuring maximum efficiency for the Pharmaceutical and Biotech industries as well as academic research. With our optical technologies like MST, TRIC, nanoDSF and DLS, we provide knowledge about the most challenging targets.

NDA Regulatory Service GmbH

CRO

Keywords: Pharmacovigilance, Drug Development, Medical Writing, R&D Service, Regulatory Affairs

NDA is a leading regulatory consultancy, supporting drug development companies of all sizes on the shortest and most economic path to approval and patient access. Our experienced team of 150 consultants (30 in Munich) provide advice on all phases of development and therapeutic areas, including procedure and submission management, for both US and EU. Our specialist Advisory Board, consisting of very senior ex-regulators, provides independent strategic advice with an inside the agencies view.



Neumarkter Straße 18
D-81673 München
Phone: +49 (0) 89 3585-4000
E-Mail: munich@ndareg.com
Internet: www.ndareg.com

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology, Molecular Diagnostics

Trusted to deliver cutting-edge solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions is central to Neaspecs philosophy. Neaspec developed the neaSNOM microscope that combines the best of two worlds the nanoscale resolution of atomic force microscopy (AFM) with the analytical power of FT-IR infrared imaging & spectroscopy.



Eglfinger Weg 2
D-85540 Haar (Munich)
Phone: +49 (0) 89 420 797 203 -30
E-Mail: info@neaspec.com
Internet: www.neaspec.com

NEOVII Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Neovii Biotech GmbH develops, commercializes and manufactures immunologically active biopharmaceutical therapeutics, especially the medicinal product Grafalon[®]. Neovii is headquartered in Switzerland (Neovii Pharmaceuticals AG, Zürcherstrasse 19, 8640 Rapperswil, Switzerland (Phone: +41 55 210 05 00; Fax: +41 55 210 55 08; E-mail: info@neovii.com) and part of the Neopharm Group, Israel.



Am Haag 6+7
D-82166 Gräfelfing
Phone: +49 (0) 89 898888-0
E-Mail: info.germany@neovii.com
Internet: www.neovii.com

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for drugs with new mechanisms of action and improved therapy of the diseases.



Keilsteiner Breiten 6
D-93055 Regensburg
Phone: +49 (0) 941 785 369-0
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com



Larezhhausen 2
D-86567 Hilgertshausen
Phone: +49 (0) 8250-92 790 32
E-Mail: service@nexttec.biz
Internet: www.nexttec.biz

NIGU

AlzChem Group

Dr.-Albert-Frank-Str. 32
D-83308 Trostberg
Phone: +49 (0) 8621 86-2622
E-Mail: info@alzchem.com
Internet: www.nigu.de



Roonstr. 25
D-90429 Nürnberg
Phone: +49 (0) 911 273-0
E-Mail: angelika.gaufer@novartis.com
Internet: www.novartis.de



Am Wildwechsel 7a
D-82031 Grünwald
Phone: +49 (0) 178 8087262
E-Mail: wb@nucleusmed.eu
Internet: www.nucleusmed.eu

nexttec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Devices, Genomics, Automation

nexttec1-Step kits for rapid purification of plasmid and genomic DNA from tissue, cell cultures, blood, bacteria and plants. The nexttec1-Step DNA purification system consists of only one buffer system for the lysis of the corresponding samples and nexttecCleanColumns, or nextteccleanPlates96. The nexttec 1-Step DNA purification is a reversal of the usual, well-known DNA purification methods. Here, proteins and other inhibiting substances are adsorbed on a special sorbent surface. The DNA does not bind, passes through the adsorbent layer and is immediately available in the eluate for the applications. This allows purification of the DNA in just 4 minutes.

NIGU Chemie GmbH c/o AlzChem AG

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics (test kits for viral RNA/DNA) is another integral part of the portfolio.

Novartis Pharma GmbH

PHARMA

Novartis is reimagining medicines to help improve and extend people's lives. We use innovation and digital technologies to develop therapies in areas with high unmet medical need. We invest a high share of our turnover in research and development. Our products reach around 800 million people worldwide and we strive to expand access to them. In Germany Novartis employs around 7,400 people at 12 locations and around 109,000 worldwide. www.novartis.de and www.novartis.com

Nucleus Medical GmbH

LIFE SCIENCE / BIOTECH

Nucleus Medical GmbH has been founded in November 2019 by private investors. The company is focused on the development of innovative immune-modulating products in the field of transplantation medicine. Nucleus combines cutting-edge pharmaceutical technologies to ensure the intended therapeutic success of the later product. Nucleus works together with a network of service companies to ensure greatest possible flexibility and efficiency to achieve market authorization in a minimum of time.

numares AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases

numares AG, based in Regensburg develops and markets innovative diagnostic tests based on NMR metabolomics. Essentially, our tests consist of metabolic constellations that are characteristic of certain diseases. To find these, we apply machine learning to clinical study cohorts measured with our AXINON[®] NMR system. We have a successful commercial base especially in laboratories in the USA.



Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 280949-00
E-Mail: jobs@numares.com
Internet: www.numares.com

Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

The NUVISAN Group is an international service provider in the field of clinical trials, laboratory services and contract manufacturing of drugs or their intermediates for the pharmaceutical industry.

Headquartered in Neu-Ulm, NUVISAN operates several sites in Germany and France.



Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
E-Mail: bdinfo@nuvisan.com
Internet: www.nuvisan.com

Octamer GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Epigenetic mechanisms promise to open new avenues to drug discovery because they allow interfering with the most basic processes of transcriptional regulation. We research nucleosomes for decades and offer the unique opportunity to provide disease-relevant substrates to epigenetic targets both for academic research and drug discovery.



Friedemann-Bach-Str. 95
D-82166 Gräfelfing
Phone: +49 (0) 89 21538575
E-Mail: support@octamer.com
Internet: www.octamer.de

Omegamatrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index[®] with a collaborator in 2004. In 2006, von Schacky founded the laboratory Omegamatrix GmbH to deal with the ever-growing number of samples. Initially proposed as a risk factor for sudden cardiac death, the HS-Omega-3 Index also indicates risk for total mortality and cardiovascular disease. Other applications encompass, but are not limited to, athletes, cognition, psychiatric diseases or pregnancy and lactation.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5506 300-7
E-Mail: info@omegamatrix.eu
Internet: www.omegamatrix.eu



Am Klopferspitz 19
D-82152 Martinsried-Planegg
E-Mail: info@omicera.com
Internet: www.omicera.com



Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161-976289-0
E-Mail: info@omicscouts.com
Internet: www.omicscouts.com



Zugspitzstr. 5
D-85757 München-Karlsfeld
Phone: +49 (0) 151 2062 1612
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com



Gollierstr. 70
D-80339 München
Phone: +49 (0) 89 927 78775
Internet: www.optores.com

OmicEra Diagnostics GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Proteome scans become a universal diagnostic for health and disease. We anticipate that MS-based proteomics becomes a cornerstone of precision medicine over the coming years. For broad applications, a new technology platform must be developed including very large analytical capabilities. We aim to build the best performing platform with the highest capacity for precision medicine.

OmicScouts GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Bioinformatics, Proteomics, Drug Development, Biomarker Discovery & Development

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies. We provide and develop proteome-wide assays that work with native proteins and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers. OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Oncology

Oncolead, is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents.

Optores GmbH

MEDTECH

Optores GmbH provides the world's fastest solutions for optical coherence tomography (OCT). With sweep rates of several million OCT A-scans per second, Optores founders coined the term "MHz-OCT". These ultrahigh speeds are ideal for novel OCT applications, such as real-time surgical guidance, endoscopic OCT, large area surveys, visualization of blood flow, and high-throughput industrial inspection.

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Origenis is a privately owned company based in Martinsried, Germany, and a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis runs its own patented drug discovery platform MOREsystem® which combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed on 20.000 square feet of integrated lab space. We are currently focusing on anti-inflammatory and CNS drugs. Origenis runs research alliances as well as active in-house programs and is offering a variety of out-licensing opportunities via its proprietary patent database Cippix® - www.cippix.com.

Oryx GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials.

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONGP) est. 2011, is a subsidiary of Otsuka Group Company with an international network of 195 subsidiaries, 47,000 employees in 31 countries. With our corporate philosophy Otsuka-people creating new products for better health worldwide, ONGP focuses on fighting tuberculosis through innovative research and development, equitable access to medicines, collaborations, and capacity building programs that strengthen the quality and delivery of care.

Oxford BioLabs Ltd.

BIOTECH DEVICES & REAGENTS

Oxford Biolabs is a science-routed company that develops and markets naturally-based nutraceuticals and cosmeceuticals aimed at helping people combat unwanted signs of ageing, from androgenetic alopecia, over skin ageing to mild cognitive decline, to name a few. Our goal is to create innovative products that are of high value for its users.

origenis

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
E-Mail: info@origenis.de
Internet: www.origenis.de



Marktplatz 1
D-85598 Baldham
Phone: +49 (0) 8106 21 311-0
E-Mail: info@oryx-medicine.com
Internet: www.oryx-medicine.com



Otsuka Novel Products GmbH

Erika-Mann-Str. 21
D-80636 München
Phone: +49 (0) 89 2060205 50
E-Mail: reception@otsuka-onpg.com
Internet: www.otsuka-onpg.com

OXFORD BIOLABS®

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 640 791 02
E-Mail: kontakt@oxfordbiolabs.com
Internet: www.oxbiolabs.com



Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 83-50
E-Mail: info-de@panaceabiotec.com
Internet: www.panaceabiotec.de



Gewerbepark 6
D-94501 Aidenbach
Phone: +49 (0) 8543 6016-30
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de



Moosstr. 3
D-82319 Starnberg
Phone: +49 (0) 89 742846-0
E-Mail: eFlow-partnering@pari.com
Internet: www.pari.com/eflow-partnering



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 51728659-0
E-Mail: info@pelobiotech.com
Internet: www.pelobiotech.com

Panacea Biotec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection.

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering/Cell Culture, Industrial Biotechnology

PAN-Biotech GmbH, founded in 1988, is a modern company manufacturing and distributing sera, media, serum-free systems, biologicals, reagents and other cell culture products. We deliver our goods to customers from research, clinics and the biopharmaceutical industry. PAN-Biotech has been certified by the international quality management standards of DIN ISO 9001 and the strict EN ISO 13485. Production takes place in its headquarters in Aidenbach, Bavaria: "Quality - Made in Germany!"

PARI Pharma GmbH

MEDTECH

Keywords: Antibiotics, Analytical Chemistry, Laboratory, Devices, Drug Delivery, Infectious Diseases, Respiratory Diseases

PARI Pharma's focus is the development and manufacturing of optimized eFlow® Technology nebulizers in cooperation with partners from the pharmaceutical industry. eFlow Technology is a platform suitable for a wide range of drug formulations and patient populations. It enables short development times for optimized drug-specific nebulizers. PARI has a committed team with a considerable track record. As of today, six commercial drug-specific eFlow Technology nebulizers administer inhaled drugs.

Pelo Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Tissue Engineering/Cell Culture, Fine Chemicals/ Reagents

PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications (GMP). Tissue Dissociation Enzymes; Defined & Xeno-free Media; Human & Animal Primary & Stem Cells from healthy & diseased donors; Tagged Cells; ES/iPS Cells, Media, Reprogramming & Small Molecules; 2D/3D Cell Culture Systems.

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY; CMO

Keywords: Ophtalmology, Respiratory Diseases

Experience in manufacturing of eye drops in bottles and single-doses for almost 40 years. Specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions and Lens care products. A modern zone concept fulfills European and international standards in production of sterile fluid pharmaceuticals. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc.

Pharmalog – Institut für klinische Forschung GmbH

CRO

Pharmalog (TÜV certified and BVMA member) offers full service with an excellent reputation for all phases of clinical trials since 1983. We operate in Germany and all EU/EEU-countries and have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products.

PhaToCon (Pharm/Tox Concept)

BIOTECH PRECLINICAL SERVICES

Keywords: Antibody, Pharmacology, Regulatory Affairs, Toxicology, Drug Development, Drug Delivery, Tissue Engineering/Cell Culture

Safety of Medical Device and Pharma for patients and manufacturers. Our competence are toxicological Assessments (in vitro / in vivo) as well as biocompatibility evaluation and related preclinical study-management. Our support is customized, adapted from international standards like GLP/GMP, ISO, and we support "hands-on", based on science, evidence, quality and pragmatism. With our network of competence and capabilities we mark the difference to your competitor on your way to success.

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem (PC) develops, produces and markets pure reference substances for the pharmaceutical industry, research, analytics and authorities and synthesizes or isolates Impurities in remedies for customers needs with best equipment and experience. PC further develops analytical methods and new products mainly focussed on natural sources for Phytopharmaceuticals, Functional Foods as well as Cosmetics. The CEO has also the status of a qualified person acc. § 65 AMG for product release in Pharma.

pharma **STULLN**

Werksstraße 3
D-92551 Stulln
Phone: +49 (0) 9435 3008-0
E-Mail: info@pharmastulln.de
Internet: www.pharmastulln.de



Oskar-Messter-Str. 29
D-85737 Ismaning
Phone: +49 (0) 89 544637-0
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com



Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899-41
E-Mail: info@phatocon.com
Internet: www.phatocon.com



Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Zeppelinstrasse 3
D-85399 Hallbergmoos
Phone: +49 (0) 811 12 447-0
E-Mail: info@pieris.com
Internet: www.pieris.com



Raiffeisenstr. 31a
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Industriestraße 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
E-Mail: info@polyquant.com
Internet: www.polyquant.com

Pieris Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Respiratory Diseases, Peptide/Protein, Drug Development, Immune Therapy

Pieris Pharmaceuticals is an international Nasdaq-listed (TICKER: PIRS), clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia.

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR

PIKA Weihenstephan GmbH, a spin-off from TU München, is specialized in microbiology and DNA analyses for the food and beverage industries including breweries. Besides consultancy and lab service, our portfolio covers development, production and sales of products for on-site testing. Major products for quality control are FastOrange® enrichment media and 4everyone™ Detection kits, besides we supply fresh yeast from our HefeFarm®. PIKA Weihenstephan is certified according to DIN EN ISO 9001:2015.

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Biomarker Discovery & Development, Peptide/Protein, Laboratory, Clinical Diagnostics, Proteomics, In-Vitro-Diagnostics, R&D Service

PolyQuant provides ISO 9001:2015 certified products, services and bioinformatics support for protein analysis and proteomics covering: Stable isotope-labelled reference standards for absolute protein quantification based on our proprietary QconCAT platform technology, Kits for LC and MS instrument calibration and standardization, entire assay development for proteomics workflows (quantitative/qualitative), comprehensive support for protein analytics (Medtech, Biotech, Life Sciences, Pharma).

Postnova Analytics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Postnova is a manufacturer of analytical instruments based on Field-Flow Fractionation. The application range of 1 nm-100 µm and 1000 Da up to many MDa, Postnova provides an analytical tool for the separation/characterization of particles, polymers, proteins, viruses, antibodies, liposomes or exosomes in complex aqueous/organic matrices. Postnova offers the complete range of FFF techniques as Electrical/Asymmetrical FlowFFF, CentriFFF and ThermalFFF along with detection as MALS, DLS, and ICP-MS.

PPD Germany GmbH & Co. KG

CRO

Keywords: Medical Writing, Logistics, Devices, Drug Development

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. With offices in 46 countries and more than 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. Visit www.ppdi.com.

PreciPoint GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Automation, Devices

PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoints core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Microscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems.



Rankinestrasse 1
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 985 688-0
E-Mail: info@postnova.com
Internet: www.postnova.com



Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
E-Mail: genl.info@ppdi.com
Internet: www.ppdi.com



Alois-Steinecker-Str. 22
D-85354 Freising
Phone: +49 (0) 8161 976979-0
E-Mail: vertrieb@preciPoint.de
Internet: www.preciPoint.de

PREOMICS

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 23 14 163-0
E-Mail: info@preomics.com
Internet: www.preomics.com



Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
E-Mail: info@presens.de
Internet: www.presens.de



Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 58 00 82-0
Internet: www.prevtecmicrobia.com/en/

PreOmics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, Proteomics, Bioanalytics, Clinical Diagnostics

The PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors and develops, manufactures and distributes microsensors, 2D imaging and non-invasive sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices with service all over the world. The out-of-box products and the engineering of customized sensors focus on parameters essential for life: oxygen, pH, CO₂ and biomass. PreSens is certified EN ISO 13485:2016 and ISO 9001:2015.

Prevtec microbia GmbH

PHARMA ANIMAL HEALTH

Prevtec microbia is an agri-food biotechnology company specialized in developing technologies and marketing products for improving the health of food animals in order to increase production performance and food safety. Prevtec microbia's mission is to be a world leader in the development and commercialization of products providing an alternative to antibiotics for the prevention of bacterial infections and the improvement of food animal performance. The company has offices in Montreal and Saint-Hyacinthe, Quebec (Canada). Its German based subsidiary is run in conjunction with Klifovet AG.

ProJect Pharmaceuticals GmbH

CRO

Keywords: Drug Development, Drug Delivery, AntibodyDrugConjugate ADC, Antibody, Peptide/Protein, Small Molecules, Viruses

ProJect Pharmaceuticals transfers delicate pharmaceutical molecules into pioneering drugs with a deep expertise in formulation and pharmaceutical process development for liquid or lyophilized proteins, high-concentration products, ADCs / cytotoxics and live viral vaccines. We develop a quality product and its manufacturing process on a scientific rationale pursuant to international guidelines. Teamed up with manufacturing CMOs, we smooth technology transfer from pre-clinical to large-scale supply.



Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
E-Mail: info@project-pharmaceutics.com
Internet: www.project-pharmaceutics.com

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros, Martinsried/Munich, Germany is a private biotechnology company aimed at drug discovery for technically demanding drug targets. Proteros is currently working for most of the big pharma and biotech companies in Europe, US and Japan in different types of service and collaborative relationships. For more information please visit www.proteros.com.

PROTEROS

REACH RIGHT FASTER

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
E-Mail: business@proteros.com
Internet: www.proteros.com

PSI CRO Deutschland GmbH

CRO

PSI CRO Deutschland GmbH is a subsidiary of PSI CRO AG (Switzerland), a globally operating service provider specialized in clinical research and development services on behalf of the pharmaceutical and biotechnology industry. With more than 100 employees in Germany and over 2500 world-wide, we plan and execute clinical trials related to the global development of new therapies in many indications like Oncology, Gastroenterology, Haematology, Infectious Diseases, MS and other rare diseases.



Behringstrasse 7
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 89996080
Internet: www.psi-cro.com

PUREN Pharma GmbH & Co. KG, ein Unternehmen der Aurobindo Pharma Ltd.

PHARMA & CHEMICAL INDUSTRY

Already in the 1980s, PUREN Pharma had an important position in Germany thanks to high-quality, inexpensive generics and numerous branded drugs. Over time strategic takeovers have led to diverse company names. The range grew in the area of therapy-relevant generics and branded medicines, the broadest parenteral portfolio for clinics in Germany and attractive OTC specialties. Actavis Germany has been part of the Actavis-Allergan group and belongs now to the globally operating AUROBINDO group.



Willy-Brandt-Allee 2
D-81829 München
Phone: +49 (0) 89 558909-0
E-Mail: info@puren-pharma.de
Internet: www.puren-pharma.de



Fraunhoferstraße 18a
D-82152 Martinsried
Phone: +49 (0) 89 4132904-0
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com

RAS AG

An der Irlter Höhe 3a
D-93055 Regensburg
Phone: +49 (0) 941 60717-300
E-Mail: office@ras-ag.com
Internet: www.ras-ag.com/kontakt



Kettelerstr. 3-11
D-97222 Rimpfing
Phone: +49 (0) 9365 8826-43
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de

REMARK



Ringstr. 3
D-85764 Oberschleißheim b. München
Phone: +49 (0) 89 31577199
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the compound management solution quattro/CM or the ELN quattro/LJ. quattro research offers software development and consulting services to solve any data management challenges in life science R&D, e.g. Biologics registration.

RAS AG

PHARMA & CHEMICAL INDUSTRY

The RAS AG emerged from the merger of rent a scientist® GmbH and the ras materials GmbH. The task of the new corporation is to develop, produce and sell new materials and technologies. The R&D services are still available as a 'rent a scientist®' division.

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies.

REMARK GmbH

Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals we offer the following services: - Strategic Consulting - Project Management - Sponsor Representative - Medical Affairs Services - Quality Assurance Services - Medical Marketing For more information visit our web site at www.remark-pharma.com.

res mechanica

BIOTECH BIOINFORMATICS

res mechanica is a Munich-based company that develops hema.to, a software service for automatic and supportive diagnosis of leukemia based on flow cytometric data using artificial intelligence. hema.to has achieved a level of reliability in the diagnosis of mature B-cell neoplasms that is comparable to the judgment of an experienced diagnostician and is demonstrably world-class.



Ainmillerstr. 22
D-80801 München
Internet: www.resmechanica.com

Ritter GmbH, Medical

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, PCR, Pharmacogenetics, Proteomics, Devices, Automation, ELISA/EIA

Ritter GmbH was founded 1965. The company is established in Schwabmünchen, Bavaria. On 25,000 m² Ritter develops and produces with about 300 employees sterile and non-sterile laboratory equipment, high precision dispensers, tips and plates, certified according to the current DIN EN ISO 9001 and 13485 standards. In more than 70 countries, millions of Ritter medical products are used in clinical and biotechnological applications every day. Products: Robotic Consumables, Liquid Handling, Clinical Products.



Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
E-Mail: medical@ritter-online.de
Internet: www.ritter-medical.de

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research-focused healthcare with combined strength in pharma and diagnostics. At Penzberg, Roche runs one of Europe's largest biotechnology centers for research, development and production as well as a pioneer in digital health. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring as well as therapeutic proteins with focus on antibodies and biomarkers for oncology.



Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
E-Mail: penzberg.allgemein@roche.com
Internet: www.roche.de

R-Pharm Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Automation, Logistics

For many years we have been manufacturing and packaging pharmaceuticals for patients in over 150 countries. Innovative technologies and a highly motivated and competent team guarantee highest reliability and quality standards as well as an extraordinary price-performance ratio besides patient safety and customer satisfaction including personal contact. A company history of more than 150 years - both independent and historically within the global production network of Pfizer, Inc. is our pride.



Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
E-Mail: r-pharm-germany@r-pharm.com
Internet: www.germany.r-pharm.com

SanoLiBio GmbH

Walpurgisstraße 4
D-81677 München
Phone: +49 (0) 89 20 333 292
E-Mail: info@sanolibio.com
Internet: www.sanolibio.com



Eine gesunde Entscheidung

Industriestr. 25
D-83607 Holzkirchen
Phone: +49 (0) 8024 908 0
E-Mail: info@sandoz.de
Internet: www.sandoz.com



Am Klopferspitz 19
DEU-82152 Martinsried
Phone: +49 (0) 89-614241230
E-Mail: info@SciRhom.com
Internet: SciRhom.com



Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 21546375
E-Mail: info@secarna.com
Internet: www.secarna.com

SanoLiBio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

SanoLiBio focuses on automated solutions in blood circulating rare cell enrichment and rare cell analysis. Cost-efficiency, accessibility, scalability, and diagnostic accuracy drive our innovations. Our technology distinguishes itself from any existing rare cell enrichment platform by our no-loss enrichment of desired cells. SanoLiBio's market priority is non-invasive prenatal testing and cancer diagnostics and ultimately, striving to pioneer disease prevention by cell-based liquid biopsy.

Sandoz Pharmaceuticals GmbH

PHARMA & CHEMICAL INDUSTRY

Sandoz Pharmaceuticals GmbH belongs to the global Sandoz-Group - number two worldwide in the field of generics. In Germany, we specialize on premium generics, biopharmaceuticals and well known minerals.

SciRhom GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Inflammation, Autoimmune Diseases, Antibody, Drug Development

SciRhom GmbH, a biopharmaceutical start-up company, develops first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the successful completion of antibody generation campaigns, SciRhom is now pursuing the preclinical and early clinical development of monoclonal antibodies against iRhom2 for the treatment of autoimmune and other serious diseases.

Secarna Pharmaceuticals GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Secarna Pharmaceuticals is the leading independent European antisense drug discovery and development company. Leveraging its proprietary LNAplus platform, Secarna develops next generation antisense oligonucleotide (ASO) therapies addressing challenging or currently undruggable targets. LNAplus™ is fully validated by over 15 in-house programs and numerous industry collaborations focusing on immuno-oncology, immunology, fibrotic-, viral-, neurodegenerative- and cardiometabolic diseases.

Securetec Detektions-Systeme AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, R&D Service, In-Vitro-Diagnostics, Infectious Diseases, Antibody, Toxicology, Small Molecules

Securetec Detektions-Systeme AG provides specific technologies for the detection of drugs and hazardous substances. We understand the worldwide demands of traffic safety, customs and enforcement authorities. Our competencies are the development and production of test solutions for a highly reliable day-to-day use for a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today's world a safer one.



Lilienthalstr. 7
D-85579 Neubiberg
Phone: +49 (0) 89 2030 8016-51
E-Mail: info@securetec.net
Internet: www.securetec.net

selectION Therapeutics GmbH, Martinsried, selectION Inc., San Diego

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

selectION is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of severe autoimmune diseases and rare oncology indications. The Company has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The most advanced drug candidate is si-544, a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 547 2695-0
E-Mail: info@selectiontherapeutics.com
Internet: www.selectiontherapeutics.com

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.



Biologische Detektions- und
Schnelltestsysteme

Provinstr. 52, Gebäude B14
D-86153 Augsburg
Phone: +49 (0) 821 455799-0
E-Mail: info@sension.eu
Internet: www.sension.eu

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Sequiserve offers the following custom services in molecular biology: Sanger-DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking, direct sequencing of bacterial pellets). Purification of PCR products and Plamid-DNA preparation for subsequent sequencing. Sequiserve - your expert in DNA-sequencing since 1994!



Joh.-Seb.-Bach-Str. 7
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de



Elsenheimerstr. 53
D-80687 München
Phone: +49 (0) 89 57095-01
E-Mail: arnd.prilipp@servier.com
Internet: www.servier.de

SIGMA-ALDRICH®

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-0
E-Mail: deorders@sial.com
Internet: www.sigma-aldrich.com



Gollier Str. 70 C
D-80339 München
Phone: +49 (0) 89 500941-0
E-Mail: info@silantes.com
Internet: www.silantes.com



Spezielle Immunologie
Forschung + Entwicklung GmbH

Kurpromenade 2
D-95448 Bayreuth
Phone: +49 (0) 921 730052-10
Internet: www.simfo.de

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Cardiovascular Diseases, Hematology, Neurology, Rheumatoid Arthritis, Oncology

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Paris-Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excl. generics) in R&D. Five areas of excellence: cardiovascular, immune-inflammatory, neurodegenerative diseases, cancer, diabetes and generics.

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

Silantes GmbH

BIOTECH DEVICES & REAGENTS

Silantes GmbH, engages in development, manufacturing, marketing and distribution of stable isotopically labeled biomass and bio-molecules. By using a new patented technique for labelling S-isotopic bio-molecules, Silantes is able to offer improved quality and reduced costs for the customers in industrial and academic research fields at the same time. Additionally, international research projects with different scientific groups and close collaboration with NMR-specialists enable synergetic effects.

SIMFO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

simfo GmbH is a research and development facility with advanced expertise in personalized medicine. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics. With maintrac[®], simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development.

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
E-Mail: info@sinatur.net
Internet: www.sinatur.net

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Transfer, R&D Service, Viruses, Cell Therapy, Gene Therapy, Drug Development

SIRION Biotech offers the world's most comprehensive viral vector AAV-, Lentivirus-, and Adenovirus-based technologies to expedite gene and cell therapy and vaccine R&D. LentiBOOST transduction reagent is actively used to improve hematopoietic cell transductions in clinical trials (USA, Europe). Commercial arrangements range from fee-for-service, all the way to milestone & licensing.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

siTOOLS Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: RNAi & Antisense

siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich's biotech cluster in Planegg/Martinsried. "siPools" are highly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects.



Lochhamer Straße 29a
D-82152 Planegg
Phone: +49 89 12501 4800
E-Mail: info@sitools.de
Internet: www.sitoolsbiotech.com



Trogerstraße 14
D-81379 München
Phone: +49 (0) 89 724 018 40
E-Mail: contact@s4dx.com
Internet: www.smart4diagnostics.com



Mühlthaler Str. 91c
D-81475 München
Phone: +49 (0) 89 854 665-13
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

Sourcia.

Lochhamer Strasse 31
D-82152 Martinsried
Phone: +49 (0) 151 74403195
Internet: www.sourcia.eu



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 160 8353331
E-Mail: bmayer@spherotec.com
Internet: www.spherotec.com

Smart4Diagnostics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Bioinformatics

Smart4Diagnostics GmbH closes the data gap between blood collection and lab analysis and enables a new quality standard for diagnostic decision making. We change medical diagnostics from a trust-based system into an evidence-based system. Our digital human sample fingerprint is a quantum leap forward for patient safety, the quality of medical decisions and sample turnaround time in the lab. We create a trustworthy and verifiably basis for the personalized medicine of the future.

SMARTEC IngenieurBüro

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/Cell Culture

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product.

Sourcia GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices

Sourcia is your high-experienced, flexible and independent partner in clinical development. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan.

Spherotec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering/Cell Culture

Spherotec is a biotech company offering humanized 3D cell culture models, i.e. 3D microtumor models and immunological models for drug testing. This diagnostic service is preclinically offered to cancer patients to identify the most effective drug treatment (personalized therapy). Drug testing includes chemotherapeutics, antibodies, immune therapeutics and natural compounds. In addition, our 3D models are used from pharma and biotech companies in the process of drug development.

SSS International Clinical Research GmbH

CRO

Keywords: Oncology, Respiratory Diseases, Hematology, Autoimmune Diseases, Ophthalmology, Cardiovascular Diseases

SSS International Clinical Research is a Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania and Poland. We provide high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for more than 25 years and through many successful projects.



INTERNATIONAL CLINICAL RESEARCH

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 800 650-0
E-Mail: info@cro-sss.de
Internet: www.cro-sss.eu

Staburo GmbH – Statistical Consulting

CRO

Keywords: Oncology, Data Management and Biostatistics, Biomarker Discovery & Development, Bioinformatics, Data Management, Cardiovascular Diseases

Staburo is a Munich-based data science company, specialized in statistical consulting and programming in the field of clinical trials. We develop tailor-made client solutions, based on our 6 pillars: Clinical statistics, Translational medicine & biomarkers, PK/PD, HTA, Non-clinical statistics and statistical programming. Our customers are pharmaceutical companies, CROs and biotech companies, with whom we work on a flexible basis.



Aschauer Str. 26b
D-81549 München
Phone: +49 (0) 89 5527 1520
E-Mail: info@staburo.de
Internet: www.staburo.de

SÜD-LABORBEDARF GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.



Starnberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 6527
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de

Swedish Orphan Biovitrum GmbH, SOBI

BIOTECH THERAPEUTICS & DIAGNOSTICS

Swedish Orphan Biovitrum is an international company specializing in rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of these patients and their families. The Swedish Orphan Biovitrum GmbH (Sobi) has been active in Germany since 2017. The company is based in Martinsried, Bavaria. Behind the success of Sobi are the nearly 40 employees in Germany whose daily motivation is to help improve the lives of patients with rare diseases.



Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 550 66 760
E-Mail: mail.de@sobi.com
Internet: www.sobi.com



Bayerstr. 53, SPI-Munich, 6. Stock
D-80335 München
Phone: +49 (0) 89 741393-0
E-Mail: SPI-Munich@synlab.com
Internet: www.synlab.com



Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 6860-0
E-Mail: info@syntacoll.de
Internet: www.syntacoll.de



Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Internet: www.synteract.com



Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 993913-0
E-Mail: reza.khosravani@syneoshealth.com
Internet: www.syneoshealth.com

SYNLAB pharma institute

CRO

Keywords: Analytical Chemistry, Bioanalytics, R&D Service, Logistics, Clinical Diagnostics, Laboratory, Biomarker Discovery & Development

SYNLAB Pharma offers a very broad range of laboratory services to the biotechnology and pharmaceutical industries as well as to manufacturers of medical devices. Our portfolio includes global clinical trial services, bioanalytical services, biomarker testing, personalized medicine concepts, logistics, sample storage, production monitoring, product release and stability studies, always working in accordance with the highest standards such as DIN/EN ISO/IEC 17025/15189, GMP, GLP, GCLP or GCP.

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is a subsidiary company and the only development and production site of Innocoll Pharmaceuticals Limited, an international pharmacy group. Since 1992, Syntacoll is developing and producing innovative, collagen-based absorbable implants and wound dressings at our production site in Saal an der Donau. Our facility is GMP compliant and ISO 13485 certified. Additionally, Syntacoll holds a manufacturing license for collagen-based drugs.

Synteract GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain

Synteract is an innovative mid-size CRO with European HQ in Munich. We are providing international, full-service, Phase I-III clinical trials services to biopharma companies. Over its nearly 35-year history, Synteract has contributed to more than 240 product approvals. Our core development areas are: oncology, dermatology, neuro sciences, general medicine and vaccination, rare/orphan disease, and pediatrics.

Syneos Health Germany GmbH

CRO

Keywords: CRO/CMO, Clinical Trial Management and Monitoring, Medical Writing

The coming together of INC Research and inVentiv Health as one global company, called Syneos Health, has created the industry's only true end-to-end solution. This one entity combines world-renowned clinical research and commercialization capabilities with today's most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide.

Systasy Bioscience GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development

At Systasy, we believe that early-on knowledge of perturbed signaling pathways will improve and accelerate the drug discovery process for genetically complex brain disorders. With our ground-breaking tools and technologies, we aim at providing an opportunity for pharma & biotech companies to identify novel drug targets based on disease biology. To achieve this goal we create highly relevant HTS-compatible pathway-centric assays in human 2D/3D disease models for functional screening.



Balanstr. 6
D-81669 München
Phone: + 49 (0) 89 2155 3085
E-Mail: info@systasy.de
Internet: www.systasy.de

T-CURX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Hematology, Personalized Medicine, Cell Therapy, Drug Development

T-CURX develops new generation of CAR T cells for personalized cancer immunotherapy built on proprietary technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CAR T therapy. T cells are reprogrammed using virus-free gene transfer technology to destroy tumor cells. CAR T cells are living drugs that persist life-long and aim to provide protection from relapse. T-CURX's target pipeline addresses several cancer indications in hematology and oncology.



Friedrich-Bergius-Ring 15
D-97076 Würzburg
E-Mail: info@t-curx.com
Internet: www.t-curx.com

TauroPharm GmbH

PHARMA & CHEMICAL INDUSTRY

TauroPharm GmbH is a healthcare company founded in 2000 and based in Waldbüttelbrunn, Germany. We want to minimize infection risks in global healthcare and thus increase patient safety worldwide. We manufacture products that prevent infections associated with central venous catheters and port systems in a variety of applications like administration of medication in the fields of oncology and haematology as well as other implanted medical devices.



August-Bebel-Straße 51
D-97297 Waldbüttelbrunn
Phone: +49 (0) 931 40480511
E-Mail: infos@tauropharm.de
Internet: www.tauropharm.de

the ncd company

non-clinical development on demand

Propst-Hartl-Straße 8
D-82398 Polling
Phone: +49 (0) 881-12123876
E-Mail: info@ncd-company.com
Internet: www.ncd-company.com

Therawis

Pharma | Diagnostics

Grillparzerstrasse 14
D-81675 München
Phone: +49 (0) 89 41 42 45 57-0
E-mail: info@therawis.com
Internet: www.therawis.com

ThermoFisher SCIENTIFIC

Im Gewerbepark B35
D-93059 Regensburg
Phone: +49 (0) 941 94276-0
E-Mail: geneart.info@lifetech.com
Internet: www.thermofisher.com

The NCD Company UG

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology

The NCD Company is an independent project company and provides all services of a non-clinical development department for biotech and pharma companies with an experienced team at highest level. By outsourcing preclinical development, you will increase flexibility, save internal resources and ensure the access to a broad spectrum of knowledge and experience. We provide Drug Development Planning and Management, Safety Testing/Toxicology, ADME/DMPK, Outsourcing, QA (GLP) and Regulatory Submission.

Therawis Diagnostics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: In-Vitro-Diagnostics, Oncology

Therawis Diagnostics GmbH was founded by an experienced team with proven track record in oncology, diagnostics, corporate development, capital markets and develops diagnostics to support and guide optimal therapy for cancer patients. Therawis Diagnostics and its partner Qjagen, Hilden, Germany, launched the thescreenPITX2 RQO PCR Kit in 2018, a novel clinically validated biomarker test to predict outcome to anthracycline-based chemotherapy in high risk breast cancer patients.

Thermo Fisher Scientific GENEART GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Combinatorics

Thermo Fisher Scientific supplies innovative solutions for the world's pharmaceutical and biopharmaceutical industries. With applications that span the drug development process - from drug discovery through large-scale commercial production - we provide a broad range of products and services including single-use technologies, customized fluid transfer systems, high-quality media and sera, freezing and storage equipment, and innovative consumables and reagents, purification, and analytics.

Thermosome GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery

Thermosome is leveraging its technology platform to create products with improved therapeutic index that exploit a novel MoA called intravascular drug release. Drug-loaded nanocarriers are created which after i.v. infusion release their content locally upon the influence of mild heat achieved by various clinically established targeted heating techniques (microwave, ultrasound). As a result, up to 15-fold higher local drug concentrations can be reached to improve therapeutic outcomes.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7167 760-31
Fax: +49 (0) 89 7167 760-49
E-Mail: info@thermosome.com
Internet: www.thermosome.com

tilibit nanosystems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, New Materials, R&D Service

tilibit nanosystems is specialized in the development and production of functional DNA nanostructures. We offer the design of custom structures for research applications, as well as collaborative development projects with industry partners for novel commercial applications. Nanostructure application fields comprise fields such as drug delivery, diagnostics, sensors, and analytical devices.



Friedenstraße 18
D-81671 München
E-Mail: info@tilibit.com
Internet: www.tilibit.com

TILL I.D. GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis

TILL I.D. is a small, innovative company in between research and industry. We develop concepts and prototypes for all areas in light microscopy. Our projects focus on an innovative microscopy platform, which is entirely tailored for digitalization. Its versatility and flexibility does not stem from a number of attachable modules, but from a fundamental design to which different imaging techniques and illumination concepts have contributed right from the start.



Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 2032 4142-20
E-Mail: info@till-id.com
Internet: www.till-id.com

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics

TOPLAB GmbH is a leading ISO 9001/GMP certified and FDA registered service provider having outstanding expertise in proteome analysis, protein identification and characterization with more than 25 years of experience. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.



Fraunhoferstr. 18 a
D-82152 Martinsried
Phone: +49 (0) 89 2441 45412-81
E-Mail: info@toplab.de
Internet: www.toplab.de



Mühlal 5
D-82392 Habach
Phone: +49 (0) 8847 695 78-0
E-Mail: info@triga-s.de
Internet: www.triga-s.de



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 766-0
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Butenandtstraße 1
D-81377 München
E-Mail: info@tubulis.com
Internet: www.tubulis.com



Industriestr. 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
E-Mail: bcdiagnostics@uroquant.com
Internet: www.uroquant.com

TRIGA-S e.K. Scientific Support

CRO

Keywords: Laboratory, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Regulatory Affairs, In-Vitro-Diagnostics, Molecular Diagnostics

TRIGA-S is a contract research organization with own BSL2 laboratory for in-vitro diagnostics and medical devices. Our high quality is certified according to DIN EN ISO 13485 and DIN EN ISO 9001. As an established service provider, TRIGA-S offers tailor-made solutions for many types of studies: from exploratory to feasibility, and performance evaluation studies. Our GCP/GCLP qualified teams work in accordance with IVDR/MDR, national and international regulations.

TRION Research GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Immune Therapy, Antibody Production Service

Our services comprise Liquid Biopsy diagnostics with the analysis of virus-infected cells and the detection of disseminated tumor cells in blood, urine and other body fluids. Moreover, we offer the full range of preclinical and clinical support from trial design over immunomonitoring and tumor biology analysis to data management and logistics solutions. We work together with our partners to elucidate the modes of action of new compounds.

Tubulis GmbH

OTHER SERVICES

Keywords: Oncology, AntibodyDrugConjugate ADC, Drug Delivery, Drug Development

Tubulis[®] generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

UroQuant GmbH

BIOTECH

UroQuant develops non-invasive cancer IVD (In Vitro Diagnostics) enabling precision medicine for clinical routine. Starting with bladder cancer, quantitative measurement of disease-specific proteins (biomarkers) will allow UroQuant to diagnose cancer much earlier and more reliably than competitive test kits. Our IVD test will significantly improve patient treatment and patient compliance leading to a substantial cost reduction for the health care system.

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.



Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

Vectura GmbH

MEDTECH

Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies.



Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
E-Mail: info@vectura.com
Internet: www.vectura.com

Velvio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Velvio develops Antisense Oligonucleotide compounds to restore organ repair functions as treatment for Orphan Diseases in Neurodegeneration - first of all Amyotrophic Lateral Sclerosis (ALS) and Idiopathic Pulmonary Fibrosis (IPF). Further, Velvio offers new opportunities in Immune-Oncology and treatment concepts in liver and brain tumors. From our broad compound pipeline, we are ready to go first in man with ALS and we are about to finish preclinical drug development in IPF.



Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 463 747 30
E-Mail: office@velvio.com
Internet: www.velvio.com



Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 15882-0
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Sonnenstr. 19/Geb. 2, 2nd floor
D-80331 München
Phone: +49 (0) 89 20602-9900
Fax: +49 (0) 89 20602-9907
Internet: www.vrtx.com



Lise-Meitner-Str. 30
D-85354 Freising-Weißenstephan
Phone: +49 (0) 8161 18516-11
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com



Kraillinger Str. 1
D-82152 Planegg
Phone: +49 (0) 89 800777-60
E-Mail: verum@verum.de
Internet: www.verum.de

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Microscopy, Laboratory, Bioanalytics, Other Diagnostics

vermicon AG offers innovative solutions for microbiology. The development of VIT[®] (vermicon identification technology) made FISH accessible not only for academic research but also for the industrial microbiology. Focusing on the direct and cultivation-independent analysis of microorganisms, the company provides fast, highly specific and reliable insight into the microbiological composition of samples. With satisfied customers worldwide, vermicon is driving the evolution of modern microbiology.

Vertex Pharmaceuticals (Germany) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying cause of cystic fibrosis (CF) and has several ongoing clinical and research programs in CF. Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases, as well as a rapidly expanding pipeline of genetic and cell therapies.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

VERTIS is a research-oriented company in the field of functional genomics. The strength of our service is customer-oriented flexibility which is based on our innovative technology platform which we have developed in our 20-year history. We offer innovative tools and strategies for the comprehensive qualitative and quantitative analysis of bacterial and eukaryotic transcriptomes, using state-of-the-art Next Generation Sequencing (NGS) of RNA molecules (RNA-seq).

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

verum is a regional CRO specializing in clinical trials management in Germany, Austria as well as in Central and Eastern Europe. Since 2001 verum served 158 trials in different areas: neuroscience, oncology, cardiology, etc. During last years verum is also focused on biosamples (BS) collection studies, sponsored by developers and manufactures of integrated systems for the analysis of genetic variation and biological function. We are an expert in regulatory and ethic affairs for BS collection.

vicron gmbh

BIOTECH THERAPEUTICS & DIAGNOSTICS

Therapy optimisation for doctors & patients in real-time vicron strives for excellence in medical expertise for proprietary algorithms, data analytics and neural networks. Our Decision Support System is designed to empower doctors for expedient and fast data analytics to make better treatment decisions for patients in hospitals. To ensure data integrity, vicron smoothly integrates with EHRs and uses decentralised data management processes.

Vifor Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Vifor Pharma is an internationally active pharma company, which researches, develops, produces and markets its own pharmaceutical products worldwide. The Company's main area of focus is iron replacement therapy, Vifor Fresenius Medical Care Renal Pharma and infectious diseases.

vicron

Föhrenstr. 12
D-85649 Brunnthal
Internet: www.vicron.com/



Baierbrunner Str. 29
D-81379 München
Phone: +49 (0) 89 324918 600
E-Mail: info-de@viforpharma.com
Internet: www.viforpharma.de




YOUR DIAGNOSTICS STUDIES IN GOOD HANDS.

TRIGA-S is a preferred CRO partner for the planning and conduction of analytical and clinical performance evaluation studies of in-vitro diagnostics according to international regulations (e.g. EU-IVDR, US-CFR).

Since 1998, our name stands for excellency and trustful collaboration.

TRIGA-S SCIENTIFIC SOLUTIONS

Mühltal 5 • D-82392 Habach
Tel. +49 (0) 88 47 - 695 78 0

info@triga-s.de
www.triga-s.de

CONTRACT LABORATORY (BSL2)

STUDY MANAGEMENT · CLINICAL MONITORING

DATA MANAGEMENT · BIOSTATISTICS

COMPLETE SAMPLE MANAGEMENT:
COLLECTION · LOGISTICS · PROCESSING · STORAGE



Semmelweisstraße 3
D-82152 Planegg
E-Mail: info@Vigeneron.com
Internet: www.vigeneron.com



Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
E-Mail: viramed@viramed.de
Internet: www.viramed.de



Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 122 287 6-90
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.com

ViGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Neuro-Degeneration, Ophthalmology, Gene Therapy, Industrial Biotechnology, Orphan Drug

ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company's pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms.

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: ELISA/EIA, Clinical Diagnostics, In-Vitro-Diagnostics, Infectious Diseases

Viramed BiotechAG produces IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisatestkits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.

vivoPharm Europe Ltd, a CGI company

CRO

Keywords: Bioanalytics, Pharmacokinetics, Oncology, Drug Development, Pharmacology, Toxicology, Vaccines

vivoPharm is a successful and fast-growing precision research organization (CRO) that provides integrated preclinical services worldwide. Using our experience and knowledge, we assist in the planning and performance of tailored studies, from discovery stage through to clinical development and beyond. We're a unique IO precision service organization, active in preclinical and clinical services. All work is carried in AAALAC accredited and GLP compliant facilities in Australia and the US.

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine.



Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
E-Mail: info@wacker.com
Internet: www.wacker.com

Winicker Norimed GmbH Medizinische Forschung

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Pharmacovigilance, Regulatory Affairs

Winicker Norimed GmbH is an independent contract research organization. We manage projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients SOPs. Winicker Norimed manages phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.



Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680-0
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com

XL-protein GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: AntibodyDrugConjugate ADC, Drug Development, Drug Delivery, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company commercializing its ground-breaking PASylation[®] technology, which enables the design of biologics with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels.



Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com



Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 9931 7446
E-Mail: info@xvir.com
Internet: www.xvir.com



Münchnerstrasse 8
D-85354 Freising
Phone: +49 (0) 8161 99210
E-Mail: manfred.seifert@zeta.com
Internet: www.zeta.com



Junkersstraße 9
D-89231 Neu-Ulm
Phone: +49 (0) 7304 9283270
E-Mail: info@zimmer.de
Internet: www.zimmer.de

XVir® Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

XVir Therapeutics GmbH is focusing on the clinical development of oncolytic adenoviruses for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. XVir Therapeutics has completed preclinical development of its most advanced product candidate XVir and is preparing a Phase I clinical study in the indication glioblastoma. XVir's therapeutic approach is covered by proprietary patents and patent applications, respectively.

Zeta GmbH

BIOTECH & PHARMA PRODUCTION

Keywords: Bioinformatics, Data Management and Biostatistics, Devices, Bioprocessing, Industrial Biotechnology, Automation

The ZETA Group, with 800 highly qualified employees and 13 subsidiaries worldwide, specializes in planning, automation, digitization and maintenance of customized biopharmaceutical facilities for aseptic process solutions. ZETA acts as a one-stop shop, combining plant engineering with HVAC and cleanroom design.

Zimmer BioTech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Zimmer BioTech, a Neu-Ulm, Germany-based start-up is advancing Alevin deep a drug based on 5-Aminolevulinic acid (ALA), used for treatment of actinic keratoses in photodynamic therapy (PDT). New developments show a huge upside potential as the drug could be used to treat Acne. Investors include Zimmer MedizinSysteme GmbH, the medical device producer, and High-Tech Gründerfonds. The company will use the funds to continue to develop a new therapy to combat skin cancer and Acne.



Tel.: +49 (89) 85 89 63 - 0
kontakt@wander-immobilien.de



You are looking for suitable laboratories?

We are your specialist!

www.wander-immobilien.de

Office, laboratories and production space

from 250 sqm – 10.000 sqm

**We are looking forward to send you
an attractive offer.**



Imprint

Editorial staff: Gabriele Klingner, Dr. Christina Grimm,
Dr. Max Pöhlmann, Dr. Stephanie Wehnelt,
Dr. Andreas Berghammer, Dr. Ruoyu Sun,
Dr. Jens Wiehler, Dr. Isabella Almstätter

Company Profiles: Dr. Christina Grimm

Advertisement: Dr. Andreas Berghammer

Podcast interviews were produced on behalf of Bio^M by Edmund Soutschek

Data analysis was compiled together with BIO-Deutschland e.V.

We thank the Bavarian companies and the regional organizations of the Bavarian Biotechnology Cluster for supporting this survey.
October, 2021

Contact

Prof. Dr. Horst Domdey, CEO Bio^M
Managing Director and Spokesman of the Bavarian
Biotechnology Cluster

**The Bavarian and the Munich Biotechnology Clusters
are managed by:**

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0)89-899679-0
Fax: +49 (0)89-899679-79
E-Mail: info@bio-m.org
www.bio-m.org



Cover: Shutterstock
The layout, graphics and other contents of this brochure of the Bavarian Biotechnology Cluster are protected by copyright law.

Layout-Design: MXM Digital Service GmbH, Munich, www.mxm.de
Pictures copyright as indicated

Supported by the Bavarian Ministry of Economic Affairs, Regional Development and Energy
www.stmwi.bayern.de/en/

About this Study:

Data collection

For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods.

The biotechnology companies were classified according to the location of their headquarters as 'international' or 'native Bavarian'. The classification into OECD and non-OECD biotech companies as found in previous reports has been dispensed with, as this does not accurately portray the diversity of the biotech pharma ecosystem.

Data were collected in cooperation with BIO Deutschland e.V., and by own surveys (Corona, EMM) between March and July 2020. Taken together, it was possible to achieve a response rate of more than 50% in the core group. These data sets were completed by public sources and via personal communication.

Possible deviations from previously published figures are the result of additional data gathered in this survey that also may refer to previous years. The period under review for this report is 2020.

There are more than 300 company profiles listed in the appendix of this brochure. Not every company listed is also considered in this survey, for example some companies with very specific services. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in the appendix. More than 500 Bavarian companies in medical engineering are not included in this survey (by numbers or with profiles).

Processing of data and estimation procedures

For the assignment of the companies to branch areas and business fields, the answers of the companies, the classifications in the databases of Bio^M and BIO Deutschland e.V., the classification by the Chamber of Industry and Commerce as well as internet research were used. To determine the number of employees, the mean of the selected size ranges was used for companies for which no precise figures or additional information were given. In addition, the values were supplemented by annual financial statements and internet research as well as reported figures from the previous year. The number was limited to 300 in the case of 3 companies with an information >250. For the extrapolation of the total number of employees per group, the mean values of the respective branch areas (biotechnology, pharmaceuticals, CRO, others) were then calculated and multiplied by the total number of companies in the areas. The assignment and the estimates given were made with the greatest possible care; however, no liability is assumed for the completeness and correctness of the information.

Published in October, 2021



Bavarian Ministry of
Economic Affairs,
Regional Development
and Energy



invest
in
bavaria



Welcome to Bavaria.

Home of cross-industry innovation.

Bavaria is one of the top BioTech regions in Europe, bringing together international pharma companies, new rising BioTech stars, R&D centers, universities and investors.

In this unique ecosystem, cross-industry innovation, notably driven by digitization, is thriving. Thanks to new and unexpected partnerships with players outside the industry, many exciting ideas and business models are evolving.

Discover the benefits of joining our ecosystem and expanding your business to Bavaria. We can help you get your business started: from arranging contacts to identifying the perfect location for your company.

Our service is confidential and free of charge. Get in touch now.

→ www.invest-in-bavaria.com



**Innovation and
Start-up Center
Biotechnology**

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Tel. + 49 (0)89.55 279 48-0
Fax + 49 (0)89.55 279 48-29
info@izb-online.de
www.izb-online.de



YOU HAVE THE IDEA – WE HAVE THE LOCATION

- Site: 26,000 m², S1 laboratories
- Real estate and facility management on site
- Faculty Club and conference rooms for up to 100 people
- Kindergarden (Bio Kids), Chemistry School Elhardt
- Hotel CAMPUS AT HOME
- Restaurant SEVEN AND MORE, Café Freshmaker
- On the Martinsried Campus: over 50 start-ups in the IZB, two Max Planck Institutes, ten faculties of the LMU, Clinic of the University Munich

WHERE THE FUTURE BECOMES REALITY